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Abstract 
Innate Antibodies, Murine Models, and Evolution: A Study of Trypanosome Lytic Factor Functions and 
Their Translational Applications 
By 
Joseph Peter Verdi 
Advisor: Dr. Jayne Raper 
Trypanosome lytic factors (TLFs) are primate-specific antimicrobial protein complexes that lyse 
African trypanosome parasites by delivering the channel-forming toxin APOL1 to the invading 
microorganisms. Human serum contains two TLFs that are delivered to the parasite by separate 
mechanisms, only one of which has been characterized. TLF1 is endocytosed by a receptor that is 
typically blocked by other serum factors in vivo, suggesting that TLF2 is the more relevant lytic factor in 
the context of trypanosome immunity. TLF2 is non-covalently associated with polyclonal immunoglobulin 
M (IgM) antibodies, which we report here to be involved in the uptake mechanism. The TLF2-IgMs are 
polyreactive and can interact with both the TLF complex and the dominant surface protein of 
trypanosomes, the variant surface glycoprotein (VSG), which likely drives uptake of the APOL1. Once 
delivered to the parasite, human APOL1 forms cation selective pH-gated channels in membranes. 
However, relatively little is known about the channel forming properties of non-human primate APOL1 
proteins or their TLF complexes. Here we also report that non-human primates, including the baboon, 
have both TLF1 and TLF2 complexes. We have investigated the channel forming properties of baboon 
APOL1 and have observed that it is less restricted by pH than human APOL1, which we have attributed 
to key amino acid differences between the two proteins. In order to better understand the function of 
human and primate TLFs, we have generated various mouse models allowing us to study them in vivo, 
including an array of targeted germline transgenic baboon APOL1-expressing animals. These mice have 
been used to model the possibility of creating genetically modified livestock with a similar strategy in order 
to potentially provide a novel method to limit the devastating agricultural burden imposed by 
trypanosomes on sub-Saharan Africa.  
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Background 
1. The Problem 
 Neglected tropical diseases (NTDs) are a group of 20 human diseases caused mostly by 
infectious agents. These NTDs, as defined by the World Health Organization (WHO), prevail in tropical 
and sub-tropical regions of the world and affect more than 1 billion individuals in 149 countries. Those 
most affected by NTDs are people living in poverty, living without adequate sanitation, and living in close 
proximity to disease vectors and/or livestock. These impoverished individuals lack a strong political voice 
when administrators determine public health priorities, relegating them to rely on philanthropic efforts from 
the WHO and pharmaceutical companies for disease control. Effective control often relies on mass drug 
administration (MDA), population screening, and vector control. These methods have proven successful 
in many isolated cases, such as the mass deworming campaigns in Nicaragua and the Philippines. 
However, the list of NTDs itself is unfortunately expanding rather than shrinking, with a group of fungal 
infections, a group of ectoparasitic (parasites such as fleas that live outside of the body) infestations, and 
snakebite envenoming being added in 2017. In this thesis, I will outline our recent endeavors to better 
understand Human African Trypanosomiasis (HAT). HAT is a devastating NTD that has been targeted for 
elimination by the WHO, perhaps over ambitiously due to its large animal reservoir and inefficient disease 
surveillance, by 2020.  
The eukaryotic protozoans of the Trypanosoma genus are ancient (Figure 1A), typically vector 
borne pathogens that parasitize a wide range of kingdom Animalia including fish, amphibians, ruminants, 
and humans. Humans and livestock are infected by members of the T. brucei clade (Figure 1B) after 
transmission by the bite of infected Glossina spp. (heretofore referred to as tsetse fly). The parasites that 
infect humans or bear important agricultural relevance are highlighted in Table 1 and Figures 1 and 2. 
After transmission to humans, Trypanosoma brucei rhodesiense and T. b. gambiense cause HAT in east 
and west Africa respectively. The WHO estimates that there are roughly 70 million at risk individuals and 
20,000 annual cases of HAT after accounting for presumed underreporting in the more remote regions of 
Sub-Saharan Africa (1,2). Despite the relatively low number of human cases, the WHO also reports that 
3-5 million bovines are killed annually by trypanosome infection, and the surviving infected animals are 
 2 
emaciated to such a degree that they are no longer of any practical use to farmers. The agricultural 
burden imposed by trypanosomes leads to a ~4 billion USD annual loss of potential gains and is therefore 
an enormous impediment to continental economic development (3). There remains a desperate need for 
novel methods to reduce this burden in animals and humans, with drug discovery efforts having stalled in 
recent decades. For example, infected cattle are commonly treated with a commercial injectable version 
of ethidium bromide (sold under the name ‘Homidium Bromide’), which is non-selective and potentially 
dangerous to the host and to subsequent human consumers given its ability to intercalate into any double 
stranded DNA. Human infections are treated with drugs that are specific to both the infective parasite 
species and the clinical presentation of the disease. There are some exciting clinical trials underway 
(Fexinidazole – recently approved for distribution (4) and Acoziborol – Phase 2/3 (5)). However, reports of 
drug resistance to virtually all trypanocidal compounds currently used in humans (6) highlight the need for 




















Figure 1. Trypanosoma phylogenetics. A) The tree shown was re-formatted from (7). Depicted is a 
Bayesian analysis of the consensus sequences of the citrate synthase gene in various species. 
Trypanosomes are more highly divergent from humans than all plants, fungi, Plasmodium (malaria) spp., 
and the amoebae (represented here by Dictyostellium). B) The tree shown was re-formatted from (8). 
Depicted is a maximum parsimony analysis of 55 Kinetoplastidae 18S ssu rRNA sequences. In some 
cases, multiple isolates from the same species were sequenced; for example, T. cruzi 1-5. Trypanosomes 
isolated from fish and amphibians form an ancient and distinct “aquatic” clade. The T. brucei clade 
contains the most common (and relevant to this thesis) human (red) and livestock (blue) -infective African 
trypanosomes. There are multiple sub-species of T. congolense, which are detailed in Table 1. T. godfreyi 
and T. simiae are apparently specific to pigs and have not been extensively characterized. The T. cruzi 
clade contains many intracellular human (pink) and animal-infective trypanosomes, including the 
causative agent of Chagas disease, T. cruzi, known as the American trypanosome. The more distant 
Leishmania spp. (pink) are also intracellular human pathogens, while the Crithidia genus is comprised of 
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insect pathogens. The Bodo and Trypanoplasma genera are commonly used outgroups for 
Kinetoplastidae phylogenetics. 
Table 1. The African Trypanosoma species that infect humans and livestock 
Parasite Species Main Host(s) Distribution Vector 
T. b. gambiense Humans Sub-Saharan Africa Tsetse flies 
T. b. rhodesiense Humans and bovines Sub-Saharan Africa Tsetse flies 
T. b. brucei Bovines and caprines Sub-Saharan Africa Tsetse flies 
T. congolense Bovines and caprines Sub-Saharan Africa Tsetse flies 
T. vivax Bovines, caprines, and 
equines 
Sub-Saharan Africa 
and South America 
Tsetse flies, horse flies, 
and stable flies 
T. evansi Bovines, equines, and 
camelids 
Africa, Asia, and South 
America 
Tsetse flies, horse flies, 
and stable flies 













































Figure 2. The global distributions of the most relevant human and livestock-infective African 
trypanosomes. The human-infective T. b. gambiense and T. b. rhodesiense are transmitted by tsetse 
flies and therefore are restricted to the distribution of the vector. The Glossina distribution map shows the 
range of the three main HAT vectors, G. palpalis, G. fuscipes, and G. morsitans. The distribution of T. b. 
brucei is also thought depend on the distribution of tsetse flies, although there is a lack of strong 
epidemiological data due to the fact that T. b. brucei is thought to make only a minor contribution to 
animal trypanosomiasis and it does not cause human disease. The human-infective T. b. gambiense 
prevails in west and central Africa, while T. b. rhodesiense prevails in the east. The two parasites are 
separated geographically by the rift valley, but also by the tsetse subspecies that more preferentially 
transmit each parasite. The countries are shaded to indicate the endemicity of HAT. The Democratic 
Republic of Congo (dark red) accounted for 76% of the 1447 confirmed cases of HAT in 2017. Countries 
contributing 5-10% of the total cases are shaded medium red, while countries contributing <5% of cases 
are shaded light red. Tsetse infested countries with either 0 cases (dark grey) or no available data (grey 
pattern) are also depicted. Uganda (the only shaded country in both maps) is historically the only known 
country where both T. b. gambiense and T. b. rhodesiense parasites are found, despite the absence of 
any cases caused by T. b. gambiense in 2017. The livestock-infective T. evansi and T. vivax have moved 
out of Africa through transmission by tabanid flies (horse flies) that are not restricted to the African 
continent. T. congolense is transmitted by the tsetse fly, although it has been reproducibly detected in 
certain game reserves and farming communities in the southern countries of Africa where small isolated 
tsetse populations (different species as compared to those depicted in the Glossina distribution map) are 
found. The diversity, distribution, and pathogenicity of the relevant trypanosomes was recently reviewed 
here (9). The distribution of T. equiperdum is not depicted, but is thought to be spread throughout Africa 
and Asia. The distribution is apparently difficult to pinpoint in part due to difficulties in diagnosing the 
infection and the fact that disease surveillance is limited to the identification of small isolated outbreaks in 
Asian, Middle Eastern, and European countries. The parasite is transmitted sexually between horses and 
causes a disease known as dourine.  
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2. Trypanosoma brucei biology and infection 
2.1. Life Cycle 
African trypanosomes are unicellular eukaryotic parasites (Figure 3A) with a complex life cycle 
that depends on both a vertebrate and invertebrate host. The T. brucei life cycle (simplified in Figure 4) 
begins when a teneral tsetse fly (newly born flies that have yet to take a blood meal) takes a blood meal 
from an infected mammal (10). The parasite infected blood is digested in the midgut, wherein the 
parasites differentiate into the procyclic stage (11). The procyclic cells must then traverse the thick 
peritrophic matrix surrounding the midgut by some uncharacterized mechanism(s) (11). Once across the 
peritrophic matrix, the procyclics differentiate into the mesocyclic morphotype and migrate to the 
proventriculous (11). The parasites then differentiate into the highly motile epimastigote morphotype that 
migrate to and attach to the walls of the salivary glands (11). In the salivary glands, the parasites divide 
asymmetrically to continually produce attached epimastigotes and free swimming mammalian infective 
metacyclic cells (11). The metacyclic cells are injected into the next mammalian host during the 
subsequent blood meal. The metacyclics differentiate into the bloodstream form (BF) that replicates in the 
blood and tissue spaces until they reach a critical concentration that triggers a recently characterized 
quorum sensing mechanism (12). Once the resulting signal, soluble molecules collectively coined stumpy 
induction factor (SIF) (13), has been detected by the population, the trypanosomes differentiate into the 















Figure 3. Trypanosoma bloodstream form cell architecture. A) False colored scanning electron 
micrograph of a T. b. brucei parasite laying on mouse epithelial tissue. Trypanosomes have a worm-like 
morphology which they use to undulate through the bloodstream and tissues of the mammalian host. 
Image credit to: Gilles Vanwalleghem, Daniel Montayne, and David Perez-Morga; Université Libre de 
Bruxelles. B) Illustration of the basic trypanosome organellar structure. The flagellum attaches to the 
kinetoplast in the flagellar pocket, which is at the posterior of the cell. The flagellar tip extends out from 







Figure 4. T. brucei life cycle. Trypanosomes undergo a multitude of morphological changes during their 
life cycle. Notably, not all of the changes are depicted here, nor are all of the changes conserved between 
the different members of the T. brucei clade (Figure 1). Indeed, this particular model is specific to T. b. 
brucei, T. b. rhodesiense, and T. b. gambiense. Tsetse flies ingest trypanosomes upon taking a blood 
meal from an infected host. Teneral tsetse flies are significantly more susceptible to trypanosome 
infection than flies that have taken prior blood meals. Successfully infecting trypanosomes differentiate 
into the procyclic stage in the midgut of the fly, and then differentiate into the epimastigote stage later in 
the cycle. Here, the nucleus repositions to the posterior of the flagellar pocket. The epimastigotes 
differentiate into the mammalian infective metacyclic cells in the salivary glands (the nucleus having 
returned to its original position), which are injected into the next host during a subsequent blood meal. 
Metacyclics rapidly differentiate into slender forms (also called bloodstream forms) that cause the disease 
in the mammalian host. Slender forms differentiate into stumpy forms in various locations of the host’s 
body, including the blood and tissue spaces, and must be present in the skin to be ingested by tsetse 
flies. Trypanosomes undergo sexual recombination within the tsetse host, making it the definitive host by 
definition. Humans and other mammals serve as the reservoir or intermediate hosts. This image was 
modified from a similar image of the life cycle, credit for which is due to Genome Research Limited.  
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2.2. Disease Symptoms 
 
Certain species of the relevant trypanosomes have significantly different niches within the 
mammalian host (14). T. b. gambiense has recently been identified as a predominantly skin-dwelling 
pathogen (15), explaining the observation that some infected individuals experience a constant and 
uncontrollable itching sensation. Although, many carriers of T. b. gambiense parasites do not present any 
symptoms and are essentially a parasite reservoir. T. congolense adheres to the inner walls of distal 
capillaries (16), although these early post-mortem observations should be validated by more precise 
techniques. T. b. brucei preferentially invades extravascular tissue spaces such as the adipose tissue 
(17), potentially explaining the cachexia (dramatic weight loss) that develops during infection. The 
cachexia has also been linked to tumor necrosis factor alpha (TNFα), also called cachexin, an 
inflammatory cytokine that is associated with weight loss in a variety of disease models.  
Animals infected with trypanosomes also develop a fever within a few weeks of infection, followed 
by anemia and edema. Similar symptoms are observed during human infections (18); however, humans 
eventually develop neurological complications after the parasites cross the blood brain barrier (BBB) and 
invade the central nervous system (CNS) (19). The mechanisms by which trypanosomes disrupt brain 
function are not understood, but the clinical manifestation of brain invasion is clear; Trypanosomiasis is 
now discernably recognized as a circadian disorder (20). Infected individuals have disrupted sleep-wake 
cycles, develop extreme lethargy, and eventually fall into a coma prior to death (21).  
2.3. Cell Biology 
The T. brucei genome has been sequenced, providing a useful resource to aid in our 
understanding of its biology and genome architecture (22). Despite being eukaryotes, T. brucei genes 
generally do not have introns and the majority of their genes are transcribed in polycistronic units that 
have a hypothetical average size of 55 genes per unit (23,24). The polycistrons are then ‘trans-spliced’ 
into individual transcription units, to which a splice-leader sequence and poly-A tail are added (25,26). 
Unlike bacterial operons, the genes expressed in the polycistronic units are often unrelated in function 
and therefore almost all Trypanosoma gene regulation is thought to be post-transcriptional (27). This and 
many other aspects of the trypanosome’s relatively primitive (Figure 1A) eukaryotic biology have made it 
a useful model organism for study. In particular, T. brucei motility, and its flagellum by association, has 
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been extensively investigated in part due to its rather elegant morphology (14). The flagellum spans the 
length of the cell body and remains attached to the plasma membrane (PM) (Figure 3B), such that the 
parasites swim by undulation. This chiral motility provides the torque required to move through the 
viscous blood and tissue spaces of the host (28). The flagellum is anchored in the flagellar pocket (Figure 
3B) by a complex of proteins that coordinate the flagellar attachment zone (FAZ) (29). The FAZ itself is 
anchored to the kinetoplast (Figure 3B), which is a mitochondrial DNA-containing organelle that is specific 
to trypanosomes and the closely related leishmania parasites (29). The kinetoplast consists of thousands 
of minicircles (1-10 kb each) and 40-50 maxicircles (20-40 kb each) of DNA that are concatenated into a 
densely-ordered network, making it the most structurally complex mitochondrial DNA storage unit found in 
nature (30). Most eukaryotes have hundreds to thousands of mitochondria per cell, while trypanosomes 
have a singular mitochondrion that spans the length of the cell (Figure 3B). In the mammalian host, the T. 
brucei mitochondrion plays a number of metabolic roles such as those involved in fatty acid synthesis and 
amino acid breakdown, although notably T. brucei ATP synthesis is almost exclusively glycolytic in the BF 
(31). Indeed, many genes required for oxidative phosphorylation are only expressed in the insect stage of 
the lifecycle, while the BF relies on glucose metabolism (32). Glycolysis occurs in a compartmentalized 
manner within specialized peroxisome-like organelles called glycosomes (Figure 3B), yet another 




3. Trypanosoma brucei vs. its mammalian host – immune response and evasion 
Perhaps the most well studied aspect of T. brucei biology is the function and regulation of the 
variant surface glycoprotein (VSG) genes, which encode proteins that form a very dense and antigenic 
surface coat at the PM of BF cells (34,35) (Figures 3B and 5A and C). Each BF cell is coated with ~5 x 
106 homodimers of VSG (36), which amounts to a staggering 10-20% of the cell’s total protein content 
(37). The density of the coat is thought to mask the presence of the invariant surface proteins from 
immune recognition (37) (Figure 5C). Indeed, the most well understood role that VSG plays in 
trypanosome biology is immune evasion. To prevent immune clearance, trypanosomes express only 1 of 
~2000 VSG alleles at a time (38). VSGs are transcribed from 1 of 15-20 polycistronic expression sites 
located in the subtelomeric regions of a subset of their chromosomes, although silent VSG genes are 
stored throughout the genome (39). Their genome consists of 11 diploid chromosomes and ~100 
intermediate and mini-chromosomes that mostly contain arrays of silent or pseudogenized VSG genes 
(22,40). During the infection, individual parasites stochastically switch VSG genes either by suppressing 
the active subtelomeric locus and activating another (41), or by recombining a stored VSG into the active 
locus (42) in order to evade the humoral immune response. The latter mechanism can also result in the 
formation of “mosaic” VSGs, which are combinations of VSG genes that recombine together to form a 
functional open reading frame (ORF) and produce completely novel and antigenically distinct proteins 
(43,44). This endless cycle of VSG switching events and antibody responses renders the adaptive 
immune system obsolete – an unwinnable war. 
VSG monomers are 50-60 kDa proteins that bear little to no amino acid sequence homology. All 
T. brucei VSGs have a small C-terminal domain connected to the PM via a GPI-anchor and a large N-
terminal domain that extends out into the extracellular space (45,46). Most VSGs are N-glycosylated with 
up to 3 glycans, which are thought to play a role in filling the spaces between adjacent homodimers (47) 
(Figure 5B and C). This extremely dense glycoprotein network provides the parasite with a physical 
barrier that prevents antibodies from efficiently binding to anything other than the VSG itself (Figure 5C). 
The VSG N-terminal domain is the antigenic portion that interacts with host-generated antibodies (48) 
(Figure 5C). Certain VSG N-terminal domains are also heterogeneously O-glycosylated at the apical tip 
(49) (Figure 5B). To clarify, a parasite expressing the O-glycosylated VSG3 is coated in VSGs that have 
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from zero to three glycans attached to the apical serine, thereby creating a heterogeneous coat that 
hypothetically requires a more elaborate antibody response to be cleared (49). Indeed, mice infected with 
VSGs that have apical O-linked glycans are more susceptible to the infection than those infected with 
non-glycosylated mutants (49). These structural properties of VSG were identified via X-ray 
crystallography. However, only 3 VSGs have been crystallized and our understanding of the surface coat 
in physiological settings is based largely on in silico models, highlighting the lack of any robust structural 
understanding of the T. brucei PM – the interface between the parasite and the immune system (48).  
Interestingly, antibody-bound VSGs are rapidly endocytosed in order to clear and destroy the 
antibodies, while the VSG is simultaneously recycled back to the PM, adding another layer of complexity 
to the mechanisms by which trypanosomes prevent effective host immune function (50). This mechanism 
is thought to be based on the hydrodynamic drag that the extracellular milieu exerts on the extended 
antibodies – a molecular sail (50). The flagellar pocket, the site of all endocytosis by the parasite, is 
located at the posterior of the cell. As trypanosomes swim, hydrodynamic forces ‘push’ the antibody-VSG 
complexes toward the pocket, thereby increasing the likelihood of being taken up. Parasites genetically 
engineered to only swim backwards are unable to digest VSG-bound antibodies, which consequently 






Figure 5. The T. brucei variant surface glycoprotein. A) Transmission electron micrograph of a cross 
section of a T. brucei bloodstream form trypanosome. F: flagellum; CB: cell body. The VSG forms a 15-
nanometer thick electron-dense coating around the entire cell. Image taken by Vickerman and Luckins 
(35). B) Ribbon structures of the crystallized VSGs 2 (left – PDB ID: 1VSG) and 3 (right – PDB ID: 6ELC). 
The green space-filling models are the N-linked glycans at the base of the VSG structure, while the red 
space-filling model is the O-linked glycan unique to VSG3. Both VSGs are shown in crystallized form; 
VSG2 crystallizes as a homodimer, while VSG3 crystallizes as a monomer. It remains unknown whether 
VSG3 exists as a monomer in vivo. Not pictured is a significant portion of the C-terminal domain and the 
GPI-anchors. Despite the lack of any amino acid sequence homology, both VSGs assume relatively 
similar structures including a wide and glycosylated basal end, a wide and disordered apical tip, and a 
narrow alpha helical core. C) A model of a VSG2-based surface coat interacting with an immunoglobulin 
G antibody (PDB ID: 1IGT). The packing and size of the VSGs prevent the antibody from accessing the 
surface of the cells. One can also appreciate that the size of the antibody is potentially significant enough 











Antigenic variation and antibody clearance from the PM are the most well understood 
mechanisms by which trypanosomes evade the mammalian immune response; however, the immune 
response to trypanosomes itself is highly complex and still poorly characterized. For example, T. brucei 
immunity in mice is heavily dependent on the pro-inflammatory cytokine TNFα (51,52) (although the 
mechanism of this dependence remains highly contentious despite being initially observed two decades 
ago (51,52)), whereas TNFα is apparently not required for immunity to the closely related T. evansi (53). 
More focus has centered around the humoral response given the early observation that trypanosome 
infections are cyclical in nature, with parasitemia rising and falling periodically. BF parasites divide 
logarithmically until they differentiate into the quiescent SF, and then parasitemia falls as the host 
antibody response clears the cells that have not switched VSGs. Clearance may be partially mediated by 
antibody-dependent complement-activity, although the relevance of complement-mediated lysis in vivo 
has been questioned (54). Many investigations have revealed that trypanosomes can be lysed by 
complement in vitro (55,56), while many others have shown that trypanosomes have specific complement 
inhibition mechanisms (50,57,58). Further, C5 knockout mice, which cannot form the lytic membrane 
attack complex (MAC), control parasitemia as well as their wild-type counterparts when infected with the 
murine pathogen T. lewisi (59). Complement factors are also important for opsonization and 
phagocytosis, which has also been observed in the context of trypanosomes. The primary mechanism of 
parasite clearance is thought to be phagocytosis by macrophages and neutrophils in a complement and 
antibody-dependent manner (54,60-62).  
Experiments using various murine strains have revealed that the class of antibodies that plays the 
most significant role in T. brucei clearance is immunoglobulin M (IgM) (53,63,64). The IgMs elicited by T. 
brucei infection are VSG specific, although notably they are produced by a T cell-independent mechanism 
in mice (65). Functional T cells are completely dispensable for T. brucei immunity in mice (65,66), 
suggesting that B cells are stimulated by trypanosomes directly. Direct stimulation of B cells by antigens 
has been reported, occurring when B cell receptors (the membrane bound isoform of IgM) are 
simultaneously bound to antigen at one zone of the PM such that B cell receptor clustering initiates a 
signaling cascade resulting in activation (67). Trypanosomes are hypothesized to stimulate B cells via this 
mechanism by providing the densely packed VSG required to form an immunological synapse with 
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clustered B cell receptors (62). For this to occur, B cells with receptors that can bind to VSG must already 
be present in the host prior to exposure to the parasites. This is indeed the case, as Muller et al., have 
clearly demonstrated that germline existing IgM antibodies from various species including humans and 
mice can interact with VSGs (68). In fact, some of the mice used in these studies were germ-free animals, 
thus formally revealing that VSG-binding B cells exist in completely foreign antigen stimulus-independent 
immune systems (68). These naturally occurring B cells produce what are called germline antibodies 
(NAbs) which are pre-encoded in the germline (69). NAbs often cross react with many structurally similar 
antigens with low affinity and are thus capable of a wide range of important functions (69). For example, 
some NAbs can interact with intracellular host proteins, suggesting that they may be involved in the 
clearance of apoptotic debris (70). Interestingly, many of the anti-VSG NAbs that exist in humans also 
interact with a variety of antigens from human cell lysates (68), suggesting that the pre-existing anti-VSG 
specific antibodies may have evolved completely irrespective of trypanosome infection. Nevertheless, the 
available data supports the hypothesis that polyreactive NAbs are a component of the immune response 
to T. brucei infection.  
The classical description of the humoral immune system involves the activation of antibody 
producing B cells, some of which then differentiate into memory B cells to prime the host against 
secondary infections by the same pathogen (71). An effective immune response to trypanosome infection 
involves B cell activation and antibody production. However, whether immunological memory is ever 
established is unknown, invoking another poorly understood mechanism by which trypanosomes evade 
the immune system of the vertebrate host – lymphocyte suppression. Early in vitro observations using 
purified T and B cell populations from T. b. brucei infected mice revealed that lymphocyte activity is 
strongly reduced by infection (72). Consequently, infected mice are incapable of generating specific 
antibody responses to foreign antigens after being infected with T. b. brucei for more than 7 days (73). 
Radwanska et al. investigated this phenotype more elaborately via fluorescence-associated cell sorting 
(FACS), revealing that particular populations of B cells become apoptotic and are subsequently depleted 
by T. b. brucei infection in mice (74). Although a direct mechanism has yet to be identified in vivo, the 
same group of investigators observed that direct contact between T. b. brucei and B cells in vitro leads to 
apoptosis of the B cells (75). They hypothesize that parasite-dependent, potentially contact-dependent, 
 16 
depletion of immature and transitional B cells in vivo prevents the host from repopulating the mature B 
cell compartment that is exhausted by the infection (75). Strikingly, the B cell depletion results in an 
inability to generate novel memory responses or maintain pre-established responses. Using the 
diphtheria, tetanus, and pertussis (DTaP) vaccine model, Radwanska et al. revealed that mice lose their 
immunity to Bordatella pertussis infection if they are challenged with T. b. brucei after being vaccinated 
(74). This discovery prompted the hypothesis that trypanosome infection may essentially reset the 
immune system of the host, suggesting that infected humans may need to be re-vaccinated against 
common pathogens post-cure (54). Given the potential implications, investigators have recently 
attempted to determine whether this effect is either trypanosome species-specific or host species-specific, 
since all previous studies had used T. b. brucei infected mice. T. b. gambiense infected humans were 
found to have significantly higher T-independent memory B cells than uninfected controls, suggesting that 
B cell depletion was not occurring (76). These patients also had anti-measles antibody titers that were 
within the range expected to provide viral immunity indicating that pre-existing memory responses 
(derived from the measles vaccine in this case) were not being abolished (76). Similar observations were 
then made using T. b. gambiense infected mice (77), suggesting that whatever mechanisms T. b. brucei 
(and both T. vivax (78) and T. congolense (79,80)) use to manipulate the host B cell compartment must 
not be present in T. b. gambiense. T. b. gambiense causes either asymptomatic or chronic infections in 
humans and is therefore thought to be a relatively avirulent parasite compared to, for example, T. b. 
rhodesiense which causes highly virulent acute infections. It remains to be determined whether T. b. 




4. Trypanosome lytic factor 
4.1. Overview 
Trypanosome lytic factors (TLFs) (Figure 6) are serum-circulating antimicrobial protein complexes 
produced in nature by only a subset of primates. This subset consists of sooty mangabeys, mandrills, 
baboons, gorillas, and humans (81,82) (Figure 7). Humans have the most well characterized TLFs, which 
are now recognized as a subset of high-density lipoproteins (HDLs) that harbor the primate-specific 
protein Apolipoprotein L-1 (APOL1) (Figure 6). Multiple cell types produce APOL1, at least at the RNA 
level, although the protein is likely only secreted by hepatocytes in vivo. After secretion, APOL1 is loaded 
onto HDL complexes that circulate in the blood, and may reach extravascular tissue spaces, where it can 
interact with trypanosomes. 
APOL1 is a cation channel-forming protein (83) that likely acts as a general antimicrobial innate 
immune factor. APOL1 restricts Leishmania infection in vitro and in vivo (84), limits HIV replication in vitro 
(85), lyses E. coli and B. subtilis bacteria in vitro (Almanzar and Raper; unpublished data), and is 
upregulated by inflammatory cytokines (86), all suggesting that it plays a role in immunity to infection by 
multiple pathogens. The most well established function of APOL1 is its capacity to mediate sterile 
immunity to infection by T. b. brucei and related species through its ion channel forming function after TLF 
is endocytosed by the parasite. Parasites that can infect humans have evolved TLF resistance 
mechanisms that are well characterized. However, the basic mechanistic question of how APOL1 lyses 
the non-infectious T. b. brucei remains contentious. One group hypothesizes that APOL1 is trafficked to 
the mitochondrial membrane after uptake, leading to mitochondrial depolarization and apoptotic-like death 
(87). The opposing model hypothesizes that APOL1 is rerouted to the PM after uptake, and is based on 
experiments revealing that the ion channel forming function of APOL1 is a 2-step process requiring an 
initial exposure to endosomal pH (below pH 6.0) followed by subsequent neutralization (above pH 7.0) 
(83). Whether the ion channels are formed at the PM or within intracellular organelles, the underlying 
requirements of APOL1 internalization and its channel activity are common themes between the two 




Figure 6. Trypanosome lytic factors are modified high-density lipoproteins. A) Illustration depicting 
HDL maturation. The structural HDL protein apolipoprotein A-I (APOA-I) is synthesized primarily by the 
liver. APOA-I dimers are partially loaded with lipid and cholesterol in the liver to form pre-beta HDL. These 
“immature” HDL complexes then collect lipid and cholesterol from distant locations of the body, converting 
into mature/spherical HDL before returning to the liver, which processes the collected material. This 
image was adapted from Kratzer et al., Cardiovascular Research, 2013. B) Illustrations depicting possible 
HDL and TLF structures. Top: A mature HDL with various HDL proteins. HDLs are dynamic in that many 
proteins can be present on HDL at any given moment, and proteins and lipids can be exchanged between 
various HDL species. The HDL proteome contains upwards of one hundred individual proteins (89). 
Middle/Bottom: Some possible structures of TLF. It remains unclear whether TLFs are mature HDLs or 
pre-beta HDLs. However, the known TLF proteome consists of only 7 proteins, suggesting that they are 
not as dynamic as total HDL and that they do not participate in protein/lipid exchange with other HDL 
species. The TLFs represented here either do or do not contain HPR because only half of the plasma-
circulating TLF contains both APOL1 and HPR (90). C) Two-dimensional illustrations representing the 
same complexes from B. The second-from-the-bottom image (TLF with APOL1 and HPR depicted as a 





Figure 7. TLFs are only present in a subset of primate species. This evolutionary tree is not drawn to 
scale, nor does it contain all characterized great apes or Old World monkeys. Estimated divergence 
times, represented as millions of years ago (MYA), are based on genetic studies from (91). Depicted in 
green are the primates known to have both the APOL1 gene and trypanolytic serum. The APOL1 gene 
arose in a common ancestor of great apes and Old World monkeys, and has since been subjected to 
deletion and pseudogenization events in certain species. Some of these species are depicted in black 
with partially green and partially black branches to indicate that the ancestor that lost the gene must have 
existed after the divergence points on the tree. Importantly, there is no evidence that the APOL1 gene or 
trypanosome lytic factors are present in any species that diverged from the human lineage prior to the Old 




4.2. TLF Endocytosis by Trypanosomes 
Trypanosomes are heme auxotrophs and must thereby scavenge heme from their mammalian 
host in order to maintain functional heme group-containing proteins (92). Mammalian heme is bound to 
hemoglobin (HB) inside red blood cells (RBCs). After RBCs rupture, HB is released into the plasma and 
bound by the HB-binding plasma protein haptoglobin (HP) (93). To prevent iron-induced oxygen radical-
mediated toxicity, HP-HB complexes are cleared from the plasma by the macrophage receptor CD163 
(94). T. b. brucei parasites have evolved a HP-HB receptor (HPHBR) that binds to HP-HB complexes and 
triggers the uptake of the heme (95,96). A gene duplication product of HP in primates called haptoglobin-
related protein (HPR) (97) associates with TLFs via a retained signal peptide (98). HPR also binds HB, 
although HPR-HB complexes are not bound by CD163 due to polymorphisms in the receptor-binding 
domain of HPR (99). However, HPR-HB complexes are bound by the parasite HPHBR which facilitates 
APOL1 uptake into the parasite (95) (Figure 8). The significance of this receptor to APOL1 uptake has 
been validated by RNAi screening, wherein it was revealed that trypanosomes resist lysis by TLF when 
not expressing the receptor (100). However, only approximately 50% of the serum circulating TLF1 
complexes contain HPR (Figure 6) (90), while the other 50% are HPR-free and therefore are likely taken 
up by fluid phase endocytosis. Fluid phase uptake of extracellular molecules is a less efficient process 
compared to receptor-mediated uptake, which concentrates the TLF at the plasma membrane prior to 
each endocytic event, making HPR and APOL1-containing complexes the most potent trypanolytic factors 
in parasites expressing a functional HPHBR. Nevertheless, this receptor and these screens do not deliver 
a complete story.  
Human serum harbors two distinct trypanolytic factors (101) (Figure 8). TLFs 1 and 2 both contain 
APOL1 and HPR, although only TLF1 binds to and is thus endocytosed by the HPHBR (102). The 
HPHBR binds to both HP-HB and HPR-HB and therefore HPR-dependent TLF1 endocytosis is inhibited 
by adding HP-HB to the assays (102). The concentrations of HP-HB required to block trypanolysis are 
within the physiological range that exists in human sera (102), suggesting that TLF1 may be irrelevant to 
trypanosome immunity in individuals with physiological HP levels in vivo (Figure 8). HP-HB was unable to 
block TLF2-mediated trypanolysis, supporting the long-standing hypothesis that TLF2 is the dominant 
trypanolytic factor in normal human serum (NHS), and that TLF1-mediated lysis is likely to predominate 
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only when circulating HP levels are depleted (102). These biochemical experiments were later supported 
by reverse genetics, revealing that genetic ablation of the HPHBR from T. b. brucei increased T. b. brucei 
resistance to TLF1 by 10,000-fold, while resistance to TLF2 was increased by only 500-1000-fold (103). 
These data together strongly suggest that there is another, to date uncharacterized, APOL1 delivery 
mechanism that is specific to TLF2-mediated trypanolysis. One group unsuccessfully used an RNAi 
screening approach in an attempt to identify the delivery mechanism in question (104). However, these 
attempts were unlikely to succeed for a number of reasons. TLF2 is a protein complex that rapidly loses 
its specific activity with freeze thaw, is unstable, and is highly sensitive to proteolysis (101), making long-
term genetic screens untenable. Furthermore, genetic screens are unable to resolve high-confidence hits 
if the gene being investigated cannot be manipulated without killing the cell. All of these confounding 
factors aside, we must acknowledge that to fully understand how NHS lyses T. b. brucei parasites, we 
must determine how APOL1 is delivered to trypanosomes in a physiologically relevant setting (Figure 8).  
The only well-characterized distinguishing characteristic that separates TLF2 from TLF1 is a non-
covalent association with IgM antibodies (101). TLF1 is a 500 kDa complex, while the inclusion of IgM 
renders TLF2 significantly larger (> 1000 kDa) (101). Purified TLF2 samples contain both lambda and 
kappa Ig light chains, defining the TLF2-IgMs as a polyclonal species (101). It remains unknown how the 
IgMs associate with the TLF or whether they play any role in TLF function or trypanosome immunity. It 
has been proposed that the TLF-associated IgMs may play some role in the TLF2-specific uptake 
mechanism, although no data supports this or any other hypothesis (88). This controversy will be 
comprehensively examined in Chapter 1, wherein we hypothesize that the TLF2-IgMs are polyreactive 
NAbs that can interact with both the TLF and the surface of the parasite (Figure 8), likely through binding 










Figure 8. Trypanosome lysis mediated by TLFs 1 and 2. The black curved shape in each panel 
depicts the plasma membrane of the flagellar pocket of the trypanosome, while the pink circles depict an 
acidic endosome (pH < 6.0) within the parasite. Top left panel: The HPR-HP component of TLF1 is bound 
by the HPHBR, triggering uptake of the complex. APOL1 is delivered to the acidic endosome where it 
then integrates into the membrane before being recycled to the plasma membrane to form open ion 
channels upon neutralization (pH 7.0 or higher) of the environment. These channels are permissible to 
cations, represented here by sodium. Top right panel: TLF1-mediated lysis is blocked by physiological 
concentrations of HP (concentrations that reflect the average amount of HP present in healthy human 
serum). Efficient lysis of the parasites is therefore inhibited. Bottom left panel: Lysis mediated by TLFs in 
physiological setting is predominantly mediated by TLF2 (a TLF1 with an immunoglobulin M bound to it). 
 23 
TLF2 is endocytosed by a not yet characterized mechanism, which we hypothesize to be driven by an 
interaction between the IgM component and some epitope on the surface of the parasite.  
4.3. APOL1 Function 
 Both TLFs 1 and 2 are protein complexes that deliver APOL1 to the endocytic compartments of 
the trypanosome such that the APOL1 can form pH-dependent ion channels within the membranes of the 
parasite, leading to lysis. APOL1-mediated trypanosome lysis can be efficiently inhibited by pre-treating 
the parasites with the weak bases chloroquine or ammonium chloride, which neutralize the endocytic 
compartments, promoting the hypothesis that APOL1 acidification is required for ion channel activity 
(102). This hypothesis is supported by recent RNAi studies, revealing that each subunit of the 
trypanosome vacuolar ATPase, which is responsible for acidifying the endolysosomal compartments, is 
required for APOL1-mediated lysis (104,105). Using purified human TLF1 and reconstituted planar lipid 
bilayers, Molina-Portela and Raper also demonstrated that APOL1 could generate a weak ionic flux at pH 
5.5, suggesting that ion channels were being formed in the planar lipid bilayers (106). Since then, the 
mechanism by which APOL1 forms ion channels has been studied almost exclusively in vitro using 
purified recombinant protein produced in E. coli. Using this system, Thomson and Finkelstein 
demonstrated that APOL1 inserts into lipid membranes under acidic conditions and generates a weak 
ionic flux, but that the ion flux is increased 100 to 200-fold after subsequent neutralization of the 
environment (83). These experiments suggested that under physiological conditions, APOL1-mediated 
lysis must require a neutralization step after membrane insertion, which is likely to occur at the PM.  
Further investigation revealed that these pH-gated ion channels are permissible to monovalent 
and divalent cations, including Na+ (83) (Giovinazzo, Thomson, and Raper; unpublished data). APOL1 
uptake leads to a Na+ influx in trypanosomes which initiates a chain reaction of ion flux across the PM, 
ultimately leading to osmotic swelling and lysis (106,107). Importantly, TLF-mediated lysis can be 
inhibited by manipulation of the extracellular ions, such as the replacement of Na+ with choline, a much 
larger monovalent cation that is hypothesized to be unable to fit through the ion channel (106). 
Trypanolysis can also be inhibited by adding osmotically active sucrose to the extracellular space, 
thereby preventing the osmotic imbalance resulting from ion flux (107). These data strongly support the 
hypothesis that the active ion channels formed by APOL1 are in the PM of the trypanosome (Figure 8). 
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However, the lack of any microscopic evidence that APOL1 is recycled to the PM remains a confounding 
factor to consider.  
The opposing model of trypanolysis, whereby APOL1 is thought to be delivered to the 
mitochondria, is derived almost entirely from reverse genetics and microscopy. APOL1 was visualized in 
small quantities in the mitochondria of trypanosomes, which preceded mitochondrial membrane 
depolarization (87). RNAi screens determined that the mitochondrial dysfunction is dependent on the 
function of a particular kinesin protein that participates in retrograde transport and is thought to traffic 
APOL1 from the endolysosomal system to the mitochondrial membrane (87). While these data cannot be 
discounted, it must be noted here of the fact that these studies utilized exclusively recombinant free 
APOL1 which does not occur in physiological settings. APOL1 is associated with TLF in humans and may 
therefore behave differently than free APOL1. Indeed, more recent RNAi screens have revealed that the 
kinesin in question bears no relevance to TLF-mediated lysis and is exclusively associated with free 
recombinant APOL1-mediated lysis (105).  
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5. The Arms Race Between Primate TLFs and Trypanosomes 
5.1. Overview of the APOL Gene Family 
The vast majority of genes in higher eukaryotes are subjected to purifying selection, whereby 
housekeeping genes such as actin remain highly conserved, maintaining functions that are crucial for cell 
survival (108). Mutations that arise in these housekeeping genes are typically deleterious, and as such 
are not maintained in the population. APOL1 is not one of these genes. Instead, APOL1 is subjected to 
positive selection, which is common to genes that play roles in pathogen immunity (82). Genes involved 
in host-pathogen interactions that are subjected to positive selection are likely involved in some form of 
molecular arms race with one or multiple genes from a pathogen(s) (108), a concept commonly referred 
to as the Red Queen hypothesis (109). APOL1 is a member of a gene family encoding APOLs1-6, which 
are all under strong positive selection in the primate lineage, suggesting that they all play roles in 
pathogen immunity (82). All APOLs are upregulated by inflammatory signaling pathways (86,110-112), 
although APOL1 is the only family member with a signal peptide, indicating that APOLs2-6 likely play 
some roles in intracellular immunity. This hypothesis is supported by the observation that APOL6 
provides protection against poliovirus infection, although a direct mechanism has not been identified 
(111). No other APOL genes besides APOL1 have been extensively investigated in physiological settings, 
although Fontaine et al. have demonstrated that purified recombinant APOL3 can lyse T. brucei when 
incubated with the parasites in vitro, at least suggesting that it has the capacity to lyse T. brucei cells 
(113). 
5.2. The Origin of APOL1 
APOLs5 and 6 are ancient genes that have distant orthologs in many mammals, while APOLs1-4 
are entirely primate specific and arose through a pattern of gene duplication (82). The APOL1 gene arose 
through gene duplication of an ancestral APOL1/2 hybrid gene approximately 24 million years ago, pre-
dating the divergence of modern Old World Monkeys (OWM) and great apes (Figure 7) (82). Since the 
appearance of APOL1, it has been subjected to a series of duplication, pseudogenization, and deletion 
events. For examples, both chimpanzees and bonobos have deleted the entire APOL1 ORF; orangutans 
encode a truncated APOL1 that has not been characterized; macaque APOL1 has been completely 
pseudogenized; and baboons encode four copies of APOL1, three of which are pseudogenes (82) 
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(Baboon Genome Project). It remains unclear which pathogens or other evolutionary pressures are 
selecting for these mutations within the APOL1 gene, although one could hypothesize that APOL1’s ion 
channel-forming function could be a deleterious one if not properly regulated. In the case of the 
chimpanzee for example, the selective benefit of being immune to T. b. brucei infection may not have 
been as favorable as deleting the APOL1 gene if the gene product had become too toxic in that species. 
APOL1 toxicity could be stimulated by species-specific viral pathogens, such as the acquired 
immunodeficiency syndrome (AIDS) causing lentiviruses, simian immunodeficiency virus (SIV) for 
example, since viruses drive strong interferon responses by the host immune system that could 
upregulate the expression of the putatively toxic APOL1.  
Many primate APOL1 sequences have not yet been identified or characterized due to a simple 
lack of available genome sequences or biological samples. However, Lugli et al. were able to reveal that 
gorillas, sooty mangabeys, mandrills, and baboons all possess trypanolytic serum suggesting that they 
possess APOL1 genes (114). There have since been APOL1 sequences published for one gorilla and 
three baboons, while the mandrill and sooty mangabey sequences are incompletely assembled (81). The 
human and gorilla APOL1 sequences share 98% amino acid identity, while the OWM APOL1 is a highly 
divergent sequence that shares only 59% amino acid identity relative to human (81). For comparison, 
both the APOA-I and HPR proteins from humans and OWMs share >95% amino acid identity (Verdi and 
Raper, unpublished data) (114). The high degree of dissimilarity between human and OWM APOL1 
prompts the hypothesis that they may have significantly different mechanisms of action (Chapter 2) or 
functions, discussed below.  
5.3. APOL1 Resistance in Human-Infective Trypanosomes 
Humans, despite expressing APOL1, are infected by T. b. gambiense and T. b. rhodesiense. 
Both parasites have independently evolved human APOL1 resistance mechanisms that prevent TLF-
mediated lysis. T. b. rhodesiense parasites evolved an APOL1-binding protein called serum resistance 
associated (SRA) protein (115,116). Ectopic expression of SRA is sufficient to mediate full protection from 
TLF-mediated lysis in T. b. brucei in vitro (116). Anecdotally, a laboratory technician was accidentally 
infected with an SRA-expressing T. b. brucei strain, formally confirming that the human infectivity of T. b. 
rhodesiense is a direct result of the evolution of SRA (117). SRA interacts with the C-terminus of human 
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APOL1 and prevents its ion channel-forming ability (81,118). It remains unclear how this binding event 
inhibits ion channel formation at a molecular level, although planar lipid bilayer experiments have 
conclusively revealed that APOL1 cannot form membrane ion channels in the presence of SRA (83). SRA 
is a membrane bound protein that localizes predominantly to the acidic endocytic compartments of the 
parasite (118-120). Immunoprecipitation assays and surface plasmon resonance (SPR) experiments 
determined that the SRA-APOL1 binding event requires acidic pH, suggesting that APOL1 is bound by 
SRA in the acidic vacuole and that this binding event must occur prior to ion channel formation (81). The 
binding event is thought to be a coiled coil interaction between the APOL1 C-terminal alpha helices and 
an N-terminal alpha helix of SRA (121). Once bound, SRA may either drag the APOL1 to the lysosome 
for proteolytic degradation, or it may recycle the APOL1 to the PM and release the APOL1 protein into the 
extracellular space upon neutralization.   
SRA is a GPI-anchored VSG-like protein that evolved through gene duplication of an ancestral 
VSG gene into one particular VSG expression site upstream of the VSG ORF (116). This restricts 
trypanosome VSG switching to some degree in that they are only able to express the single SRA-
containing expression site in the presence of human serum (116). As a result, many strains of T. b. 
rhodesiense isolated from animals have APOL1-sensitive phenotypes, because the SRA gene was not 
required and therefore the SRA-containing expression site was not expressed during the infection. VSG 
expression sites also encode 5 to 15 expression site associated genes (ESAGs), some of which have 
been characterized (122). For example, the trypanosome transferrin receptor (also derived through VSG 
duplication) is a heterodimer encoded by ESAGs 6 and 7 (123). The SRA-containing expression site 
encodes only SRA, a VSG, the transferrin receptor, and the uncharacterized ESAG5 (116). T. b. 
rhodesiense cells expressing SRA grow at the same rate as cells expressing VSG via a complete 
expression site (116). Nevertheless, SRA expression is readily lost in the absence of human serum (116), 
raising the possibility that SRA expression is associated with some as yet undefined fitness cost. This is 
supported by multiple lines of evidence including a set of unsuccessful attempts to knockout the nuclear 
protein ESAG8 in T. b. brucei, suggesting it is essential for survival at least in the particular strain of 
parasites used in these experiments (124,125).  
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 APOL1 resistance in T. b. gambiense relies on the combinatorial effect of multiple genes. 
Mutations in the HPHBR reduces its binding affinity for HP(r)-HB complexes, thereby reducing TLF1 
uptake (126-128). Expression of the T. b. brucei variant of the HPHB receptor in T. b. gambiense 
parasites restores receptor-mediated endocytosis of TLF1, although it is not sufficient to restore TLF-
mediated lysis (129). This is hypothesized to be primarily due to another APOL1-resistance factor called 
the Trypanosoma gambiense-specific glycoprotein (TgsGP). TgsGP (yet another gene derived through 
VSG duplication (130)) is a hydrophobic protein that has the capacity to modify the curvature of lipid 
membranes, at least in vitro, which is hypothesized to ‘stiffen’ the endocytic membranes of the parasite 
(129). This membrane stiffening would act as a physical barrier for APOL1, thereby preventing insertion 
and ion channel formation. Notably, neither TgsGP expression nor HPHBR deletion in T. b. brucei is 
sufficient to mediate complete resistance to human TLF, suggesting that more factors are involved (129).  
Hypothetically, T. b. gambiense parasites would only need to prevent APOL1 from inserting into 
the membranes long enough to allow the lysosomal proteases to destroy the toxic protein. The lysosomal 
protease Cathepsin-L (CATL) was identified as an APOL1 resistance factor by RNAi screening (100). 
Interestingly, pharmacological inhibition of CATL in T. b. gambiense lead to increased TLF susceptibility, 
although CATL inhibition in T. b. brucei had no effect (129). This suggested that increased CATL 
activity/dependence is another T. b. gambiense-specific APOL1 resistance factor. The mechanism by 
which CATL activity is increased has yet to be conclusively determined, although T. brucei Cathepsin 
activity is pH dependent (131). The authors calculated that the predicted average pH of the endosomal 
compartments of T. b. gambiense is significantly lower than that of T. b. brucei, possibly explaining the 
increase in CATL activity in T. b. gambiense. However, how the lower pH is maintained was not identified, 





Figure 9. Resistance to TLF-mediated lysis by the classically human-infectious trypanosomes. 
Left: Human TLF resistance by T. b. rhodesiense is mediated exclusively by the SRA protein. SRA binds 
to the C-terminus of APOL1 in the acidic compartments of the endocytic pathway and prevents functional 
ion channel formation. APOL1 is either dragged to the lysosome (not shown) or released into the 
extracellular space upon neutralization after endocytic recycling. Right: Human TLF resistance by T. b. 
gambiense is multifactorial. Mutations in the HPHBR reduce binding to TLF1, thus reducing some of the 
APOL1 uptake. The TgsGP protein localizes to the endocytic compartments where it is thought to prevent 
channel formation by modifying the rigidity of the endosomal membranes. The parasite also has more 
acidic endosomes (represented by the darker coloration of the vesicle) which potentially increases the 





5.4. “Atypical” APOL1 Resistance in Trypanosomes 
Human serum resistance has clearly evolved in trypanosomes more than once, although it 
remains unclear exactly how many times it has occurred. There are multiple variants of both SRA and 
TgsGP, although it is likely that they each originated from singular ancestral gene duplication events 
(129). However, a separate series of human-infective parasites classified as T. b. gambiense group 2 
transiently emerged as important pathogens in the 1980s, causing epidemics in Burkina Faso and Cote 
d’Ivoire (132). The parasite may now be extinct in nature, although without systematic surveillance of all 
humans and animals, it is difficult to reach that conclusion (133). Genetic evidence suggests that T. b. 
gambiense group 2 is actually a recently-evolved human-infective strain of T. b. brucei, rather than a 
divergence from the T. b. gambiense group 1 lineage (132,133). Further, group 2’s TLF resistance 
mechanism is uncharacterized, although we understand that it does not depend on TgsGP (132), a 
dysfunctional HPHBR (134), or SRA (115,132), suggesting that it evolved human serum resistance 
independent of the classical human trypanosomes.  
  While only T. b. rhodesiense and the two groups of T. b. gambiense are recognized as human 
pathogens, evidence suggests that many more trypanosomes are capable of establishing human 
infections. Truc, et al. reviewed the history of “atypical human infections by animal trypanosomes” in 
2013, highlighting a number of case studies wherein humans were infected with classically animal-
infective African trypanosomes (135). The most famous case was that of an Indian farmer who was 
infected by the predominantly horse-infective T. evansi (136). The individual was found to have 
heterozygous non-sense mutations in both APOL1 alleles (136), prompting the hypothesis that APOL1 
protects humans from a wide range of African trypanosomes, as opposed to only the model T. b. brucei 
strains that had been tested prior. Indeed, APOL1 can lyse T. evansi (136) and even the more 
evolutionarily distant and livestock-infective T. congolense parasites (137). These and other experiments 
established the accepted dogma that APOL1 protects humans from infection by all African trypanosomes 
apart from the human-infective T. brucei subspecies (138). However, despite almost never establishing 
human infections, human serum-resistant isolates of T. congolense do exist in nature (139) and can be 
generated in laboratory conditions (140). Further, recent work has revealed that the typically rodent-
infective T. lewisi, which accounts for the majority of the case studies reviewed by Truc, et al. (135), is 
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completely resistant to APOL1-mediated lysis leading to its recent classification as a potential human 
pathogen (141). One could argue that the extremely low rate of human T. lewisi infections is due to 
something as simple as blocks in the transmission cycle between rodents and humans. However, this 
hypothesis cannot be applied to the livestock-infective parasites to which humans are frequently exposed 
through, for example, cattle farming. Evidence suggests that the widely distributed cattle-infective T. vivax 
may also be APOL1 resistant to some degree (113,142) (Chapter 3), suggesting that TLF is not likely the 
only primate-specific trypanosome resistance factor.  
5.5. Evolution in Action – Human APOL1 Polymorphisms 
Recently evolved human APOL1 polymorphisms are at the forefront of current research. In 2010, 
a landmark study identified particular mutations in the APOL1 gene that exist almost exclusively in 
individuals with recent African ancestry called genotype (G)1 and G2 (143). Relative to the most common 
human APOL1 variant (G0), G1 and G2 share one amino acid substitution at position 150, where a lysine 
is substituted by a glutamic acid. It remains unknown whether this polymorphism in particular impacts 
trypanosome immunity. G1 also has two amino acid substitutions (S342G and I384M) and G2 has an in-
frame two amino acid deletion (delN388 and Y389). These C-terminal polymorphisms generate human 
APOL1 proteins with the capacity to lyse T. b. rhodesiense parasites in vitro and in vivo by preventing the 
interaction between the C-terminus of APOL1 and the SRA protein (81,143). Surface plasmon resonance 
experiments using recombinant SRA and immobilized C-terminal fragments of APOL1 revealed that the 
binding affinities between G1/G2 and SRA are reduced by 2 and 5-fold respectively, relative to the 
binding affinity between G0 and SRA (81). However, the C-terminal fragments used in these experiments 
likely do not represent the interaction between the natively folded full-length APOL1 protein and SRA. 
Importantly, the “G1 fragment” only included the I384M substitution, making it impossible to draw firm 
conclusions. Nevertheless, these data taken together suggest that these human APOL1 variants may 
have been selected for by the evolutionary pressures posed by the human-infective trypanosomes.  
 A recent population study revealed that humans harboring the G1 and G2 alleles are indeed more 
resistant to human-infective trypanosomes (144). Individuals harboring a G2 allele are 5-fold less likely to 
be infected with T. b. rhodesiense parasites (144). G1 does not correlate with T. b. rhodesiense infection 
(144) which is consistent with experimental data revealing that G2 lyses SRA-expressing parasites 
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significantly more efficiently than G1 (81). Instead, G1 is associated with a 3-fold decreased risk of 
proceeding to the neurological stage of T. b. gambiense infection (144). These data remain an 
unexplained mystery, given that there is no evidence that G1 can directly lyse T. b. gambiense parasites 
in any system. Enigmatically, the G2 variant is associated with a 3-fold increased risk of proceeding to the 
neurological stage of T. b. gambiense infection, with no proposed mechanism (144).  
Another recent population study with similar statistical power (compared to ref 142) found no 
significant association between G2 and T. b. rhodesiense infection (145). The authors proposed that the 
APOL1 genotype of an individual must not be the only determining factor, and that other genetic factors 
may be more or less prominent depending on the population (145). The relationships between human 
genetics – APOL1-related or otherwise – and clinical trypanosome infection merit more consideration. No 
individual population study can tell the story of an entire continent given the relatively low number of 
sleeping sickness cases. To this end, The Human Heredity and Health in Africa (H3Africa) Consortium 
has established the TrypanoGEN project – a network of investigators tasked with filling a publically 
accessible biobank of trypanosome infected patient DNA samples to be used for genome association 
studies (146). Hopefully, this exciting new resource can be leveraged to help resolve the question of 
whether the APOL1 genotype is truly a major contributing factor in disease resistance.  
5.6. The Casualties of War – Dr. Joseph Giovinazzo’s Thesis in Two Paragraphs 
 Individuals with two copies of G1 or G2 (a “risk genotype”) have a significantly increased risk of 
developing various chronic kidney diseases (CKDs) (143). The currently circulating model is one of 
heterozygote advantage, whereby having one copy of G1 or G2 protects an individual from 
Trypanosomiasis and does not damage the kidneys, while having two copies leads to tissue destruction, 
similar to the infamous sickle cell anemia – malaria paradigm (144). An estimated five million African 
Americans and many more individuals in sub-Saharan Africa have a risk genotype (147). The risk of CKD 
associated with the risk genotype is compounded by HIV infection, suggesting that long term APOL1 
upregulation (mediated by inflammatory anti-viral signaling pathways) eventually leads to irreversible 
damage (148). The damage manifests as a loss of the terminally-differentiated podocyte cells which form 
the filtration barrier between the blood vessels and the urine-collecting tubules in the glomerulus (149). 
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The disease progresses as more and more glomeruli are lost, eventually forcing many patients onto the 
transplant list.   
The mechanism of podocyte injury is a hotly debated topic. APOL1 over-expression in in vitro cell 
culture systems has been shown to lead to cell death by a multitude of pathways including autophagy 
(150), apoptosis (151), pyroptosis (152), and stress-activated protein kinase signaling (153). There 
remains little consensus regarding the molecular mechanism by which APOL1 triggers these pathways. 
Our lab has recently observed that G1 and G2, but not G0, over-expression leads to a significant increase 
in intracellular calcium, and that this increase is dependent on APOL1 trafficking to the PM (Giovinazzo 
and Raper; unpublished data). Since the ion channels formed by APOL1 are pH-dependent, we 
hypothesize that APOL1 forms active ion channels at the neutral PM of the cell after trafficking through 
the acidic trans-Golgi network. The APOL1 then, either directly or indirectly, permits the entrance of 
calcium into the cell, which acts as a potent second messenger. Calcium signaling plays a prominent role 
in the majority of the APOL1-induced cell death pathways (154-156), providing the crucial mechanistic 
link between each of the published investigations. However, it remains unclear how APOL1 toxicity is 
restricted to G1 and G2 either in in vitro systems or in humans, which remains a focus of others in our 
laboratory and throughout the greater scientific community. 
5.7. It’s Better to be a Baboon 
 Baboons remain immune to T. b. rhodesiense infection. The resistance phenotype is likely due to 
the properties of baboon APOL1. Baboon APOL1 is not bound by the T. b. rhodesiense SRA protein and 
can therefore lyse these parasites as efficiently as it lyses T. b. brucei (157). The failure of SRA to bind 
baboon APOL1 is due to structural and/or biochemical changes to the C-terminus of baboon APOL1 
relative to the human G0 variant. Swapping individual baboon and human C-terminal amino acids 
revealed that a set of lysine residues specific to the baboon sequence prevent SRA binding (81). In fact, 
inserting one individual baboon lysine into the corresponding spot of the human sequence, position 388, 
was sufficient to prevent SRA binding (81). Interestingly, the two amino acid deletion that creates the 
human G2 variant (delN388 and Y389) shifts lysine 390 into the 388 position, thereby aligning it with the 
critical baboon lysine. SRA has a decreased affinity for G2, although no binding between SRA and 
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baboon APOL1 was ever detected, suggesting that baboon APOL1 is still the best SRA-evader, despite 
human evolution’s best efforts (81).  
 Certain baboon species are immune or at least refractory to T. b. gambiense infection. Inoculating 
a small number of baboons with T. b. gambiense parasites revealed that Papio papio baboons are fully 
immune, P. hamadryas baboons are refractory, and P. cynocephalus baboons are susceptible to infection 
(158,159). These resistance/susceptibility phenotypes may be APOL1-related, although the evidence is 
limited. Recombinant P. papio APOL1 can lyse T. b. gambiense in vitro (160). However, P. papio serum 
lyses T. b. gambiense with 1000-fold lower efficiency than T. b. brucei due to the reduced TLF1 uptake 
mediated by the HPHBR mutations (160). TLF2-mediated lysis, being independent of the HPHBR, may 
predominate in vivo, although it is important to note here that it remains undetermined whether baboons, 
or any other primate for that matter, harbor any TLF2-like complex (see Chapter 1). Nevertheless, the fact 
that P. papio TLF has any lytic effect suggests that it can somehow overcome the effects of the TgsGP 
protein and whatever other APOL1 resistance mechanisms that T. b. gambiense utilizes to establish 
human infections. How baboon TLF manages this feat will be addressed in Chapter 2.  
In humans, the ability to resist T. b. gambiense and T. b. rhodesiense infection is coupled to 
kidney disease – are baboons subjected to this same fate? In an attempt to model the host toxicity in a 
model system, Thomson and Genovese transiently transfected mice with various APOL1 variants by 
hydrodynamics-based gene delivery (HGD) (161). Due to technical restrictions, the vast majority of the 
protein expression after transfection by HGD is liver derived. Therefore, they analyzed the livers of the 
transfected mice as a proxy for the kidney. Remarkably, the G1 and G2 variants caused significant 
damage to the livers, while both the G0 and baboon APOL1 were not toxic (81). These data remain the 
only published results that address the question of baboon APOL1 toxicity. Nevertheless, they suggest 
that baboon APOL1 is less toxic than the human renal risk variants. To summarize what is known about 
baboon APOL1 in brief, we understand that; baboon APOL1 evades binding to SRA, circumvents the 
activity of TgsGP, and is not toxic to the host. It is, therefore, better to be a baboon.   
5.8. Baboon APOL1: Even More Unanswered Questions 
There remain several disconnects between our understanding of human and baboon TLF 
function. For example, human serum-APOL1 concentration varies from approximately 1 to 100 µg/ml 
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(162), while circulating APOL1 levels in the baboon remain uncharacterized, making some previous 
analyses somewhat unreliable. For example, serum from the T. b. gambiense susceptible P. 
cynocephalus baboon was completely non-lytic to T. b. gambiense in vitro, although this could simply be 
due to the investigators using one individual serum sample that may have had a limited amount of APOL1 
(163). The same possibility applies to the in vivo infections, wherein only three P. cynocephalus baboons 
were challenged with T. b. gambiense (158).  
Another possible explanation for this century old data is that P. cynocephalus-specific 
polymorphisms produce a less potent ion channel-forming APOL1 protein. There is no published P. 
cynocephalus APOL1 sequence, although none of the three available sequences (P. anubis, P. 
hamadryas, P. papio) are identical, at least suggesting that the gene is polymorphic between the species. 
This then raises another question – is the APOL1 gene also polymorphic within individual baboon 
species? In humans, at least 13 haplotypes of APOL1 exist in >1% of the population (1000 Genomes 
Project, HapMap Project, ExAC Database). Is the same true within baboon species? More specifically, 
could species-specific or even individual-specific APOL1 polymorphisms govern the balance between 
trypanosome resistance and susceptibility?  
There also remains an elephant in the room – the fact that baboon and human APOL1 proteins 
are equivalent in length, but APOL1 isolated from baboons (but not when purified from E. coli) migrates 
significantly slower on SDS-PAGE gels, suggesting that it is post-translationally modified. Therefore, no 
single investigation analyzing the specific activity of baboon APOL1 has used a physiologically relevant 
protein. Each of these controversies will be examined in Chapters 2 and 3 of this thesis.  
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6. Addressing the Problem 
I opened by declaring that there remains a desperate need for alternative measures to reduce the 
burden imposed by Trypanosomiasis in Africa. The burden is primarily associated with livestock, to this 
day still treated with toxic drugs. We have proposed that our expertise in the world of TLF can open a new 
door that leads to an alternative – drug independent – disease preventing measure (157,164). We have 
generated murine models that have been genetically engineered to produce baboon TLF. The mice 
provide a platform for us to investigate whether we may be able to create genetically modified livestock 
via the same strategy. Cattle that produce baboon TLF would hypothetically be resistant to all forms of 
trypanosome infection with ideally no increased risk of kidney disease or any other unintended negative 
consequences. The Mzima (healthy) cattle would provide farmers with dependable livestock populations 
to be used for haulage, milk and meat production, and financial support. Bovine trypanosomiasis alone 
accounts for a 4 billion USD annual loss in sub-Saharan Africa (3) and the economic benefits of 
eliminating it have been modeled extensively (165). In the horn of Africa, a model of eliminating 
trypanosomiasis by the most inexpensive method possible (trimonthly prophylactic treatment) yielded a 
benefit-cost ratio (BCR) in cattle-harboring regions of up to 20, indicating investment returns amounting to 
2000% (165) (any BCR above 1 is considered a worthy business endeavor). Because trypanosome 
resistance in the Mzima cattle would be self-sustaining, in such a model the farmers would not need to 
rely on the costly prophylaxis, making the potential profits even higher. Additionally, by producing baboon 
TLF, the cattle would significantly reduce the reservoir of T. b. rhodesiense parasites that currently exists 
in livestock (166), rendering the farming community less susceptible to the disease. In fact, T. b. 
rhodesiense transmission to humans is thought to occur in a cattle-tsetse-human pattern, while human-
tsetse-human transmission rarely occurs (166). Therefore, the Mzima (healthy) cattle would likely bring 
east African HAT closer to elimination. Further, the Mzima cattle could also provide environmental 
benefits. Sub-Saharan Africa is by far the largest producer of livestock-generated greenhouse gases in 
the world (167). On average, cattle typically produce 41 kg of CO2 per kg of animal protein, while the 
cattle in the horn of Africa produce roughly 1000 kg of CO2 per kg (167). This is in part due to farming 
practices, but also to the state of emaciation that the cattle perennially exist in. In other words, unhealthy 
cattle generate a net negative environmental impact by producing greenhouse gases and consuming 
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costly feed, while simultaneously yielding far less of the desired products. The motivations for generating 
these transgenic cattle are evident (Figure 9). The biological and technical feasibility of this project is 





Figure 10. Distribution of cattle compared to the distribution of the tsetse fly. Map traced from the 
Bovine Trypanosomiasis Consortium. There remains a roughly 25 million square kilometer (grey + green) 
region of Africa that is agriculturally undeveloped, in part due to the burden posed by bovine 
trypanosomiasis. The cattle surviving in the green regions are either wasting due to trypanosome 
infection or are trypanotolerant but less efficient breeds that do not provide adequate agricultural utility. 






 Do any non-human primates produce TLF2? 
 How does the TLF2-IgM interact with TLF to drive complex assembly? 
 What is the origin of the TLF2-IgMs? 
 What drives TLF2 endocytosis by trypanosomes, and is the mechanism related to or dependent 
on the IgM component? 
Chapter Two 
 Do African Green Monkeys produce APOL1? 
 Is APOL1 polymorphic in non-human primate populations? 
 What is the mechanism of baboon APOL1 ion channel formation? 
 How does the baboon ortholog of APOL1 drive the lysis of T. b. gambiense? 
Chapter Three 
 Will germline expression of baboon APOL1 protect mice from infection by trypanosomes? 
 How does resistance to APOL1 develop in previously sensitive trypanosomes? 
 How can we most effectively transfer parasite resistance to animals using the TLF genes? 
  
 40 
Materials and Methods 
1. Cell Lines  
Trypanosomes: The APOL1 sensitive T. b. brucei Lister 427 and the APOL1 resistant derived 
strain T. b. brucei 427-SRA that was generated by the G. Cross lab. T. b. brucei Antat1.1, T. b. 
rhodesiense KETRI423, T. b. rhodesiense RUMPHI, T. b. gambiense ELIANE, T. evansi Antat 3, T. 
congolense STIB 68-Q, T. vivax. All trypanosome cell lines, including those that are human infective, are 
biosafety containment level 2 pathogens.  
Human cell lines: HepG2 cells (ATCC HB-8065) and NTera-2 cells (ATCC CRL-1973). 
2. Mouse Lines 
Mouse lines: The AID knockout and A/J mice used in this study were obtained from Jackson 
Laboratories: JAX stock #007770; JAX stock #000646. Outbred Swiss Webster mice were sourced from 
Taconic Biosciences. The transgenic lines and their respective recombinant DNA constructs were 
generated by Regeneron Pharmaceuticals. The mice were originally produced in a C57 BL/6N genetic 
background and are coded as follows: P. anubis APOL1 locus in the ROSA26 locus - 6144; P. anubis 
APOL1 locus with two point mutations inserted into the open reading frame in order to create P. 
hamadryas APOL1 in the Myh9 locus - 6146, P. hamadryas APOL1 cDNA alone in the ROSA26 locus - 
2582; P. hamadryas APOL1 and HPR splice - 2591; P. hamadryas APOL1 and HPR Alb - 2637. All 
animal experiments were approved by the Institutional Animal Care and Use Committee at Hunter 
College, which have currently approved Animal Welfare Assurance Agreements with the National 
Institutes of Health Office for Protection from Research Risks. 
3. Human and Primate Plasma Samples 
Peripheral venous blood from healthy donors in New York (United States) was obtained. Approval 
was obtained from the Institutional Review Board (IRB) at New York University School of Medicine. 
Human African trypanosomiasis patient and control plasma samples were a randomly selected subset of 
those previously described in (168). Subjects or their guardians signed consent forms after receiving 
standard information in their local language. Protocols were approved by the Grampian Research Ethics 
Committee (Aberdeen) and the Ministry of Health (Uganda). Before-treatment samples were taken on 
admission prior to commencement of treatment. After treatment samples were taken as part of the 
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diagnostic confirmation of cure 6 weeks after admission. Staging criteria and treatment regimens were 
fully described previously in (18). The malaria patient and control samples were collected from consenting 
donors in a German hospital after returning from trips to African endemic regions. The patients were 
being treated for the infection for anywhere between 0 and 31 days with various combinations of 
atovaquon/proguanil, piperaquine, artesunate, and clindamycin. Baboon plasma samples were obtained 
from the Southwest National Primate Research Center at the Texas Biomedical Research Institute.  
4. Antibodies 
Antibodies used in western blots: For the detection of baboon APOL1, we generated a novel 
antibody (at a 1:500 dilution) through AnaSpec Incorporated, which was raised in rabbits against the 
following peptide: CSVEERARVVEMERVAESRTTEVIRGAKIVDK. All other antibodies are commercially 
available. Anti-Hu APOL1 rabbit polyclonal (1:10,000) (ProteinTech 16139-1-AP), Anti-Hu HP rabbit 
polyclonal (1:10,000) (Sigma H8636), Anti-Mu APOA-I rabbit polyclonal (1:10,000)  (Abcam ab20453), 
Anti-Hu APOA-I goat polyclonal (1:5000) (Novus Biologicals NB400-147), Anti-Mu IgM conjugated to HRP 
(1:10,000) (Jackson Immuno Research Labs 115-036-075), Anti-Rb TrueBlot conjugated to HRP (1:5000) 
(Rockland Antibodies 18-8816-33), Anti-Hu IgM μ chain conjugated to HRP (1:10,000) (Jackson Immuno 
Research Labs 09-035-129), Anti-Hu IgM lambda chain (1:50,000) (Rockland Antibodies 609-1311). 
Control antibodies used in western blots: Pooled human IgM (Sigma I8260), pooled mouse IgM (Sigma). 
All conventional western blots and dot blots were blocked with 5% milk in tris buffered saline with 0.05% 
Tween-20 prior to the addition of antibodies. All Far western blots were blocked with 5% BSA in tris 
buffered saline with 0.05% Tween-20 prior to the addition of antibodies. Antibodies used in Co-IP 
experiments: Anti-Hu HP mouse monoclonal (Sigma H6396), Mouse IgG1 (Invitrogen 02-6100). 
5. Primers 
 






















Primers to amplify the bovine C-reactive protein promoter and add KPN1 and SAL1 restriction sites for  





Primers to amplify the bovine haptoglobin promoter and add KPN1 and SAL1 restriction sites for cloning 





Primers used to confirm the identity of various trypanosome isolates, including the T. vivax isolate used in 
figure 40. The majority of these primers have been previously published, with the exception of the T. b. 
gambiense specific primers that we have generated. These primers amplify almost the entire open 
reading frame of the Trypanosoma gambiense specific glycoprotein (TgsGP), with the exception of the N 
and C-terminal signal peptides. 
 
T. evansi - ACATATCAACAACGACAAAG 
T. evansi - CCCTAGTATCTCCAATGAAT (169) 
 
T. congolense forest - GGACACGCCAGAAGTACTT 
T. congolense forest - GTTCTCGCACCAAATCCAAC (170) 
 
T. congolense kilifi - GTGCCCAAATTTGAAGTGAT 
T. congolense kilifi - ACTCAAAATCGTGCACCTCG (170) 
 
T. congolense savannah - TCGAGCGAGAACGGGCACTTTGCGA 
T. congolense savannah - ATTAGGGACAAACAAATCCCGCACA (170) 
 
T. b. rhodesiense - ATAGTGACAAGATGCGTACTCAACGC 
T. b. rhodesiense - AATGTGTTCGAGTACTTCGGTCACGCT (115) 
 
T. b. gambiense - GAGGACAGTGCAGGCGAAAATG  
T. b. gambiense - GCTTGCTGTGGTGTTTGCC (novel) 
 
T. vivax - GCCATCGCCAAGTACCTCGCCGA  
T. vivax - TTAAAGCTTCCACGAGTTCTTGATGATCCAGTA (171) 
 
T. brucei clade rDNA - GCGTTCAAAGATTGGGCAAT 
T. brucei clade rDNA - CGCCCGAAAGTTCACC (172) 
 
T. brucei clade cathepsin L - CAGTGACCCCAGTGAAGGAT 
T. brucei clade cathepsin L - GAGACATTGGTTTGTGCCCT (Ph.D. Thesis of Dr. Eric DeJesus) 
 
Primers to create the P. cynocephalus variant of APOL1 that was used for biochemical testing based on 
mutagenesis of a P. hamadryas APOL1 template.  
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Q150E - GCGACCTTGCAGGTGAGGTTCAGAAGGTCCACA 
Q150E - TGTGGACCTTCTGAACCTCACCTGCAAGGTCGC 
 
K330E - GAGGAGCCAAGATCGTTGATGAGGTCTTTGAAGGC 
K330E - GCCTTCAAAGACCTCATCAACGATCTTGGCTCCTC 
 
G343S - CTGGATGTAGTCAGCCTCGTGTGCCAGTTAAAC 
G343S - GTTTAACTGGCACACGAGGCTGACTACATCCAG 
 
Primers to create a more hydrophobic human APOL1 hairpin region by inserting baboon APOL1 specific 
amino acids by mutagenesis. 
 
E201A - GGCACCCTTCACAGCGGGAGGCAGCCTTGTAC 
E201A - GTACAAGGCTGCCTCCCGCTGTGAAGGGTGCC 
 
E213G - GGAACCTGGGATGGGGTTGGGAATCACAG 
E213G - CTGTGATTCCCAACCCCATCCCAGGTTCC 
 
Primers to create a less hydrophobic baboon APOL1 hairpin region by inserting human APOL1 specific 
amino acids by mutagenesis. 
 
A187E - GGCACCCTTCACAGAGGGGAGCAGCCTTG 
A187E - CAAGGCTGCTCCCCTCTGTGAAGGGTGCC 
 
G199E - GGAACCTGTGACGGAGTTGGGAATCGCAG 
G199E - CTGCGATTCCCAACTCCGTCACAGGTTCC 
 





Quantitative PCR primers used to amplify a segment of the T. congolense cathepsin L gene from 





6. Size Exclusion Chromatography  
Size exclusion chromatography (SEC) was performed via fast performance liquid 
chromatography (FPLC) on either a Superose 6 (V0: 34 ml, flow rate: 0.4 ml/min, fraction size: 500 μl) or a 
Superdex 200 10/300 (V0: 7 ml, flow rate 1 ml/min, fraction size: 500 μl) column to maximize or minimize 
sample loading respectively. All columns were equilibrated and run in tris-buffered saline (150 mM NaCl, 
50 mM Tris, pH 7.4) (TBS). 
SEC of baboon serum was performed by loading 500 μl of baboon plasma onto a Superose 6 
column. Collected fractions were diluted in SDS-PAGE loading buffer and electrophoresed on 10% tris-
glycine gels and transferred to PVDF membranes before being probed for the presence of APOL1. 
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Fractions containing TLF2 were concentrated to a 500 μl volume (Centricon – Fisher Scientific) and 
resized on the same column with the same specifications. Collected fractions were diluted in SDS-PAGE 
loading buffer and electrophoresed on 10% tris-glycine gels and transferred to PVDF membranes before 
being probed for the presence of APOL1. 
To determine whether TLF2-sized APOL1-containing complexes were present in activation 
induced cytidine deaminase knockout (AID-/-) mouse plasma, mice were exsanguinated using 200 μl of 
heparin (Abraxis) per mouse 24 hours after HGD (2 mice per transgenic group; 1 mouse with saline 
control) and the isolated plasma was pooled (800 μl per group; 400 μl for saline group) for immediate 
SEC on a Superose 6 column. Collected fractions were diluted in SDS-PAGE loading buffer and 
electrophoresed on 10% tris-glycine gels and transferred to PVDF membranes. Where shown, IgM, 
APOA-I, and APOL1 were visualized on the same membrane for all groups, while HPR was visualized 
from a separate membrane. 
To determine whether TLF2-sized APOL1-containing complexes were present in trypanosome 
infected and cured animals, individual mice were exsanguinated using 200 μl of heparin (Abraxis) per 
mouse 48 hours post-HGD. The isolated plasma was immediately processed by SEC on a Superdex 200 
10/300 column. Collected fractions were diluted in SDS-PAGE loading buffer and electrophoresed on 
10% tris-glycine gels.  
SEC of African Green Monkey (AGM) sera was performed on a Superdex 200 10/300 column. 
Collected fractions were diluted in SDS-PAGE loading buffer and electrophoresed on 10% tris-glycine 
gels.  
7. Density Gradient Ultracentrifugation 
To separate the fractions of baboon or mouse plasma by density gradient ultracentrifugation, the 
density of baboon or mouse plasma was changed to 1.25 g/ml using potassium bromide and the samples 
were then ultracentrifuged in an NVTi-65 rotor (Beckman Coulter) for 16 hours at 49,000 RPM, 10°C. For 
mouse HDL isolations, the top 33% of the resulting gradient was aspirated and dialyzed against 5 
changes of 150 mM NaCl, 50 mM Tris, 2.5 mM EDTA, pH 7.5 before storing at -80°C. For baboon plasma 
fractionations, the centrifuged tube was aspirated at the very bottom to allow 1.5 ml fractions to collect 
dropwise. The fractions were then dialyzed individually against 5 changes of 150 mM NaCl, 50 mM Tris, 
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2.5 mM EDTA, pH 7.5. The dialyzed fractions were diluted in SDS-PAGE loading buffer and 
electrophoresed on 10% tris-glycine gels. 
8. Native Agarose Protein Gel Electrophoresis 
Non-denaturing agarose protein gels were run analogously irrespective of the samples being 
analyzed. 1.5 μl plasma samples diluted in 2X native loading buffer (126 mM Tris-HCl pH 6.8, 15% Ficoll 
Type 400 [Sigma], 0.002% bromophenol blue) to a final volume of 3 μl were electrophoresed for 2 hours 
at 100 mV through 0.7% SeaKem agarose (Lonza) in tris-borate buffer (90 mM Tris, 90 mM borate, pH 
8.5). A pigmented Ferritin marker (Pharmacia) that migrates the same distance as the bulk of human HDL 
was used to determine retention values. Proteins were transferred to PVDF membranes for western 
blotting via capillary transfer overnight. 
9. Native Polyacrylamide Gel Electrophoresis 
1 μl baboon plasma samples were diluted in 2X loading buffer (126 mM Tris-HCl pH 6.8, 15% 
Ficoll Type 400 [Sigma], 0.002% bromophenol blue) to a final volume of 2 μl and were loaded into each 
well of a 7.5% Tris-glycine poly-acrylamide gel (Bio-Rad) for separation prior to transfer to a PVDF 
membrane. Both the running and transfer of the gel were performed in the same buffer; 25 mM Tris, 192 
mM glycine, pH 8.3 (20% methanol was incorporated into the transfer buffer). The NativeMark Unstained 
Protein Standard (Invitrogen) was visualized by staining the membrane with 0.1% Ponceau S in 5% 
acetic acid to determine migration distances.  
10. Human Trypanosome Lytic Factor 2 Purification 
TLF2 was purified as described previously with modifications (173). The density of the isolated 
human plasma (100 ml, haptoglobin haplotype 1-1) was adjusted to 1.25 g/ml using potassium bromide. 
The plasma was then ultracentrifuged at 49,000 RPM, 10°C, 16 hours. The bottom 50% of the resulting 
density gradient was collected and dialyzed using three changes of 150 mM NaCl, 50 mM Tris, 2.5 mM 
EDTA, pH 7.5 at 4°C. The dialyzed product was concentrated (Centricon – Fisher Scientific) to 
approximately 40 ml and sized (5 ml per run) on a Superose 6 column (V0: 34 ml, flow rate: 1.5 ml/min, 
fraction size: 1.5 ml). Fractions in the TLF2-sized range (800-1,400 kDa) were pooled, concentrated to 10 
ml, and immunoaffinity purified using a mouse monoclonal antibody raised against human HP that binds 
to human HPR (Sigma H6396). The antibody was coupled via amino groups to a 1 ml HiTrap N-
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hydroxysuccinimide column as per the manufacturer’s instructions (GE Healthcare Bio-Sciences). The 
pooled TLF2 was then loaded onto the column and allowed to bind for 10 minutes, followed by a wash 
with five column volumes of TBS. The bound TLF2 was then eluted with a gradient of a 100 mM glycine-
150 mM NaCl solution at pH 2.8. Eluted fractions were immediately neutralized with 1.5 M Tris-HCL (pH 
8), pooled, and concentrated. The unbound fractions were also pooled and concentrated prior to being re-
subjected to immunoaffinity chromatography. To maximize yield, this was repeated at least 10 times. The 
affinity-purified sample was reduced in SDS-PAGE loading buffer containing β-mercaptoethanol and run 
on 10% polyacrylamide gels for silver staining or transferred to PVDF membranes for immunoblotting. 
11. Far Western Blotting 
Protein-protein interactions were analyzed by Far western blotting, reviewed here (174). SDS-
PAGE gels were used to separate proteins by size, which were then transferred to PVDF membranes. 
Protein samples were reduced with 100 mM β-mercaptoethanol where indicated. Membranes were 
blocked using 5% BSA in TBS with 0.05% Tween-20. Where indicated, membranes were then probed 
using 20 μg/ml of purified human TLF2, or an equimolar amount of pooled human IgM (Sigma, Cat: 
I8260), in the presence of 5% BSA in TBS with 0.05% Tween-20 for 1 hour at room temperature. This 
was followed by three washes (ten minutes each) in TBS with 0.05% Tween-20. Membranes were 
visualized using an anti-Hu IgM polyclonal antibody conjugated to HRP. The Far western blot protocol 
was performed analogously for the dot blot experiments with the following exception: Proteins were not 
denatured in SDS loading buffer in order to facilitate the maintenance of native protein structure. Protein 
samples (2 μl) were applied directly to a nitrocellulose membrane and allowed to dry for approximately 15 
minutes prior to blocking and probing. 
12. Hydrodynamic Gene Delivery 
The genes of interest were cloned into the pRG977 (Regeneron Pharmaceuticals) mammalian 
expression vector. Each gene of interest is flanked by an intron (5' with respect to the coding sequence) 
and a polyadenylation signal (3' with respect to the coding sequence) to stabilize the resulting RNA 
transcripts. The expression of each gene is driven by a mammalian ubiquitin promoter, which functions in 
any murine cell type. Each plasmid contains a beta-lactamase gene for antibiotic selection and an origin 
of replication for propagation in E. coli. Plasmids are isolated from bacteria such that all contaminating 
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endotoxin is removed (Qiagen). Mice were transfected by HGD as described in (161). Briefly, 25 μg of 
plasmid DNA diluted in approximately 2 to 3 milliliters of saline is then injected directly into the tail vein of 
an adult mouse (amount of saline is 10% of the weight of the mouse in vol/g). The majority of gene 
expression in mice receiving plasmids encoding TLF genes by tail vein injection is observed in the liver 
(175). 
13. Co-Immunoprecipitations 
Co-immunoprecipitation was performed using magnetic protein A/G beads (Thermo-Pierce). 
Briefly, antibodies were cross-linked to beads using disuccinimidyl suberate, which were then incubated 
with protein samples for either 1 hour at room temperature or overnight at 4°C. Beads were then washed 
5X with tris-buffered saline (TBS) (pH 6.7 in order to increase the stringency of the wash steps and 
prevent non-specific interactions between the TLFs and the beads) before being boiled in SDS-PAGE gel 
loading buffer. 
14. Trypanosome Lytic Factor 2 Generation in Trypanosome Infected and Cured Mice 
Swiss Webster and A/J mice were infected on day 0 with 5000 monomorphic T. b. brucei Lister-
427 parasites i.p. followed by treatment with diminazene aceturate on day 4 post-infection. Cure was 
confirmed by periodically preparing blood smears on various days after treatment and checking for any 
living parasites; none were detected. Mice were transiently transfected with a vector encoding APOL1 
and HPR by HGD on day 12 post infection and were subsequently exsanguinated using 200 μl of heparin 
(Abraxis) per mouse on day 14 post-infection. 400 μl of plasma was immediately loaded onto a Superdex 
200 10/300 column and fractionated via FPLC. Collected fractions were diluted in SDS-PAGE loading 
buffer and run on 10% tris-glycine gels. 
15. Analysis of Human Sleeping Sickness and Malaria Patients 
To quantify IgM, plasma samples were diluted between 10,000 and 100,000-fold prior to being 
screened in a commercially purchased sandwich ELISA (Invitrogen, biological limit of detection: 15.6 
ng/ml). Plasma interferon (IFN) gamma concentrations were measured using ELISA (BD OptEIA, BD 
Biosciences, Oxford, UK, biological limit of detection: 1.8 pg/ml). Note that the “before treatment” data are 
a subset of values previously published in (168) but are included for clarity and for comparison with “after 
treatment” data. To quantify APOL1, 0.375 ul of each plasma sample was electrophoresed on 10% 
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polyacrylamide gels alongside a serially diluted sample of purified recombinant APOL1 at a known 
concentration. The gels were blotted onto PVDF membranes for western blotting and pixel density 
quantification studies (FIJI – NIH). The levels of APOA-I were measured by the same method except that 
only 10-20 nl of each plasma sample was electrophoresed alongside a serially diluted sample of 
recombinant APOA-I (Peprotech 350-11). The ratio of TLF2:TLF1 was calculated by western blot and 
pixel density quantification (FIJI – NIH) after native agarose gel electrophoresis. 1.5 ul of each plasma 
sample was electrophoresed for 2 hours in 0.7% agarose and blotted onto PVDF membranes via capillary 
blotting overnight. The membranes were probed for the presence of APOL1 which was used to indicate 
how much of each TLF species was present in each sample. The ratio was determined by comparing the 
pixel density of the signal corresponding to TLF2-associated APOL1 to TLF1-associated APOL1.  
16. Quantifying the Cholesterol Content of Human Trypanosome Lytic Factors 
The cholesterol content of human TLF1, TLF2, and bulk HDL was quantified using a 
commercially available colorimetric kit (Wako Diagnostics). The cholesterol esters are converted to 
cholesterol by cholesterol esterase. The free cholesterol then reacts with cholesterol oxidase. This 
reaction produces a hydrogen peroxide byproduct which is detected by horseradish peroxidase to 
produce a color. The amount of cholesterol in a sample is calculated by comparing the absorbance at 600 
nm to the absorbance of various standards of known amounts of cholesterol.  
17. Electron Microscopy of Human Trypanosome Lytic Factors 
Charged copper grids were prepared by glow discharging. Human TLF1, TLF2, and HDL samples 
were applied to the grids in 3 μl volumes. Grids were prepared with approximately 1 mg/ml, 0.2 mg/ml, 
and 0.05 mg/ml samples of TLF1 and TLF2, while HDL grids were prepared with 1 mg/ml and 0.2 mg/ml 
samples only. The protein complexes were allowed to adhere to the grids for 1 minute prior to being 
negatively stained with uranyl acetate at pH 4.5. The staining was performed by adding 3 μl of stain for 10 
seconds before dabbing the liquid off using whatman paper. This was repeated 3 times. Grids were then 
stored with a desiccant at room temperature until imaging. 
18. Identification of the African Haptoglobin-Related Protein Variant V1 
Phased genotype data from 1,092 individuals was downloaded into the Galaxy webserver from 
the 1,000 Genomes project at ftp://ftptrace.ncbi.nih.gov/1000genomes/ftp/release/20110521/ (NCBI 
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October 2011). The downloaded variant call format (.vcf) files were sliced, using the 1,000 Genomes 
project slicing tool, to create files that contained only the called exonic variants present within the HPR 
and APOL1 loci. The variants were viewed using the University of California at Santa Cruz genome 
browser. The genome browser allows the user to view the allele frequency of any particular SNP 
unbiasedly or based on ethnicity. We therefore copied the data for each African-specific HPR SNP into 
Microsoft Excel and cross referenced these data with the concomitant data for the APOL1 locus of each 
individual. We have not performed any statistical tests to determine if there is a statistically significant 
enrichment of any HPR variants in humans that harbor the renal-risk variants of APOL1.  
19. 24-Hour in vitro Trypanosome Lysis Assays 
Cultured T. b. brucei Lister-427 parasites were diluted to 5 x 105 ml-1 in HMI-9 medium with 10% 
fetal calf serum (Laboratory Disposable Products) and 10% Serum Plus (SAFC Biosciences) and 100 μl 
was added to each well of an opaque 96 well plate. Parasites were then diluted 1:1 with various 
concentrations of human TLF2, rAPOL1 proteins, or AGM lipoproteins suspended in HMI-9. After 20 
hours of incubation at 37°C with 5% CO2, 20 μl of alamarBlue (Invitrogen) was added to each well. The 
assay involves the reduction of resazurin by metabolically active cells to the fluorescent resorufin, 
allowing quantitation of non-lysed cells at 4 hours post-reagent addition in a spectrofluorometer. Where 
indicated, the trypanosomes were pre-treated for 30 minutes with 10 mM ammonium chloride (which 
remained present throughout the assay), a weak base that inhibits APOL1-mediated lysis of 
trypanosomes by neutralizing the endocytic compartments of the organism.   
20. Phylogenetic Analysis of Baboon Apolipoprotein L1 
Variant call format (.vcf) files that had been sliced such that they contained information pertaining 
only to exonic SNPs within the baboon APOL1 locus (bound by the following genomic coordinates in the 
baboon reference genome Panu_2.0/papAnu2: chr10:76,724,427-76,734,622) were downloaded from the 
Baboon Genome Consortium after donation by Dr. Jeffery Rogers. The variants were viewed using the 
University of California at Santa Cruz genome browser. The data for each variant for the entire population 
were manually copied and pasted into Microsoft Excel. The genomic data were phased using Phase2.0 to 
obtain haplotype information. The haplotypes were then input into the phylogeny building webserver 
phylogeny.fr. Using this server, the haplotype sequences were aligned using MUSCLE and the alignment 
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was curated using Gblocks. The curated alignment was then analyzed using a maximum parsimony-
approach via PhyML, which was then visualized in tree format using TreeDyn.  
21. Recombinant Apolipoprotein L1 Purification 
We expressed and purified N-terminally 6xHIS-tagged full length rAPOL1 using the pNIC vector 
from E. coli BL21 Codon Plus RIPL cells (Agilent) grown in Overnight Express media (Novagen) using a 
previously described procedure (83). Inclusion bodies were isolated and washed while maintaining a 
working concentration of the HALT protease inhibitor cocktail during each wash step. The inclusion 
bodies were then solubilized in 1% zwittergent 3-14 (SB3-14, EMD-Millipore). Solubilization was 
facilitated by adjusting to pH 12 with 10 mM NaOH and 150 mM NaCl for one minute before adding 30 
mM Tris-HCl (pH 7.4) to reduce the pH to 8.0. The APOL1-containing solubilized mixture was then bound 
to a nickel affinity column (HisTRAP, GE Life Sciences) equilibrated in 20 mM Tris-HCl, pH 8.5, 150 mM 
NaCl, 10 mM imidazole and 0.5% SB3-14 and eluted with a 10-500 mM imidazole gradient in the same 
buffer. APOL1 proteins were purified from any remaining detectable contaminants via SEC using a 
Superdex-200 16/60 column equilibrated in 50 mM Tris-HCl, pH 8.5, 150 mM NaCl, and 0.05% n-
Dodecyl-beta-Maltoside (Thermo Scientific). Purified proteins were flash-frozen and stored at -80°C.  
22. Electrophysiology 
Planar lipid bilayers were used to analyze the channel forming activities of baboon APOL1 
variants as has been previously described using human APOL1 (83). Briefly, planar lipid bilayers were 
formed from soybean asolectin and cholesterol at room temperature across an approximately 100 μm 
hole in a Teflon partition. The bilayer separates two 1 ml capacity chambers, the contents of which can be 
modified independently by the experimenter. Each side was maintained in 0.5 M potassium chloride for 
the duration of all experiments, while the pH was modulated by the addition of either 5 mM potassium 
succinate pH 5.3 or 5 mM potassium Hepes pH 7.5. To test the pH dependence of channel formation and 
channel gating, rAPOL1 proteins were added to the Cis side of the chamber and the Cis pH was modified 
as indicated.  
23. PNGase F Treatment of Baboon High-Density Lipoproteins 
PNGase F was obtained from New England BioLabs and de-glycosylation was performed in 50 μl 
under denaturing conditions for one hour at 37°C according to the manufacturer’s instructions except that 
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1 mM EDTA, 1 mM EGTA, 1 mM PMSF (final concentrations), and 0.33 μl of the HALT protease inhibitor 
cocktail were added to the lipoproteins and incubated for 20 minutes prior to denaturation.  
24. Development of Transgenic Mice Expressing Baboon Trypanosome Lytic Factors 
Transgenic mice expressing baboon APOL1 and/or HPR were generated by the VelociGene and 
VelociMouse divisions of Regeneron Pharmaceuticals. The mice were generated by first using CRISPR-
assisted gene insertions to create transgenic mouse embryonic stem cells. The stem cells were then 
injected into 8-cell stage mouse embryos, which were then implanted into surrogate females. This 
process results in F0 generation mice that are fully transgenic, compared to more conventional methods 
which produce chimeric animals (176).  
The vectors used to create the mice expressing baboon APOL1 genomic DNA were bacterial 
artificial chromosomes containing 20 kb worth of P. anubis genomic DNA obtained from the Children’s 
Hospital Oakland Research Institute with added homology arms that were approximately 40 kb in length. 
One vector was integrated into the ROSA26 locus, while the other vector was modified with two point 
mutations such that the resulting ORF encoded a P. hamadryas APOL1 protein before being integrated 
into the Myh9 locus. The vectors used to create the mice expressing P. hamadryas APOL1 and/or HPR 
cDNA-based constructs were between 10 and 15 kb in length and contained only 300-500 bp homology 
boxes to assist in the integration into the ROSA26 locus. All vectors also contained the required selection 
markers and other cloning features needed to propagate the plasmids and select for properly integrated 
clones. 
25. In vivo Trypanosome Infections in Transgenic Mice 
A total of 5000 parasites (unless otherwise indicated) were injected i.p. into transgenic or wild 
type C57 BL/6N or C57 BL/6N-J mice derived from the transgenic founder mice produced by Regeneron 
Pharmaceuticals via the VelociGene system. Parasitemia was monitored in certain infections by tail 
bleeding and counting the number of parasites present in the blood by blood smear estimation or by 
hemocytometer. Mice that were also transiently transfected with P. hamadryas HPR were infected 48 
hours after plasmid injection to allow for high levels of transiently expressed protein to accumulate and to 
allow for the decrease in circulating liver enzymes prior to infection. 
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26. Kidney Histology 
Kidneys were excised from >1 year-old mice. The kidneys were sliced into two longitudinal halves 
and were then washed in phosphate buffered saline before being fixed overnight in 4% paraformaldehyde 
at 4°C. The kidneys were then transferred to 70% ethanol in phosphate buffered saline for storage. The 
kidneys were submitted to the New York University pathology core facility. 5 μm sections were cut, fixed 
in formalin, and embedded in paraffin prior to being stained with hematoxylin and eosin.  
27. Development of a Trypanosoma congolense Quantitative PCR System 
To design primers usable for quantitative PCR specific to T. congolense parasites, we targeted 
the T. congolense cathepsin L (CATL) gene. CATL is a multicopy gene, existing in up to 20 copies in 
some isolates, making it a good candidate for highly sensitive PCR reactions. Using previous published 
broadly specific CATL primers, we amplified and subsequently sequenced the gene from T. congolense 
STIB 68-Q. We then designed primers that amplified a small segment (90 bp) of the gene to be used in 
quantitative PCRs. The quantitative PCR cycling conditions are as follows: Initial denaturation at 94°C for 
1 minute, followed by 38 cycles of 98°C for 5 seconds, 59.5°C for 30 seconds, and 72°C for 20 seconds. 
PCRs were performed in 20 μl final volumes consisting of 10 μl of SYBR select Master Mix (Applied 
Biosystems), and 10 μl of remaining components amounting to 30 ng of genomic DNA and 0.5 μm primer 
concentrations. 
28. Mouse Tissue Collection for Quantitative PCRs 
Infected mice were manually transcardially perfused through the left ventricle after aspirating the 
right atrium with 20 ml of ice cold heparinized phosphate buffered saline. After cutting the atrium and prior 
to starting the injection of saline, 100 μl of blood was collected from the thoracic cavity and immediately 
pipetted into 500 μl of TriReagent (Zymo Research). After perfusing the animal, sections of the lung, liver, 
gonadal adipose depot, spleen, and brain were excised, washed in phosphate buffered saline to remove 
residual blood, weighed, and placed into 500 μl of TriReagent (Zymo Research). Tissue samples were 
stored at 4°C until being homogenized by sequential needle passing. Tissue homogenates were then 
mixed with an equal volume of molecular grade ethanol before isolating the genomic DNA using a 
commercially available kit (DNeasy Blood and Tissue Kit - Qiagen). 
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29. Aspartate Amino Transferase Activity Assays 
Aspartate amino transferase (AST) is an intracellular enzyme that is released into serum when 
liver cells are damaged. The amount of active serum-circulating AST enzyme is representative of the 
amount of liver damage after HGD. The injection itself causes liver damage which results in plasma 
circulating AST enzyme levels that peak at 24 hours post-HGD and return to baseline by 48 hours post-
HGD. Any remaining circulating AST after the 48-hour time point is due to the transiently expressed 
protein of interest. AST activity was quantified using a commercially available colorimetric kit (BioVision 
Inc.). AST catalyzes the conversion of aspartate and ⍺-ketoglutarate to oxaloacetate and glutamate. The 
glutamate then reacts with the AST developing reagent, resulting in a color change. The assay was 
performed according to the manufacturer’s instructions. Briefly, 1.25 μl of mouse plasma was mixed with 
the assay buffers and incubated at 37°C for ten minutes before reading the optical density of the media at 
450 nm. The samples were then returned to 37°C for approximately one hour before reading the optical 
density of the media at 450 nm again. AST activity levels were calculated by determining the amount of 
glutamate produced during the assay, as indicated by the color change, compared to a standard curve of 
known glutamate concentrations.  
30. Intravenous Delivery of Human Serum into Trypanosome Infected Mice 
Swiss Webster mice were infected with 5000 T. vivax parasites i.p. and parasitemia was 
monitored by blood smear every 24 hours. Once living parasites were initially detected (3 days post-
infection), the mice were injected i.v. with 150 μl of human serum or saline. Parasitemia was monitored by 





Chapter One: The Germline IgM Antibodies Associated with 
Trypanosome Lytic Factors 
Introduction 
Trypanosome lytic factors (TLFs) contain the primate-specific hemoglobin (HB) binding protein 
haptoglobin-related protein (HPR). HPR-HB complexes are endocytosed after binding the trypanosome 
haptoglobin-hemoglobin receptor (HPHBR), which drives the uptake of the lytic component of TLF, 
apolipoprotein L1 (APOL1) (95). HPHBR-mediated APOL1 uptake can be completely inhibited by 
saturating the receptor with physiological concentrations of haptoglobin (HP)-HB complexes (102). 
Receptor-mediated endocytosis of TLF1 is dependent on the HPHBR; however, TLF2 endocytosis cannot 
be inhibited by HP-HB complexes and is therefore independent of the HPHBR (102). These biochemical 
experiments have been supported by reverse genetics, wherein knockdown of the HPHBR increased T. 
b. brucei resistance to TLF1 by 10,000-fold, while resistance to TLF2 was increased by only 500-1000-
fold (103). We aim to investigate the nature of the decreased HPHBR dependence of TLF2 as well as 
attempt to elucidate any currently uncharacterized alternative uptake pathways that are specific to TLF2.  
 TLF2 is distinguished from TLF1 by the association of IgM antibodies with the TLF2 complex, 
which may play a role in TLF2 endocytosis (173). IgM antibodies typically bind with relatively low affinity 
and high avidity to their cognate antigen. These low-affinity TLF2-associated IgMs (TLF2-IgMs) are 
polyclonal and interact with the complex non-covalently (173). The exact stoichiometry is unclear. 
However, based on the sizes of the TLF1 and TLF2 complexes, we hypothesize that each TLF2 is 
comprised of one TLF1 and one IgM. All healthy humans produce IgM antibodies as the first humoral 
response to infection. All healthy humans also produce IgM antibodies that do not undergo affinity 
maturation called germline antibodies (NAbs) (177). NAbs often bind to self-antigens, such as apoptotic 
debris and other damage associated molecular patterns (DAMPs), and do not require an infectious 
stimulus to be produced. TLF2-IgMs are present in every human serum sample screened thus far, 
suggesting that they are NAbs that interact with ubiquitous antigens while simultaneously interacting with 
TLF1. TLF1 has been studied in humans, non-human primates, and various murine models. However, the 
study of TLF2-IgMs is limited by the fact that there are currently no animal models. In fact, it remains 
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unknown whether any APOL1 and HPR-expressing primate other than humans produces TLF2-IgMs and 
therefore TLF2.  
 Trypanosome parasites proliferate extracellularly in the bloodstream and interstitial spaces and 
are able to evade antibody-mediated adaptive responses by antigenic variation of their surface coat (43). 
Trypanosomes monoallelically express only one of 2000 alleles of the dominant coat protein, the variant 
surface glycoprotein (VSG). Muller et al. clearly demonstrated that anti-VSG antibody specificities preexist 
in humans and mice that have never been exposed to the trypanosome (68). These germline anti-VSG 
antibodies also cross-react with – and are possibly raised against – DAMPs (68). Given that many 
germline antibodies target trypanosome surface proteins, and many germline antibodies are polyreactive, 
we hypothesized that TLF2-IgMs are NAbs that can interact with trypanosome antigens such as VSG with 




1. Baboons Produce TLF2 
To determine whether non-human primates produce TLF2, we obtained Papio hamadryas 
baboon plasma and performed a series of biochemical analyses. Human TLFs 1 and 2 can be efficiently 
separated by size-exclusion chromatography and density gradient ultracentrifugation (101). By size-
exclusion, multiple baboon individuals displayed at least two distinct APOL1-containing protein complexes 
in plasma, with one being in the TLF2-sized range (800-1400 kDa) (Figure 11A). We then pooled and 
concentrated the TLF2-sized fractions from one baboon individual and re-sized the product to confirm that 
the majority of the APOL1 remained in the TLF2-sized range (Figure 11B). To further characterize the 
putative baboon TLF2-sized APOL1-containing complex, we performed density gradient 
ultracentrifugation on the baboon plasma samples. Starting the density gradient at 1.25 g/ml reproducibly 
shifts human lipoproteins and TLF1 to the top of the gradient, while the TLF2 equilibrates to the bottom 
half of the gradient (101). After ultracentrifugation, the majority of the baboon APOL1 equilibrated to the 
top of the gradient along with the majority of the HDL protein apolipoprotein A-I (APOA-I) (Figure 11C). 
However, a significant fraction of the APOL1 equilibrated to the bottom of the gradient, along with a small 
but significant portion of the APOA-I (Figure 11C). There was also a significant amount of APOL1 at the 
very bottom of the gradient, although it was partially proteolyzed protein (50 kDa vs 55 kDa) and was 
therefore uninformative because it may have been derived from degraded lipoproteins (Figure 11C).  
To further characterize the baboon APOL1-containing complexes, we performed non-denaturing 
gel electrophoresis in both agarose and polyacrylamide. We used native agarose gels to rapidly and 
inexpensively separate the TLFs based primarily on the native charges of the complexes (Figure 11D). 
These analyses revealed that the baboon plasma samples contained multiple APOL1-containing 
complexes (Figure 11D). Importantly, the putative TLF2-containing fraction from the density gradient in 
Figure 11C migrated in the TLF2 range, while the TLF1-containing fraction from the same density 
gradient migrated in the TLF1 range (Figure 11D). We then used native PAGE in order to achieve a more 
robust estimation of the sizes of the APOL1-containing complexes in baboon plasma. We determined that 
all baboons have TLF1-like complexes, with APOL1 migrating in the TLF1-sized range in all of the tested 
samples (Figure 11E). We observed APOL1-containing complexes in the TLF2-sized range in most but 
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not all baboons (Figure 11E). We also observed that the APOL1 formed discrete banding patterns that 
only partially overlapped with APOA-I, suggesting that there are non-HDL baboon TLFs although we have 
not investigated this hypothesis any further. Taking all of these data together, we concluded that non-
human primates have the capacity to form TLF2-like complexes. However, we have not yet confirmed this 
by immunoaffinity chromatography, primarily due to a lack of applicable antibodies to use for the 
purification. In the future, we must determine if there is a non-covalent association between primate IgM 











Figure 11. Baboons produce TLF2. A) Anti-baboon APOL1 western blot of size fractionated baboon 
plasma. B) Anti-baboon APOL1 western blot after re-sizing ml 60-64.5 from A. ml 62.5 was lost during 
fractionation. C) Anti-baboon APOL1 (top) and anti-human APOA-I (bottom) western blots of density 
separated and fractionated baboon plasma. The top of the density gradient, where the least dense protein 
complexes are found, is density gradient (DG) fraction 8, while the densest fraction is DG1. The blots 
were performed sequentially on the same PVDF membrane. D) Anti-APOL1 western blots of human and 
baboon samples after non-denaturing agarose gel electrophoresis. Multiple gels and membranes were 
combined in post to generate this image. Specifically, the human and baboon samples were analyzed 
separately because the anti-APOL1 antibodies are species specific. Fully purified human TLF2 (lane 2) 
reproducibly contains TLF1, which will be discussed in subsequent sections. The migration distance of 
ferritin (Pharmacia), a marker that migrates the same distance as bulk human HDL, is denoted by **. E) 
Anti-baboon APOL1 (right) and anti-human APOA-I (left) western blots after non-denaturing PAGE. 











2. Developing a Murine Model of TLF2 
 Primate samples are not easily attainable, and even human plasma samples can be difficult to 
obtain. We therefore decided to design a modular laboratory system for the in vivo study of TLF2 using 
mice. TLF1 has been reconstituted in various mouse genetic backgrounds through a process called 
hydrodynamic gene delivery (HGD) (161). To do this, we express the human TLF genes by injecting 
plasmid DNA encoding the cDNAs of APOL1 and HPR through the tail vein of adult mice in a large bolus 
of saline. Mice expressing APOL1 and HPR by this transfection strategy load both proteins onto plasma 
circulating HDLs therefore generating TLF1. However, there has yet to be a report of TLF2 formation in 
any of these transiently transfected mouse models. We considered that TLF2-IgMs are likely germline 
antibodies that associate with TLF in some concentration dependent mechanism. Many germline 
antibodies interact with proteins found within human cells, so we decided to probe human cell lysates with 
TLF2-IgMs from purified TLF2 and observed many protein interactions. Since TLF2-IgMs behave like 
germline antibodies, we therefore decided to generate TLF2 in mice that produce germline IgM antibodies 
at higher concentrations than conventional mice via genetic ablation of the gene encoding activation-
induced cytidine deaminase (AID) (12). AID mediates both class switch recombination and somatic 
hypermutation. AID-/- mice produce the same amount of total IgM as AID-expressing mice, although 100% 
of that IgM is germline IgM. We analyzed plasma from AID-/- mice transfected by HGD by size-exclusion 
chromatography to separate TLF2 (~1000 kDa) and TLF1 (~500 kDa). Mice expressing human APOL1 
and HPR produced both TLF2-like and TLF1-like HPR and APOL1-containing complexes (Figure 13A), 
although the TLF2-like complexes had smaller hydrodynamic radii than human TLF2 (i.e. they eluted later 
than human TLF2 typically does). By non-denaturing agarose gel electrophoresis, both the concentrated 
TLF2-containing fractions (lane 1) and whole plasma (lane 3) had APOL1 in the TLF2 range, while 
APOL1 was detected in the TLF1 range only in whole mouse plasma (lane 3) (Figure 13B). The TLF2-like 
complexes in ml 67-67.5 of Figure 13A were immunoprecipitated (IP) using HPR as the target antigen, 
which precipitated both APOL1 and IgM, indicating that all three components were present in the same 
complex (Figure 13C). Therefore, we assembled TLF2 in mouse serum using HGD delivery of APOL1 





Figure 12. Human TLF2-IgMs interact with proteins present in human cells. Far western blot 
showing the interactions between TLF2-IgMs and cell lysates prepared from human HepG2 (human liver 






Figure 13. Developing a murine model of TLF2. A) Western blots (reducing) of size fractionated pooled 
plasma from 2 mice expressing full length human APOL1 and HPR. B) Anti-APOL1 western blot of pooled 
ml 67 and 67.5 from A, transfected mouse plasma, and normal human plasma after separation by native 
agarose gel electrophoresis. The migration distance of ferritin (Pharmacia), a marker that migrates the 
same distance as bulk human HDL, is denoted by (**). A component of the marker that is not visible 
colorimetrically interacts non-specifically with the secondary antibody at (*). C) Western blot analysis of a 
co-immunoprecipitation using an anti-human (Hu) HP antibody that binds to human HPR (Sigma H6395) 








3. TLF2-IgMs Interact with HPR to Drive TLF2 Assembly 
HGD-generated TLF2 contains germline IgM from mouse serum and we wanted to know how it 
interacted with the TLF components. We used our HGD mouse model to generate components of TLF 
and assess their individual interactions with IgM. To analyze the interaction between TLF2-IgM and native 
HDLs, we expressed either HPR or APOL1 in AID-/- mice by HGD and analyzed the mouse plasma by 
size exclusion chromatography. Expression of HPR in AID-/- mice resulted in the formation of an HPR-
HDL-IgM immunocomplex that co-migrated with APOA-I and eluted from the column prior to the bulk of 
the mouse HDL complexes (Figure 14A). The HPR-HDL-IgM complex was validated by Co-IP (Figure 
14B). Expression of APOL1 in AID-/- mice did not produce a detectable immunocomplex (Figure 14C), 
and HGD of saline alone did not shift the migration pattern of APOA-I (Figure 14D). These findings were 
validated through Far western experiments in which we used human TLF2-IgM to probe APOL1 HDLs or 
HPR HDLs derived from transfected mice. We found that TLF2-IgMs interacted with human HPR but not 
human APOL1 (Figure 14E). Due to the polyclonal IgM component, TLF2-IgMs also interact with many 
unidentified components of human and mouse plasma, although the strongest detectable interaction was 
with the 45 kDa human HPR protein (Figure 14F), which is associated with TLF in vivo. We therefore 
concluded that an interaction between the TLF2-IgMs and HPR-bound HDL is required for TLF2 




Figure 14. TLF2-IgMs interact with human HPR to drive TLF2 assembly. A) Western blots of size 
fractionated human HPR expressing AID-/- mouse plasma. Fractions containing IgM-HPR-HDL 
complexes are marked by ‘immunocomplex’ and fractions containing HPR-HDL that is not bound by IgM 
are marked by ‘HPR-HDL.’ B) Co-immunoprecipitation of pooled fractions 66 and 66.5 from A using an 
antibody that binds to human HPR (Sigma H6395). C) Western blots of size fractionated human APOL1 
expressing AID-/- mouse plasma. D) Western blot of size fractionated untransfected AID-/- mouse 
plasma. E) Far western blot using TLF2 as the bait to detect prey proteins in mouse plasma, mouse HDL, 
mouse HDL after transfection with human HPR, and mouse HDL after transfection with APOL1. The band 
in lane 3 at ~45 kDa likely corresponds to human HPR as denoted by the ‘huHPR’ caption between the 
35 and 55 kDa MW markers. F) Far western blot showing the interactions between TLF2-IgMs and prey 
proteins in human plasma, bovine plasma, mouse plasma, mouse HDL, mouse HDL after transfection 
with human HPR, and purified human TLF1. Four identical membranes were prepared and probed as 
indicated. Panel ‘a’ was probed with an anti-HP antibody that binds to both HP (high molecular weight 
bands) and HPR (~45 kDa). Panel ‘b’ was probed with an anti-human IgM secondary antibody. Panel ‘c’ 
was probed with pooled human IgM at a concentration equimolar to that which was used in panel ‘d’ as 
determined by ELISA. 
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4. TLF2-IgMs Interact with Trypanosome Proteins Including VSG 
While both TLF1 and TLF2 have been identified as trypanosome lytic factors, previous work has 
demonstrated that TLF2 is likely more relevant in the context of human disease (102). Given that TLF1 
and 2 differ by a single component (IgM) and that the trypanosome surface is densely coated with VSG (a 
target for IgM), we and others (88) hypothesized that human TLF2-IgMs could facilitate TLF2 uptake by 
trypanosomes via low-affinity interactions with trypanosome surface antigens. To investigate this in vitro, 
we first probed total trypanosome lysates with human TLF2-IgMs under native (dot blot) and denaturing 
(SDS-PAGE) conditions and observed interactions between TLF2-IgMs and many trypanosome antigens 
(Figure 15A and B). Since the dominant trypanosome surface antigen, representing 10-20% of the cell’s 
total protein and 99% of the cell surfeome (178), is the ~60 kDa GPI-anchored VSG, we then investigated 
whether TLF2-IgMs could interact directly with VSG. To do so, we first isolated the GPI-anchored 
trypanosome proteins from three clones, each expressing a different VSG, by hypotonic lysis to enrich for 
VSG as described previously (179) (Figure 15C). Under native conditions, TLF2-IgMs interacted most 
strongly with the VSG3 preparation, while lower-affinity interactions were observed between TLF2-IgMs 
and VSGs 2 and 13 (Figure 15D). VSGs have been classified into multiple groups based on the 
distribution of cysteines throughout the amino acid sequence (180). Both VSG2 and 13 are class A VSGs, 
while VSG3 is a class B VSG that is highly structurally divergent (49), suggesting that TLF2-IgMs may 
have some structural specificity, although this will require further investigation. Taken together, these data 
reveal that the polyclonal IgM component of TLF2, as it is present in the serum of uninfected humans, can 
interact with VSG and other trypanosome proteins. Various kinetic experiments investigating the rate at 
which parasites are lysed by TLFs suggest that TLF2 uptake occurs more rapidly than fluid phase 
endocytosis, despite the lack of an identified receptor (181). We hypothesize TLF2-bound VSG is 







Figure 15. TLF2-IgMs interact with trypanosome proteins including VSG. A) Native dot blot using 
TLF2-IgMs as bait and non-denatured trypanosome lysates, human IgM, or human HP as prey. B) Far 
western blot using TLF2-IgMs as bait and an SDS-PAGE denatured trypanosome lysate preparation as 
prey. C) Coomasie stain showing the enrichment for VSG and other GPI-anchored proteins released into 
the supernatant after hypotonic lysis. VSG samples were prepared from cultured parasites expressing the 
indicated VSG variant. D) Native dot blot using TLF2-IgMs as bait and VSG2, 3, and 13 preparations or 












5. AID-Expressing Mice Produce TLF2 when Infected with Trypanosomes Prior to HGD Transfection 
Given that human TLF2-IgMs interact with trypanosome antigens, we hypothesized that 
trypanosome infection could increase the production of IgMs that could interact with TLF2 in wildtype 
mice. Swiss Webster and A/J mice were infected with T. b. brucei for 4 days prior to treatment with 
diminazene aceturate to cure the infection. We then used HGD to express the TLF genes in the mice 12 
days post-infection and analyzed the plasma by size-exclusion chromatography at 14 days post-infection, 
during the peak of the IgM response (53). Sizing the plasma revealed that the APOL1 protein migrated 
exclusively with the bulk HDL in uninfected mice, while a significant portion of the APOL1 shifted to the 
1000 kDa range in the infected and cured mice and co-migrated with bulk IgM (Figure 16A). To further 
investigate whether the IgM elicited by trypanosome infection in mice is TLF2-IgM, we used plasma from 
another trypanosome infected mouse to screen for potential interactions with human TLF proteins. 
Trypanosome infection-derived IgMs interacted with human HPR and another unidentified mouse HDL 
protein that was the size of APOA-I, while IgM from an uninfected mouse did not bind to any HDL or TLF 
proteins (Figure 16B). We therefore conclude that while infection substantially increases levels of IgM in 
mice, only a fraction of those are amenable to recruitment into TLF2 complexes and are therefore TLF2-
IgMs. Nevertheless, these data suggested that TLF2-IgMs, while likely germline antibodies, can be 
elicited by trypanosome infection. Germline antibody production can be increased through T-cell 
independent B-cell responses, which are the classical humoral responses by which anti-VSG IgMs are 
expanded during infection (65). To investigate this in our own laboratory conditions, we infected AID-/- 
mice with a pleomorphic strain of T. b. brucei and followed the parasitemia waves over time. We observed 
that AID-/- mice and AID-expressing mice were equally capable of suppressing the peaks of parasitemia 
(Figure 16C and D) and were equally susceptible to long-term infection (Figure 16 E). This conclusively 
reveals that, in mice, germline antibodies are sufficient to control parasitemia and are likely the antibodies 
that are expanded during trypanosome infection. We therefore conclude that the generation of TLF2 in 
trypanosome infected AID-expressing mice was likely mediated by the increased production of particular 





Figure 16. AID-expressing mice produce TLF2 when infected with trypanosomes prior to HGD 
transfection. A) Anti-APOL1 western blots of size fractionated human APOL1 and HPR-expressing 
mouse plasma samples. Top panel: A/J mouse infected with and cured of T. b. brucei. Middle panel: 
Swiss Webster mouse infected with and cured of T. b. brucei. Bottom panel: Uninfected Swiss Webster 
mouse. B) Western blot showing the interaction between mouse IgMs and SDS PAGE separated proteins 
from human plasma, bovine plasma, mouse plasma, mouse HDL, and mouse HDL from an animal 
transfected with human HPR. Samples were probed with non-specific mouse IgM (a), healthy mouse 
plasma (b), and mouse plasma that was isolated from a T. b. brucei AnTat 1.1-infected animal (c). The 
amount of non-specific IgM used in ‘a’ was at an equimolar concentration relative to panel ‘c’ as 
determined by ELISA. C) Parasitemia curve showing the number of parasites in the blood of mice 
infected in the intraperitoneal cavity with 5000 T. b. brucei AnTat DRF parasites. Parasitemia was 
monitored approximately every 2-3 days until day 17 post-infection, after which only mouse survival was 
monitored. D) The same data as shown in ‘C’ although the parasitemia of each individual mouse is 
plotted. E) Survival of the mice shown in panels ‘C’ and ‘D.’ The curves in ‘E’ are not statically different 

















6. Trypanosome Infection Increases TLF2-IgM Production in Sleeping Sickness Patients 
The production of TLF2-IgMs in mice was likely due to an increased concentration of circulating 
germline IgMs that can interact with TLF. This suggests that there is a threshold of (or binding quality of) 
germline IgM concentration that is required in order to form detectable quantities of TLF2. In humans, 
TLF2-IgMs are present regardless of infection status. We investigated whether trypanosome infection, 
akin to the mice, would increase the concentration of circulating TLF2-IgMs in sleeping sickness patients 
(patient demographics are in Table 2). We found that trypanosome infection led to an approximately 50-
fold increase in circulating total IgM concentration (Figure 17A). We then analyzed the ratio of TLF2-
associated APOL1 to TLF1-associated APOL1 by non-denaturing agarose gel electrophoresis and found 
that the ratio was substantially shifted towards TLF2 in infected individuals, while uninfected African or 
American control samples contained >95% TLF1 (Figure 17B). Importantly, there was a statistically 
significant pairwise decrease (2-tailed parametric T Test P = 0.0419) in the TLF2:TLF1 ratio within the 
samples taken from individuals before and after treatment. This suggests that, while only a small fraction 
of the circulating IgMs in healthy individuals are TLF2-IgMs, trypanosome infection increases that fraction 
by increasing the abundance of polyclonal trypanosome-reactive IgMs that then dissipate after the 
infection has been cured.  
One hallmark of trypanosome infection is an increase in circulating type 2 interferons (182), which 
we confirmed in the study of this cohort of patient samples (Figure 17C). Type 2 interferon signaling is 
known to upregulate APOL1 mRNA expression (183), and human T. b. gambiense infection stimulates 
APOL1 RNA upregulation (184), suggesting that total TLF levels increase during trypanosome infection. 
This was demonstrably not the case, as we instead found that trypanosome infection did not significantly 
change the circulating APOL1 concentration relative to uninfected controls (Figure 17D). The regulation of 
circulating APOL1 concentration is likely multifactorial, and therefore we investigated whether the total 
amount of HDL was affected by trypanosome infection, as it is reduced during many other infections 
(185). Indeed, the circulating HDL concentration (APOA-I protein) was reduced 5 to 6-fold in infected 
individuals relative to healthy controls (Figure 17E). These data reveal that trypanosome infection does 
not change the total amount of circulating TLF, but that it leads to a redistribution of the available 
circulating APOL1 into TLF2 complexes by increasing the circulating levels of TLF2-IgMs.  
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Table 2. Details of sleeping sickness patients and controls. 
Characteristic Patients (n=21) Controls (n=19) 
Male:Female 10:11 9:10 
Age: Median (range) 25 (6-65) 35 (8-59) 
Early/Late stage infectiona 4:17 n/a 
aEarly (hemolymphatic) and late (meningoencephalitic) cases. Staging criteria and treatment regimens 






Figure 17. Trypanosome infection increases TLF2-IgM production in sleeping sickness patients. A-
E) Samples were taken from patients infected with T. b. rhodesiense before or after treatment with 
suramin or melarsoprol. A) Plasma IgM levels determined by ELISA (Invitrogen) in sleeping sickness 
patients compared to control samples from healthy donors (****P<0.0001; Bonferroni-corrected Mann-
Whitney; error bars indicate mean +/- SD). B) Determination of the ratio of TLF2-associated APOL1 to 
TLF1-associated APOL1 by western blot following native agarose gel electrophoresis in sleeping 
sickness patients compared to control samples from healthy donors (****P<0.0001; Bonferroni-corrected 
Mann-Whitney; horizontal bar indicates the median of each group). C) Plasma IFN-gamma levels 
determined by ELISA in sleeping sickness patients compared to control samples from healthy donors 
(****P<0.0001, ***P<0.005; Bonferroni-corrected Mann-Whitney; error bars indicate mean +/- SD). D) 
Plasma APOL1 levels determined by western blot in sleeping sickness patients compared to control 
samples from healthy donors (Kruskal-Wallis P = 0.0778; error bars indicate mean +/- SD). E) Plasma 
APOA-I levels determined by western blot in sleeping sickness patients compared to control samples 
from healthy donors (****P<0.0001, **P<0.01, *P<0.05; Bonferroni-corrected Mann-Whitney; error bars 
indicate mean +/- SD). 
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7. The Increased Circulating TLF2-Levels During Infection May be Specific to Trypanosome Infection 
 We hypothesized that an increase in any pathogen-specific IgM could increase the levels of TLF2 
in humans. To address this, we performed the same biochemical analyses as above on a cohort of 
malaria (Plasmodium falciparum)-infected individuals (patient demographics are in Table 3). P. falciparum 
is an antigenically variable parasite that displays multiple proteins on the surface of its resident red blood 
cell during infection, including PfEMP1 (186). PfEMP1 proteins are encoded by the monoallelically 
expressed var genes, of which the malaria parasite has approximately 60 alleles (186). We hypothesized 
that antigenically variable pathogens like Malaria would provide the best comparison to trypanosome 
infection in the context of B cell stimulation and therefore IgM generation. However, we observed that the 
total levels of IgM in these infected individuals were only 2-fold higher (not statistically significant) than the 
IgM levels in their control cohort (Figure 18A). There was no increase in the ratio of TLF2 to TLF1 (Figure 
18B) or change in total TLF levels (Figure 18C) in this cohort of individuals. In the future, we would like to 
investigate whether there even are any human infections that increase the circulating IgM levels as much 






























Table 3. Details of malaria patients and controls.  
Characteristic Patients (n=26) Controls (n=3) 
Male:Female 19:7 Unk 




aComplicated (cerebral malaria and severe anemia) and uncomplicated (cyclical fevers and flu-like 






Figure 18. Malaria infection does not detectably increase TLF2-IgM production in human patients. 
A-C) Samples were taken from German travelers infected with P. falciparum and a small cohort of local 
German control samples. A) Plasma IgM levels determined by ELISA (Invitrogen) in malaria patients 
compared to control samples from healthy donors (error bars indicate mean +/- SD). B) Determination of 
the ratio of TLF2-associated APOL1 to TLF1-associated APOL1 by western blot following native agarose 
gel electrophoresis in malaria patients compared to control samples from healthy donors (horizontal bar 
indicates the median of each group). C) Plasma APOL1 levels determined by western blot in malaria 





























8. TLFs 1 and 2 are the Same Protein Complex in an IgM-Dissociated and IgM-Associated State 
 Since TLF2-IgMs interact with the proteins on the TLF complex, and TLF2 levels increase in a 
germline IgM concentration dependent manner, we hypothesized that TLF2 is an IgM-bound TLF1. To 
clarify this, we hypothesize that both TLFs are the same HDL complex that exists in two different states 
dependent on the concentration of circulating TLF2-IgM. To investigate this hypothesis, we sought to 
determine whether TLF1 and TLF2 were members of the same class of HDL (Figure 6). HDLs 
accumulate cholesterol during their maturation, and so we assessed the amount of cholesterol that the 
TLFs carry in order to estimate which class of HDL that they belong to. Mature HDLs carry 25-100 mols of 
cholesterol per mol of HDL, while pre-beta HDLs carry very little cholesterol (187). We found that both 
TLFs carry a small amount of cholesterol that is characteristic of pre-beta HDLs (Figure 19). However, 
TLF1 is among the largest of all HDLs, while typical pre-beta HDLs are smaller than mature HDLs. We 
therefore hypothesize that the TLFs are the same class of HDL, but do not conform to the classical 
definition of pre-beta HDL and instead accumulate a high amount of protein or some other non-







Figure 19. TLF1 and 2 both contain a negligible amount of cholesterol. TLFs 1 and 2 were isolated 
from human plasma and compared to total human HDL also isolated from human plasma. The number of 
mols of cholesterol per mol of HDL was quantified using a colorimetric kit from Wako Diagnostics. The 
graph shows one of two biological replicates (error bars represent the mean +/- SD of experimental 





































In order to characterize the structure of the TLFs in a more robust way, we used transmission electron 
microscopy to analyze the structure of the complexes. The HDL components of both TLF1 and TLF2 
appeared to be identical, forming approximately spherical complexes reminiscent of bulk HDL complexes, 
while the IgM component was immediately juxtaposed to the HDL component of TLF2 (Figure 20). These 
data suggested that the TLFs are indeed the same protein complex, with or without an attached IgM, 
although we acknowledge that a more detailed visual representation of TLF structure is required and are 
currently pursuing Cryo electron microscopy-based structural data.  
Taking all of these data together, we interpret that TLF1 and IgM exist in equilibrium with TLF2 in 
vivo, and that the circulating concentration of TLF2 is entirely dependent on the amount of circulating 
TLF2-IgMs at any given time. Consistent with this hypothesis, purified human TLF2 samples reproducibly 
contain TLF1 (see representative sample in Figure 11D, lane 2), likely due to a depletion of TLF2-IgMs 
from the sample during the stringent purification strategy. These data reveal that the interaction between 
germline IgMs and TLF1 is a low-affinity interaction that forms TLF2, and that this interaction likely plays a 






Figure 20. TLF1 and 2 are the same protein complex in an IgM-dissociated and IgM-associated 
state. Transmission electron micrographs of purified human TLF1 (top), TLF2 (middle) and bulk HDL 
(bottom). Images were captured using 50,000x total magnification. The scale bar applies to all three large 
images. The black boxes are insets that are magnified on the right. The red arrows point towards 
lipoprotein complexes which appear spherical in all conditions, while the blue arrow points to an IgM 
which are only observed in the TLF2 image.  
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Discussion 
Both TLF1 and TLF2 are trypanolytic protein complexes that harbor most of the same 
components, with the exception of the IgMs associated with TLF2 (173). Here, we have investigated the 
properties of the TLF2-IgMs and the nature of their association with TLF. Based on our findings, we 
hypothesize that TLF1 and TLF2 are the same protein complex that is IgM-free as TLF1 and IgM-
associated as TLF2, and that TLF and IgM exist in equilibrium. The TLF-associated IgMs are likely 
germline antibodies, given that all tested humans have detectable levels of TLF2 (Figure 18B) and AID-/- 
mice produce TLF2-IgMs (Figure 13 and 14). This hypothesis also stipulates that while the circulating 
concentration of TLF2-IgMs is high enough to mediate TLF2 formation in trypanosome-naïve humans, an 
increase in the production of TLF2-IgMs would subsequently lead to an increase in the circulating levels 
of TLF2. We have indeed observed that trypanosome infected mice (Figure 16A) and humans (Figure 
18B) produce more TLF2 than their uninfected counterparts. However, since uninfected mice do not 
produce detectable quantities of TLF2 except in the absence of AID, we hypothesize that there is a 
particular intrinsic quality of IgM that is amenable to TLF2 formation, which uninfected WT mice do not 
produce in high quantities. Since AID-/- do produce these antibodies in evidently high enough quantities to 
generate TLF2, we hypothesize that some uncharacterized feature that is specific to germline IgM, 
possibly their antigen specificity, avidity, valence, or glycosylation profile, is the key element required to 
produce TLF2.  
The data presented here indicate that TLF2-IgMs interact with the HPR component of TLF1 in 
order to form TLF2 (Figure 14). HPR is a glycoprotein bound to HDL complexes via a retained signal 
peptide. This directed association ensures that the receptor binding face of HPR is consistently exposed 
to the external environment, thereby increasing the probability of binding the trypanosome HPHB receptor 
and receptor-mediated uptake. TLF2 is taken up by trypanosomes independently of the HBHPR. We 
propose that the source of TLF2’s HPHBR independence is a due to the 950 kDa IgM antibody interacting 
with HPR and therefore blocking the interaction with the receptor. This HPR-IgM interaction is non-
covalent and low affinity, such that the IgM may dissociate at any time and reveal the receptor-binding 
domain, permitting HPHBR-mediated uptake. Ten thousand-fold more TLF1 was required to lyse 
parasites with decreased HPHBR expression as compared to wild type T. b. brucei, while only 100 fold 
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more TLF2 was required (103), suggesting that TLF2 uptake is partially dependent on the HPHBR. 
However, this model of TLF-IgM equilibrium may suggest that a fraction of the TLF in those purified TLF2 
samples had disassociated from IgM, thereby forming TLF1, leading to HPHBR-mediated uptake. This is 
supported by our observation that purified TLF2 samples invariably contain free “dissociated” TLF1 
(Figure 11D). This particular piece of data leads us to hypothesize that the incubation of dissociated TLF1 
with germline IgM should result in re-association of the complex. These and other experiments must be 
conducted in the future to determine whether the equilibrium model of TLF1 and 2 formation is the correct 
interpretation of our in vivo data.  
Trypanosome lytic factors are not a uniform species. Using isoelectric focusing followed by 
APOL1-specific western blotting, one group has been able to separate APOL1-containing TLF1 
complexes into three distinct species, so called the alpha, beta, and gamma complexes (188). The 
structural or biochemical differences between the three complexes remains unclear, however, another 
group used tandem affinity purifications to show that approximately only 1/3 of the HPR or APOL1-
containing TLF1-sized complexes in serum actually contain both proteins simultaneously (90). There are 
also therefore a certain number “HPR-only” HDL complexes (that aren’t actually trypanolytic) and a 
certain number of “APOL1-only” TLFs. We hypothesize that the “APOL1-only” species and the APOL1-
HPR species (a ‘complete’ TLF1) comprise two of the three TLFs detected by Weckerle et al. (188), while 
the third remains uncharacterized entirely.  
TLF2-IgMs are particularly promiscuous antibodies that interact with many self (Figure 12 and 
Figure 14) and non-self antigens (Figure 15B and D). This remarkable polyreactivity is classic 
characteristic of germline IgM antibodies. We hypothesize that the TLF2-specific trypanosome uptake 
pathway may involve this polyreactive property of TLF2-IgMs, whereby the decavalent IgMs could interact 
with both the TLF and the surface of the parasite simultaneously. Trypanosomes endocytose antibody-
bound VSGs within 2 minutes of antibody binding in order to evade antibody-mediated immunity (50). We 
therefore hypothesize that TLF2-bound VSG would lead to TLF-associated APOL1 uptake by this same 
mechanism. A TLF2 uptake mechanism that depends on anti-VSG germline antibodies is consistent with 
work from Muller et al., who revealed that auto-reactive IgMs in humans and other mammals bind to VSG 
proteins from various trypanosome isolates (68). In fact, some of the murine antibodies analyzed by 
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Muller et al. were derived from germ-free mice, thereby formally revealing that foreign antigen stimulus-
independent systems produce anti-VSG IgMs. VSG is not the sole potential TLF2-IgM target epitope, as 
TLF2-IgMs can interact with a wide range of trypanosome antigens (Figure 15B). However, the fact that 
VSG exists in a roughly 10,000-fold molar excess relative to all other trypanosome surface proteins leads 
us to hypothesize that it is the most relevant surface protein with regard to TLF2 uptake. Under this 
assumption, it is possible that trypanosome infection-elicited TLF2-IgMs may afford TLFs with adaptive-
like targeting potential by preferentially binding to particular infection-specific VSG classes or variants. 
This assumption also hinges on the hypothesis that the TLF2-IgMs interact with VSG via the antigen-
binding regions. While this is likely to be the case, based on classical antibody-antigen interactions, we 
cannot confirm that using the experiments presented here. Similarly, we are unable to determine whether 
the antibody simultaneously interacts with the HPR component of TLF via the antigen-binding region or 
the constant region, although the lipoprotein component of the TLF2 appears to be engaged with the Fab 
of the antibody via transmission electron microscopy (Figure 20). In the future, it will be prudent to 
determine the orientation of these interactions, possibly by obtaining higher resolution images of the 
complex engaged with the surface of an African Trypanosome via cryo-electron microscopy.  
Having two non-redundant mechanisms of APOL1 delivery to invading trypanosomes provides an 
immunological advantage. In normal human serum, while TLF2 uptake is unabated, TLF1-mediated 
APOL1 uptake is effectively inhibited by the physiological levels of circulating HP (102). HP is an acute 
phase response protein that prevents hemoglobin-induced toxicity and is induced by inflammatory 
cytokines (189). Therefore, in both the acute phase and healthy states, TLF2-mediated trypanosome 
immunity likely predominates. However, TLF1-mediated trypanosome immunity may play a more 
prominent role when haptoglobin levels are low, such as in the case of chronic malaria infection. Malaria 
infection is associated with sharply decreased serum haptoglobin levels as a result of cyclical red cell 
lysis and subsequent HBHP complex clearance by macrophages, reviewed here (190). Human co-
infection with malaria in the context of trypanosome infection is common, as trypanosome endemic 
regions typically overlap with the distribution of malaria in Sub-Saharan Africa (191). The estimated 200 
million annual cases of malaria could select for an HPHBR-mediated trypanocidal effect in co-infected 
individuals. To clarify this explicitly, we hypothesize that TLF2 is the main lytic component of normal 
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human serum and that the entry of TLF2 into the parasite is dependent on low-affinity interactions 
between the TLF2-IgMs and VSG, but that under conditions when circulating haptoglobin levels are low, 
TLF1 uptake will predominate.  
Human-infective trypanosomes are resistant to TLF-mediated lysis. T. b. rhodesiense parasites 
express serum resistance associated protein (SRA) which binds to and inhibits the activity of human 
APOL1 (118), while T. b. gambiense uses a combinatorial APOL1 resistance mechanism that is 
dependent on reduced APOL1 uptake via a mutated HPHBR and the Trypanosoma gambiense-specific 
glycoprotein (TgsGP), which is associated with the inhibition of APOL1 activity (129). However, human 
population studies (144) and in vivo experiments using transgenic mice (81) have revealed that the 
relationship between trypanosomes and human APOL1 is complicated. Human variants of APOL1 called 
G1 and G2 provide increased resistance to human-infective trypanosomes. The G2 variant of APOL1 has 
a decreased affinity for the SRA protein from T. b. rhodesiense (81), and humans harboring the G2 allele 
are 5-fold less likely to be infected with T. b. rhodesiense parasites (144). The G1 variant is associated 
with a 3-fold decreased probability of developing clinical symptoms during T. b. gambiense infection 
(144), although the mechanism has not been characterized. Importantly, studies have revealed that 
human TLF can lyse T. b. gambiense parasites when TLF1 associated APOL1 uptake is increased by 
expressing the T. b. brucei HPHBR in the absence of HP (129). However, HP levels are elevated during 
trypanosome infections (192), which prevents TLF1-mediated lytic activity (102). Thus, in individuals 
infected with African trypanosomes, we hypothesize that TLF2 would be the predominant lytic factor that 
prevents or controls the infection, and indeed we have observed that T. b. rhodesiense infected humans 
have markedly increased levels of circulating TLF2 relative to TLF1 (Figure 18B). We interpret these data 
as a shift in the TLF1/TLF2 equilibrium towards TLF2 due to an increase in the production of IgM 
antibodies to the trypanosome infection.  
Despite having only characterized the TLF levels in one non-trypanosome infection (Figure 19), 
after conducting extensive literature searches, we hypothesize that there aren’t any appropriately 
comparable chronic infections. The biology of VSG switching stimulates the host’s humoral response in a 
way that seemingly no other pathogen does. Malaria infection in particular is an antigenically variable 
infection, although the parasite population coordinates the switching of var genes (the genes that encode 
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the antigenically variable PfEMP1 protein) such that the entire population expresses the same or only few 
var genes at any given time (186). Comparatively, murine experiments have shown that trypanosome 
infected hosts can have up to 97 different VSG-expressing populations stimulating their immune system 
at any given time (43). Therefore, with respect to circulating IgM levels and therefore TLF2 levels, the 
increase in circulating TLF2 levels is likely a trypanosome-specific response as a result of the sheer 
number of antigens being presented at any given time, rather than antigen specificity.  
There are human syndromes associated with the overproduction of IgM in the uninfected state. 
Individuals with any of the hyper IgM syndromes are typically more susceptible to a variety of infections, 
due to a general inability to produce antigen specific adaptive responses and an inability to class switch 
away from IgM production resulting in a lack of high-affinity IgG-mediated effector functions. However, 
based on the data presented in this chapter, we would hypothesize that individuals with hyper IgM 
syndromes may actually have an increased innate resistance to trypanosome infection through an 
increase in TLF2 production. To our knowledge, no such association study has been conducted, although 
we would at least like to determine the trypanolytic potential of hyper IgM sera in the future.  
Taken together, these data suggest that the balance between trypanosome immunity, control, 
and active infection is determined by APOL1 genotype and both the rate and ultimately the functional 
amount of APOL1 taken up by the parasites. We maintain that the field to this day does not have a full 
understanding of the structure and function of TLFs, and that continuing to investigate how these HDL 
complexes and their associated antibodies impact trypanosome immunity is crucial to understanding the 




Chapter Two: The Evolution of the Primate TLF Genes APOL1 and 
HPR 
Introduction 
Both APOL1 and HPR are primate-specific genes with complex evolutionary histories. APOL1 
arose through gene duplication events prior to the divergence of OWMs and great apes approximately 24 
million years ago (82). APOL1 has since been rapidly evolving in the primate lineage, displaying marks of 
positive selection in APOL1-expressing primates (82). Many positively selected genes evolve under the 
pressure posed by some pathogen or pathogens. APOL1 clearly participates in multiple host-pathogen 
interactions, likely protecting primates from infection by HIV (possibly the simian counterparts) (85), 
certain bacterial infections (Almanzar and Raper; unpublished data), Leishmania parasites (84), and of 
course the African trypanosomes. The evolutionary relationship between APOL1 and trypanosomes is the 
most well understood, in part due to the expansion of APOL1-related research programs stimulated by 
the discovery of the human renal risk variants. There are at least 13 human APOL1 haplotypes, including 
G1 and G2, that exist in >1% of the global population (common variants) (81). These variants were 
identified by the combined efforts of a number of genome sequencing consortiums aiming to sequence 
seemingly everyone in the world. Less effort has been allocated to sequencing non-human primate 
genomes. To better understand the evolutionary history of the APOL1 gene and the host-pathogen 
interactions that it participates in, we must combine human and non-human primate genomics to broaden 
the scope of our collective investigation.  
T. b. gambiense parasites resist lysis by human APOL1 through a combinatorial mechanism. 
Central to this mechanism is TgsGP, the endolysosomally localized hydrophobic protein that is 
hypothesized to prevent APOL1-mediated channel formation by modifying the structure of the 
endolysosomal membranes (129). Hypothetically, the TgsGP-bound endosomal membranes become too 
“stiff” to allow APOL1-mediated channel formation. This mechanism, while itself poorly characterized, 
does not address the fact that baboon APOL1 can lyse T. b. gambiense parasites with seemingly similar 
efficiency as compared to T. b. brucei (160). This could be explained by determining the membrane 
insertion kinetics of the two proteins. If baboon APOL1 evolved certain residues that allow it to insert into 
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lipid membranes more efficiently, and that increased efficiency is required for T. b. gambiense lysis, then 
the membrane stiffening model would be supported. However, if baboon and human APOL1 insert into 
membranes with similar kinetics, then the field must revisit the role of TgsGP.  
HPR arose through a gene duplication event around the same evolutionary time as APOL1, the 
ancestral gene being HP (97). HPR has at least two distinct roles in primate immunity. HPR is required for 
TLF-mediated Leishmania immunity through an unknown mechanism (84); and HPR participates in TLF-
mediated Trypanosoma immunity by facilitating TLF1 uptake by the parasite (88). Since HPR participates 
in host-pathogen interactions, we hypothesize that HPR, similar to APOL1, has been evolving under the 
pressures posed by pathogens. There are SNPs that are exclusive to individuals of recent African decent 
in the HP-HPR locus, and HPR copy number variants exist in approximately 25% of individuals with 
recent African decent, with some individuals having up to 8 copies of the gene (193,194). This HPR 
amplification was found to have a slight but non-significant association with T. b. gambiense infection 
prevention in one population study, although the statistical power of this analysis was limited (193). 
Importantly, it remains unknown whether any of these genetic variants are biochemically significant with 
respect to trypanosome infection outcomes or any other aspect of human biology. Here, we present a 
series of bioinformatic and biochemical investigations designed to expand on the evolutionary 
understanding of both APOL1 and HPR in humans and primates, with particular respect to the interaction 




1. The African HPR Variant V1 
 We used human genome sequencing data from the 1000 genomes project to manually identify 
rare genetic variants in the HPR gene. Three coding SNPs (rs1065360 - V11; rs2021171 - V12; rs1049933 
- V13) (Figure 21) were exclusive to individuals with recent African descent. The SNPs are rarely present 
as individual mutations and are instead inherited together as a distinct haplotype. V11 is likely the 
evolutionarily oldest variant, present in 32.2% of the individuals with recent African ancestry. 98% of 
those carrying V11 also carry V12, while approximately 80% carry V13. Importantly, there are no 
individuals that carry V12 or 3 without also carrying V11, demonstrating their haplotypic inheritance. 
Whether these variants are associated with trypanosome infection outcomes has not been determined 
but is unlikely. A series of publications from the TrypanoGen project have already performed these 
studies using a panel of genes including HPR in various native African populations, reviewed here (146). 
One of the investigations found a weak but significant association between trypanosome infection 
outcomes and an intronic SNP in the HP-HPR locus (195), although no HPR missense mutations have 
ever been associated. 
 A long-standing hypothesis in the field of APOL1-mediated nephropathy states that there may be 
some chaperone protein that titrates G0-mediated toxicity but does not regulate the risk variants G1 and 
G2 (essentially an APOL1-interacting protein that functions analogously to the T. b. rhodesiense SRA 
protein). It is then possible that the G1 and G2 mutations in APOL1 were followed by more recent 
mutations in the putative chaperone protein that could reestablish the prevention of toxicity. We 
hypothesized that HPR could act as the chaperone in question, since the two proteins are associated with 
each other post-translationally (on TLFs). We observed that V11 in particular appeared to co-inherit with 
the G2 variant of APOL1. Explicitly, V11 is present in 30.2% of the individuals with recent African ancestry 
that do not carry the G2 allele, while it is present in 38.3% of the G2 carrying individuals (Table 4). We 
cloned this variant of HPR into our eukaryotic expression vector pRG977 but have not yet investigated 
whether this variant changes the biochemical properties of HPR or whether it has any effect on APOL1-






Figure 21. The African HPR variant V1. Illustrated is the linear structure of the HPR protein before 
complete post-translational processing. The protein is a dimer of 1 alpha and 1 beta chain which are 
translated simultaneously, cleaved, and then bound together by a disulfide linkage. There is an N-terminal 
signal peptide (SP - green) that is not-cleaved during translation, which allows the protein to be secreted 
and loaded onto TLFs. The alpha chain contains two Sushi domains (complement protein binding 
domains), while the beta chain has strong structural homology with chymotrypsin family proteins despite 
having an inactive catalytic triad. The V1 variant mutations are indicated above the model, with both the 
SNP code and the amino acid change that results (ancestral amino acid - codon number - V1 amino acid) 
(A: alanine, V: valine, R: arginine, K: lysine). All three mutations fall within the chymotrypsin domain of the 
beta chain.  
 
Table 4. The African HPR SNP V11 is enriched in individuals that carry the APOL1 G2 allele. 
HPR Genotype at rs1065360 Africans without G2 (n=502) Africans with G2 (n=159) 
Ancestral (valine) 350 (69.80%) 98 (61.70%) 





2. African Green Monkeys do not Produce Plasma-Circulating APOL1 
 There are five known APOL1-producing primates. However, certain primate species have not 
been extensively investigated in this context including the African Green Monkey (AGM). The AGM is an 
OWM related to baboons that currently inhabits a region of east Africa that partially overlaps with the 
distribution of tsetse flies and is therefore likely exposed to trypanosomes. We obtained AGM plasma 
samples in order to determine if this primate had APOL1-containing plasma. Using a polyclonal antiserum 
raised against baboon APOL1, we were unable to detect APOL1 protein in AGM plasma, sized-plasma, 
or purified HDL (Figure 22A). Further, the livestock-infective T. b. brucei was not susceptible to lysis 
mediated by purified AGM HDL. Although the lipoproteins were able to kill 50% of the parasites in these 
assays, the lysis could not be inhibited by NH4Cl and therefore cannot be attributed to APOL1 (Figure 





Figure 22. The African Green Monkey does not produce plasma-circulating APOL1. A) Anti-baboon 
APOL1 western blot of AGM plasma, AGM sized plasma, and purified AGM HDL from 3 separate 
monkeys. Multiple blots were performed separately and then combined to generate this image. B) UV 
absorbance chromatogram of the sized AGM plasma blotted in A. ml 7.5 is void. Human TLF2 would 
typically elute between ml 8 and 10, while TLF1 would elute between ml 11 and 13. C) 24-hour 
trypanosome lysis assay using purified HDL samples from the 3 separate monkeys blotted in A in the 









3. Baboon APOL1 is Highly Polymorphic 
Baboons express APOL1 and are thus resistant to T. b. brucei and the human-infective sub-
species. However, it remains unknown whether baboon APOL1 is polymorphic, akin to human APOL1, or 
more highly conserved with only 3 published baboon APOL1 sequences representing individuals from 3 
different baboon species. To determine whether APOL1 polymorphisms exist within the baboon lineage, 
we analyzed data collected by the Baboon Genome Consortium (baboon sources are detailed in 
Appendix Table 1 and all SNPs are detailed in Appendix Figure 1). By analyzing data from 39 individual 
baboons (therefore 78 alleles), representing all six Papio species (Figure 23A), we identified a total of 39 
polymorphic sites within the 5 exons of baboon APOL1. These sites were used to construct haplotypes, 
revealing 33 unique APOL1 gene sequences. 20 of these 33 unique sequences appeared only once 
between the 78 sequenced alleles, leaving 13 relatively common gene variants. However, more baboons 
will need to be sequenced in the future in order to determine which variants are truly ‘common’ given that 
our low N number means that every variant we detect is technically present in at least 2.5% of this 
population.  
A phylogenetic analysis of the gene sequences revealed different patterns of heterozygosity and 
homozygosity between different baboon species (Figure 23B). For example, all four P. papio alleles were 
completely identical, suggesting that this allele has been selected in this species (Figure 23B). However, 
both of these DNA samples were collected from baboons living together in captivity (Supplementary 
Table 1), thus breeding with a limited gene pool. More highly confident conclusions can be drawn for the 
P. cynocephalus species which accounts for 14 of the 39 individuals, 12 of which were sourced from their 
natural habitat in central Tanzania (Supplementary Table 1). Four of the P. cynocephalus baboons were 
homozygous for the APOL1 variant Cyno1, and the same variant was present on one allele of four other 
baboons (Figure 23B). In total, the Cyno1 haplotype accounts for 43% of the P. cynocephalus alleles, 
with the next most common haplotypes (Cyno2 and 3) accounting for only 14% of the total alleles each. 
This may suggest that the Cyno1 allele is the most highly selected variant in the P. cynocephalus 
population, although an increase in statistical power (more sequences) is required to draw definitive 
conclusions in this case as well. Nevertheless, these analyses bring the total number of baboon APOL1 




Figure 23. Phylogenetic analysis of the baboon APOL1 gene. A) The map illustrates the distribution of 
the six Papio species. The map is reformatted from the Ph.D. thesis of Dr. Kenneth Chu. B) The 
phylogenetic tree was constructed using the webserver phylogeny.fr using polymorphisms within the 
baboon APOL1 gene locus (chr10:76,724,427-76,734,622 in the Panu_2.0 reference genome) from 
whole genome and whole exome sequencing reads of 39 baboon individuals of various species and 
geographical sources. The average read depth at the APOL1 locus in this baboon dataset was 13.85X 
(ranging from 2-43X). The IDs following the species name of each individual on the tree were arbitrarily 
assigned by the Baboon Genome Consortium. Both haplotypes from each individual are included within 
the tree, with one of the two haplotypes arbitrarily assigned the letter ‘B’ (ex. Cynocephalus15977 and 
Cynocephalus15977_B). The APOL1 sequence of the Mandrill, a closely related OWM, was used to root 
the tree. Trees were generated using haplotypes constructed using all exonic SNPs within the locus. The 


















Figure 24. The consensus sequences of each baboon species APOL1 protein. (Top) Illustration of 
the putative domain architecture of APOL1. APOL1 has an N-terminal signal peptide that directs the 
protein to the secretory pathway during translation. APOL1 has four predicted membrane-spanning 
regions. APOL1 also has a C-terminal leucine zipper motif that is hypothesized to drive subunit 
multimerization during ion channel formation (Schaub, Thomson, and Raper, unpublished data). The 
numbers above the illustration highlight the location of the polymorphic sites that differentiate the 
consensus sequences of the various species. (Bottom) Only the polymorphic amino acids that define the 
consensus sequences are listed, meaning that every non-listed amino acid position is identical between 
all species consensus sequences. However, there are more rarely polymorphic sites that are specific to 
certain subgroups that are listed in Supplementary Table 1. Sites that differ from the overall consensus 
among the different species are highlighted in red. Positions 169 and 385 in the P. ursinus APOL1 cannot 
























4. The Relationship Between Papio APOL1s and T. b. gambiense 
P. papio APOL1 lyses T. b. gambiense parasites with a similar efficiency as compared to T. b. 
brucei (160). No other baboon APOL1 proteins have been reported to lyse T. b. gambiense, however, P. 
hamadryas baboons are refractory to T. b. gambiense infection in vivo (159), suggesting that their APOL1 
protein may have some lytic activity towards T. b. gambiense. Our phylogenetic analysis revealed that the 
P. papio and P. hamadryas APOL1 sequences are highly similar, despite these two baboon species 
inhabiting very different regions of Africa (Figure 23A). To determine if the ability to lyse T. b. gambiense 
was restricted to P. papio APOL1, we isolated recombinant P. papio and P. hamadryas APOL1 variants 
from E. coli (Figure 25A and B) and performed in vitro trypanolysis assays. Both proteins lysed T. b. 
gambiense (Figure 25C), suggesting that the ability to lyse T. b. gambiense may be afforded to all Papio 
APOL1s despite that many Papio species, including P. hamadryas, do not currently live in T. b. 
gambiense endemic areas (Figure 23A). To investigate this, we expressed a variant of P. cynocephalus 
APOL1 in E. coli (Figure 25A and B) and performed the same analysis. We chose P. cynocephalus 
APOL1 in particular because previous in vivo analyses revealed that P. cynocephalus baboons were 
susceptible to T. b. gambiense infection (158), and P. cynocephalus serum could not lyse T. b. 
gambiense parasites in vitro (163). In our studies, we found that P. cynocephalus APOL1 was less lytic to 
trypanosomes than P. hamadryas (Figure 25D), but it could still lyse T. b. gambiense at higher 
concentrations (Figure 25C). To determine if the concentrations required to lyse T. b. gambiense were 
physiologically relevant, we quantified the plasma-APOL1 levels in a panel of baboon samples (Figure 
25E). We found that baboon plasma-APOL1 levels range from 100-800 ng of protein per ml of plasma 
(Figure 25F). The IC50s obtained in the rAPOL1 trypanolysis assays all fell within this range of protein 
concentration. We therefore concluded that the balance between T. b. gambiense infection and immunity 
in baboons is likely multifactorial, involving both heterogeneous plasma-APOL1 levels and particular 




Figure 25. Characterizing the trypanolytic potential of baboon APOL1s from various Papio 
species. A) UV absorbance chromatograms of the final size exclusion chromatography step of three 
different baboon APOL1 protein purifications. B) Coomasie stained gels of the purified proteins from A. C) 
24-hour trypanolysis assay showing the lytic capacity of 1,250 ng/ml of each of the indicated rAPOL1 
proteins against T. b. brucei and T. b. gambiense. Reproducible data from multiple assays were 
combined to generate this graph (error bars represent mean +/- SD of three experimental replicates). D) 
24-hour trypanolysis assay showing the lytic capacity of serially diluted P. hamadryas and P. 
cynocephalus APOL1 proteins against T. b. brucei parasites. E) Representative anti-baboon APOL1 
western blot of multiple baboon plasma samples. F) Quantification of the plasma-APOL1 levels in three 
baboons. The samples with the highest, lowest, and average band intensities from E were re-blotted on a 
separate membrane and compared to a serially diluted sample of rAPOL1 via pixel counts using FIJI 

















The mechanism by which certain Papio APOL1 proteins efficiently lyse T. b. gambiense, or any 
other trypanosome, remains poorly understood. We analyzed the channel forming capacity of P. 
hamadryas APOL1 in planar lipid bilayers (Figure 26A) relative to human APOL1. In planar lipid bilayers, 
human APOL1 associates with membranes at pH 5.5 and proceeds to form open cation channels once 
the pH is neutralized (83). In contrast, P. hamadryas APOL1 begins to form channels at neutral pH (as 
indicated by the green bar highlighting the detectable current prior to Cis acidification) and forms open 
channels at both acidic and neutral pH (Figure 26B). There is a 2.5-fold increase in the conductivity once 
the Cis pH is neutralized after acidification (Figure 26B), although this does not represent classical pH 
gating as observed when using the human protein (200-300-fold increase).  
We then characterized the pH dependence of the P. cynocephalus APOL1 variant and observed 
that this protein also forms open channels at acidic pH (Figure 26C), but that it does not insert as 
efficiently as P. hamadryas APOL1 under neutral conditions (Figure 26C - green bar), suggesting that its 
decreased lytic capacity is a function of suboptimal membrane insertion properties. To confirm this, we 
tested the insertion efficiency of both proteins at a neutral pH on the same bilayer to rule out experiment 
by experiment variation, revealing conclusively that the P. hamadryas protein inserts into membranes at a 
neutral pH more readily than the P. cynocephalus protein (Figure 26D). Notably, the P. cynocephalus 
variant is capable of inserting at neutral pH when enough protein is added to the bilayer (not shown), 
while the human protein absolutely must be acidified. Taken together, we interpret that the channel 
forming capacity of the baboon APOL1 variants is less restricted by pH than the human APOL1 variants, 
although the P. cynocephalus variant is more restricted than the P. hamadryas variant, potentially 





Figure 26. Channel formation by baboon APOL1 variants. A) Schematic illustrating the planar lipid 
bilayer system (modified from illustrations made by Dr. Russell Thomson and Charles Schaub). Two 
aqueous environments (each with an approximately 1 ml capacity) are separated by a phospholipid 
bilayer. The experimenter can modulate the ion concentrations and pH on each side of the membrane 
separately. A battery supplies a unidirectional voltage (V) to the environment, which forces ion flux across 
the membrane if it has been permeated by, in this case, APOL1 (green). The output of ion flux is read as 
a current (I). B-D) The experimentally applied voltage (in millivolts) is shown in blue in the lower panels, 
and the current output (in picoamperes) is shown in red in the upper panels. B) The channel forming 
capacity of P. hamadryas APOL1 at various Cis pH values. The green bar represents a region of interest 
explained in the main body of the text. Within this region, ion flux is detected prior to Cis acidification. C) 
The channel forming capacity of P. cynocephalus APOL1 at various Cis pH values. The green bar 
represents a region of interest explained in the main body of the text. In contrast to B, there is no 
detectable ion flux in this region prior to Cis acidification. D) The channel forming capacities of P. 
cynocephalus APOL1 and P. hamadryas APOL1 at neutral pH on the same bilayer. The black bar 
(marked as ‘Perfuse’) indicates a washout step wherein any non-membrane associated protein is washed 
out of the Cis aqueous environment by the experimenter.  
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5. Increasing the pH Dependence of Baboon APOL1 with Human-Specific Residues Does Not Prevent 
Lysis of T. b. gambiense 
The endolysosomally localized TgsGP protein of T. b. gambiense prevents human APOL1 from 
associating with the endosomal membrane by modifying membrane structure (129). We hypothesized 
that the less-restricted channel-forming properties of baboon APOL1 circumvent this mechanism by 
inserting into the membrane immediately following endocytosis, prior to reaching the TgsGP-containing 
compartments. To investigate this hypothesis, we generated a P. hamadryas APOL1 protein that could 
not insert into lipid membranes at a neutral pH by site-directed mutagenesis of particular residues in the 
hydrophobic hairpin between the first two putative transmembrane domains. Specifically, we exchanged 
two baboon-specific residues (an alanine and a glycine) for two human-specific glutamic acid residues. 
We chose these residues because forming a channel requires some transmembranous portion of the 
protein to insert into the lipid membrane. Glutamic acid residues are likely to be charged at a neutral pH 
which would prevent membrane insertion, while at acidic pH the residues would be neutralized and more 
amenable to channel formation (Figure 27A). The less hydrophobic baboon APOL1 chimera was 
incapable of inserting into lipid bilayers at neutral pH (Figure 27B), but could form channels at acidic pH 
(Figure 27C), suggesting that these glutamic acid residues play a role in pH sensing. However, this 
protein was still lytic to T. b. gambiense in vitro, suggesting that the decreased pH dependence for 
membrane insertion is not likely to be the determining factor that permits Papio APOL1-mediated T. b. 
gambiense lysis (Figure 27D). Indeed, when we performed the inverse experiment by inserting the 
baboon APOL1-specific residues into the human sequence to make it less pH dependent, the protein still 











Figure 27. Increasing the pH dependence of baboon APOL1 with human-specific residues does 
not prevent lysis of T. b. gambiense. A) Model of membrane insertion mediated by neutralization of the 
hydrophobic hairpin between putative transmembrane domains 1 and 2. At neutral pH, the glutamic acid 
residues in the human hairpin (E201 and E213) will be negatively charged, preventing membrane 
insertion, while the baboon residues will be neutral. To insert into a bilayer, the human hairpin would need 
to be acidified, thus protonating the glutamic acid residues making them more hydrophobic. B) The 
channel forming properties of the P. hamadryas variant of APOL1 with the human glutamic acid residues 
compared to wild type P. hamadryas APOL1 at neutral pH. C) The channel forming properties of the P. 
hamadryas variant of APOL1 with the human glutamic acid residues at acidic pH. D) 24-hour trypanolysis 
assay showing the lytic capacity of serially diluted P. hamadryas APOL1 variants against T. b. gambiense 
parasites in the presence or absence of the APOL1 inhibitor NH4Cl.  
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6. OWM APOL1 Proteins are Post-Translationally Modified 
The human and Papio APOL1 proteins are 398 and 388 amino acids long respectively. Both 
human and Papio E. coli-derived recombinant APOL1 proteins migrate at approximately 45 kDa on 
denaturing polyacrylamide gels. However, Papio APOL1 derived from baboons migrates significantly 
slower through denaturing gels than human APOL1 derived from humans (a difference of approximately 
13 kDa), suggesting that the Papio protein is post-translationally modified under physiological conditions. 
We used various bioinformatic prediction softwares to determine whether any particular post-translational 
modification motifs were present in the Papio APOL1 amino acid sequence. We found that the Papio 
protein has at least two sites (a third site was below the confidence threshold) that are predicted to be 
modified by the N-linked glycosylation machinery (which is not present in Prokaryotes such as E. coli) 
using NetNGlyc 1.0, a site that was conserved among all 36 of the baboon APOL1 protein sequences. 
Treatment of Papio HDL, containing APOL1, with the deglycosylase PNGase F reduced the size of the 
APOL1 significantly, revealing that the protein is N-glycosylated in baboons. The modification(s) is 
resistant to Endo H digestion, indicating that the protein has trafficked through the Golgi of the secreting 
cell. The modification(s) is also insensitive to O-glycosidase and Neuraminidase, suggesting that the 
protein is not O-glycosylated or sialylated. This finding adds another layer of complexity to the differences 
between great ape and OWM APOL1 proteins. Is this modification(s) required for optimal function? Our 
mechanistic understanding of the optimal channel forming capacity of Papio APOL1 is based exclusively 
on E. coli-derived APOL1, meaning that a more physiologically relevant investigation is absolutely 






Figure 28. OWM APOL1 proteins are post-translationally modified. Anti-baboon APOL1 western blot 







 Here, we have used a combination of bioinformatics and biochemical analyses to investigate the 
primate TLF genes APOL1 and HPR from an evolutionary perspective. These studies have revealed two 
key findings: 1) important genetic variants of APOL1 in the baboon population; 2) a functional 
understanding of the mechanism of baboon APOL1-mediated channel formation and trypanolysis. These 
and our other minor findings related to HPR and APOL1 discussed below combine to expand the 
evolutionary understanding of the function of the TLF proteins.  
HPR has been the subject of far fewer research programs as compared to APOL1, despite also 
participating in multiple biological processes. Here, we have identified a new HPR haplotype that is 
specific to individuals of recent African descent, finding that the most ancestral HPR missense SNP V11 is 
enriched in individuals with the G2 variant of APOL1. APOL1 trafficking and secretion is thought to be 
mediated by one or more chaperone proteins that could be functional analogues of SRA in that they 
prevent G0-mediated toxicity but not G1 or G2-mediated toxicity. HPR coexpression in HEK293 cells 
overexpressing APOL1 prevents cell toxicity, albeit incompletely (Giovinazzo and Raper, unpublished 
data), suggesting that HPR could act as one of these chaperone proteins. HPR and APOL1 are 
associated with one another post-translationally at least after secretion. Our lab has modeled APOL1 
secretion and HDL loading previously using a transiently transgenic animal model, finding that APOL1 
diffuses among all HDLs in the absence of HPR, but that it becomes restricted to a certain class of large 
HDLs when HPR is coexpressed (137). Therefore, we hypothesize that the localization of HPR and 
APOL1 on TLFs is not random, and that they are associated with each other during, and potentially prior 
to, the TLF biogenesis process. Immediately preceding secretion onto TLF, APOL1 is trafficking from the 
Golgi to the PM and is therefore being acidified and subsequently neutralized. APOL1 therefore likely 
forms channels in the PM of these cells unless its activity is inhibited by these chaperone proteins 
potentially including HPR. The HPR V11 SNP may have some gain of function that allows it to restrict 
even G2-mediated cell toxicity to some degree, leading to enrichment in individuals that have the G2 
allele. However, these hypotheses require extensive biochemical and cell biological investigation prior to 
being reported as a firm conclusion. 
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The APOL1 locus is polymorphic in the baboon lineage. We have shown here that some of these 
polymorphisms are coupled to functional differences between the proteins produced by certain alleles, 
although we would like to investigate this in a much more unbiased way in the future. It remains to be 
determined whether the selection pressure affecting the evolution of APOL1 is due to trypanosomes, 
some other pathogens, or a combination of multiple pathogens simultaneously. The differential 
trypanolytic capacities of P. hamadryas and P. cynocephalus APOL1 are noteworthy, but perhaps there 
are much stronger phenotypes to be observed in the context of some other pathogenic infections.  
It remains to be determined whether these APOL1 polymorphisms are purely random, or whether 
they are indicative of selection. Previously, Smith and Malik have shown that the APOL gene family is 
likely being positively selected across the primate tree, although the number of available sequences was 
limited at the time (82). Another group investigated whether the human APOL1 gene (specifically exon 5) 
is being subjected to positive selection in African populations. By using Tajima’s D statistic, for example, 
they were unable to reject the null hypothesis of neutral selection (196). Since we now have expanded 
the number of baboon specific sequences, we can create more robust hypotheses with respect to the 
types of putative selection being applied to the APOL1 gene specifically in this primate. Directional 
selection is commonly associated with allele fixation, due to the presence of a strong selective pressure 
that favors one particular allele. In contrast, balancing selection is associated with heterozygosity, 
possibly due to the presence of multiple selective pressures being simultaneously applied to a given 
gene. In the latter model, heterozygotes have the highest fitness, which is associated with the 
maintenance of a higher than expected level of heterozygosity in the gene pool of the population. With 
respect to these baboon APOL1 sequences, all analyzed P. hamadryas individuals, all analyzed P. 
ursinus individuals, and all except 1 P. anubis individual have many heterozygous codons between their 
two APOL1 alleles, which is indicative of balancing selection. There is also a high degree of 
heterozygosity in the P. cynocephalus and P. kindae populations, while the two P. papio baboons are 
exclusively homozygous for one particular species-specific APOL1 allele. Collaborators have used these 
sequences to compute omega (the dN/dS statistic; equates to the ratio of non-synonymous polymorphisms 
[dN] versus synonymous polymorphisms [dS] across a given segment of DNA), a numerical representation 
of the overall amount of selective pressure being applied to a gene. A value greater than 1 could indicate 
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positive selection, while a value of less than 1 could indicate balancing, neutral, or purifying selection. The 
calculated omega was 0.5773 (Li and Qiu, unpublished data), suggesting that there may be some 
adaptive evolutionary pressure being applied to APOL1, since the average genome wide dN/dS in 
primates is 0.25 (197). Notably, certain famously anti-viral genes, including the HIV restriction factor 
SAMHD1, can have omega values below 1 (approximately 0.4 in the case of SAMHD1) (198). However, 
the omega statistic assumes that the gene is being uniformly selected across all amino acids, which is not 
always the case. Therefore, we have also performed the McDonald-Kreitman test (MK test), which can 
determine whether individual codons display marks of evolutionary selection within a given gene. The MK 
test revealed that while 74.9% of the variable codons displayed marks of purifying selection, the 
remaining 25.1% are either under balancing or neutral selection (Li and Qiu, unpublished data). To 
speculate as to which selective model fits the data the most reliably; the high level of heterozygosity, the 
fact that APOL1 is known to provide protection against at least two distinct parasites, and that the G1 and 
G2 human APOL1 variants lead to the development of kidney diseases in homozygous individuals all 
suggest that a model of balancing selection favoring heterozygosity is the most likely outcome.  
There are five primate species, including humans, known to produce APOL1. However, there 
remain more great apes and OWMs that have yet to have their putative trypanolytic factors characterized 
such as the AGM. The AGM was previously found to have partially trypanolytic HDL, although the critical 
negative controls that would rule out non-APOL1-mediated lytic activity were absent from this analysis 
(114). No APOL1 protein was identified from AGM sera (114). However, these analyses were performed 
prior to the development of OWM APOL1-binding antibodies. Here, we have revisited this primate and 
conclusively determined that the AGM does not have a plasma circulating APOL1 protein using a 
polyclonal antibody that binds to all OWM APOL1s tested thus far and fully controlled trypanolytic assays. 
This finding provides additional support for the hypothesis that APOL1 is rapidly evolving in the primate 
lineage, being duplicated and deleted in various primates ad nauseam. However, the AGM is of particular 
interest because its range overlaps with the distribution of the tsetse fly, meaning that it is likely 
susceptible to trypanosome infection. This remains speculative with respect to the AGM, although the 
hypothesis is supported by the fact that wild chimpanzees (also lacking APOL1) harbor T. brucei 
parasites (199). Together, these data can be interpreted in a variety of ways. We favor the hypothesis 
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that the APOL1 gene produces a toxic protein regardless of host. Maintaining disease resistance, be it 
against trypanosomes or any other pathogen, must be weighed against the adverse consequences that 
the APOL1 protein creates. Throughout the course of primate evolution, certain primates managed the 
toxic effects in different ways, with many of them deleting the deleterious gene. These gene deletion 
events are arguably just as informative with respect to what is driving APOL1 evolution in primates as 
studying the protein’s mechanism of action.  
The mechanism by which APOL1 lyses trypanosomes remains contentious. One hypothesis 
suggests that APOL1 is somehow imported into the mitochondria after being endocytosed by the 
parasites, which leads to mitochondrial depolarization and cell death (87). However, the parasite factors 
important for mediating this mechanism, most importantly an anterograde trafficking kinesin, are irrelevant 
to trypanosome lysis mediated by naturally occurring TLFs and instead only determine parasite sensitivity 
to recombinant APOL1 derived from E. coli (105). The alternative hypothesis that we have previously 
proposed is that APOL1 channels are formed in the PM of the parasite after endocytic recycling. This line 
of thinking is best supported by the discovery that APOL1 channel formation is strictly governed by pH. 
The human APOL1 channels insert into lipid membranes only under acidic conditions and are only 
permissible to cations when the pH is subsequently neutralized (83). However, here we have revealed 
that the P. hamadryas variant of APOL1 is less restricted by pH for membrane insertion. Planar bilayer 
experiments have conclusively revealed that the baboon APOL1 protein readily inserts into lipid 
membranes under neutral conditions. This finding suggests that the mechanism by which baboon APOL1 
lyses trypanosomes is not as dependent on an initial acidification step as its human counterpart. 
However, the fact remains that under physiological conditions, the protein will be delivered to 
trypanosomes by a TLF complex. Therefore, in order to insert in a lipid membrane, the APOL1 likely also 
requires a yet-to-be-characterized TLF-disassociation step that may be dependent on endolysosomal 
acidification. We therefore stress that determining the physiological mechanism of action of various 
human or primate APOL1 proteins will require an explanation of both how the APOL1 is delivered to the 
parasites and how it migrates from the TLF to the endosomal membrane.  
The decreased pH dependence of baboon APOL1 may enhance the lysis of T. b. gambiense 
parasites under physiological conditions if the APOL1 is able to insert into the endosomal membrane prior 
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to reaching the TgsGP-containing acidic compartments. However, we have also generated less pH 
sensitive variants of human APOL1 which remain non-lytic to T. b. gambiense and a more pH sensitive 
variant of baboon APOL1 which remains lytic. It then becomes conclusive that the pH sensitivity, with 
respect to channel formation, is not the only determining factor that governs T. b. gambiense immunity in 
baboons. pH sensitivity is not irrelevant, however, as we have also determined that the P. cynocephalus 
variant of APOL1 is less trypanolytic than the P. hamadryas variant. P. cynocephalus APOL1 channel 
formation is more pH dependent than the P. hamadryas protein, albeit through completely different amino 
acid changes relative to our human/baboon chimeras. These data are unfortunately inconclusive with 
respect to the mechanism(s) by which T. b. gambiense resists human but not baboon APOL1 proteins. 
Nevertheless, we have identified key amino acid residues that govern pH sensitivity in both the human 
and baboon APOL1 proteins through genomics, in silico predictions, and biochemical analyses. The 
mechanism of channel formation is perhaps the most fundamental feature of APOL1-related biological 
processes including but not limited to trypanosome immunity and APOL1-mediated nephrotoxicity 
 
Chapter Three: Using Baboon APOL1 to Address the Problem; 
Towards Generating Trypanosome Resistant Livestock 
Introduction 
 Trypanosome endemicity restricts the agricultural and economic development of the African 
continent with 3 million cattle fatalities per year and subsequent annual losses in the range of 4 billion 
USD (3). Despite the recent approval of the potential miracle drug Fexinidazole for use in humans, cattle 
remain a fledgling trypanosome host because the therapies reserved for humans cannot be used in cattle 
without the risk of rapidly selecting for resistant parasites, rendering the drug obsolete (200). Instead, 
veterinary trypanosomiasis is controlled through the use of various decades old toxic compounds. 
Ethidium bromide was introduced as a treatment for cattle trypanosomiasis approximately 70 years ago, 
while the most state-of-the-art treatment (the arsenic-based compound melarsomine dihydrochloride) was 
established in 1992, highlighting the need for more modern approaches (201). Multiple research 
programs, including ours, have proposed the usage of APOL1-based therapies as a means to an end of 
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trypanosomiasis. Treating trypanosome infected mice with a modified recombinant baboon APOL1 
apparently cured the infection (113), although the instability of the protein and that fact that the APOL1 
will likely be identified as a foreign antigen and therefore induce an adaptive immune response after the 
first treatment render this option likely impossible to implement on a continental scale. In an attempt to 
design a more self-sustaining model of veterinary trypanosomiasis prevention, we have proposed the use 
of genetics and modern biotechnology to create trypanosome resistant cattle by integrating baboon 
APOL1 into the genome (164). By this method, sterile immunity to African trypanosomes could rapidly 
spread throughout the endemic regions by artificial insemination of multiple founder cows. Trypanosome 
resistant cattle would expedite the agricultural development of sub-Saharan Africa and reduce the most 
significant reservoir of east African HAT.  
We previously used a transiently transgenic mouse model to test the possibility of expressing 
functional baboon APOL1 in a non-primate. Initial experiments were unsuccessful, revealing that P. 
hamadryas APOL1-expressing mice were not protected from infection (157). However, it was then 
observed that the mice were resistant to the infection when coexpressing human APOA-I, although the 
mechanistic requirement of human APOA-I was not determined (157). The protection was further 
augmented by coexpressing P. hamadryas HPR, to drive APOL1 uptake by the parasites through the 
HPHBR (157). Together, the data suggested that in the HGD based transfection model, a fully formed 
primate TLF was required to completely protect from African trypanosome infection, while baboon APOL1 
alone was not sufficient. However, these experiments were performed prior to the generation of baboon 
APOL1-binding antibodies, therefore the plasma levels of APOL1 in these mice could not be determined.  
Our transiently transgenic mice expressing APOL1 and HPR are the only model that has been 
used to study primate TLFs in vivo. The other genetically modified murine models express the human 
APOL1 variants in a kidney-specific system to model the G1 and G2-mediated nephrotoxicity. However, 
kidney cells cannot secrete APOL1 protein and therefore cannot produce TLFs. APOL1 is primarily 
secreted and loaded onto HDLs by the liver (202), which is the main transfection target when expressing 
genes by HGD (161). However, at least at the RNA level, APOL1 expression appears to be ubiquitous in 
humans (GTEx), suggesting that it also plays some non-TLF-related role(s) in physiological settings. 
Therefore, there remains a need for a more physiologically relevant murine model of primate APOL1 
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biology. Here, we have designed a panel of CRISPR targeted transgenic mice that express P. hamadryas 
APOL1 with or without P. hamadryas HPR and/or human APOA-I to both model the possibility of creating 




1. Integration of the Entire Baboon APOL1 Locus in Mice is Not Sufficient to Protect from T. b. brucei 
To investigate the function of baboon APOL1 in vivo, we generated a panel of genetically 
modified mice expressing baboon APOL1 via different combinations of promotors, open reading frames, 
and target loci (see materials and methods). We first obtained a 20 kilo base segment of the P. anubis 
genome in a bacterial artificial chromosome from the Children’s Hospital Oakland Research Institute that 
contained all five APOL1 exons, the putative endogenous promoter, and the up and downstream 
untranslated regions of the gene which were predicted to contain the endogenous enhancer regions 
required for expression (Figure 29A). This segment of P. anubis DNA was originally isolated from the 
individual used to sequence the baboon reference genome Panu2.0, which differs from the P. anubis 
APOL1 consensus in Figure 24 at amino acid position 180, encoding a leucine instead of a methionine. 
We also generated a version of the bacterial artificial chromosome that encoded the P. hamadryas 
APOL1 protein by inserting two separate base pair changes that encoded the E150Q and L180M 
substitutions (Figure 24). In an attempt to express APOL1 in the most physiological way, the P. 
hamadryas APOL1 construct was inserted into the mouse genome immediately upstream of the myosin 
heavy chain 9 (Myh9) gene (Figure 29A), which is next to the endogenous location of APOL1 in primates. 
In case the Myh9 locus was not suitable for transgene expression, we inserted the P. anubis APOL1 
construct into the ROSA26 locus (Figure 29B), a ubiquitously euchromatic region of the genome 
commonly used for transgene placement in mice. We then tested whether the mice were capable of 
producing TLF. We were unable to detect any serum circulating APOL1 protein in either of these mouse 
lines even after purifying the HDL to enrich for putative TLFs (not shown), although we were able to 
detect APOL1 RNA production in liver lysates, suggesting that both loci were transcriptionally active 
(Kovacsics and Raper, unpublished data). However, the mice were not protected from infection by T. b. 
brucei parasites (Figure 29C). Since baboon APOL1 expression had previously only protected mice from 
trypanosome infection in human APOA-I transgenic mice, we crossed our mouse lines with human 
APOA-I-expressing mice. These double transgenic mice were also susceptible to infection by T. b. brucei 
(Figure 29D). Coexpressing baboon HPR by HGD in the P. anubis APOL1-expressing mice was able to 
provide a slight but not statistically significant level of protection from T. b. brucei infection (Figure 29E), 
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suggesting that even though we were unable to detect any APOL1 protein, there may be a small amount 
of circulating and functional APOL1 protein in the sera of these mice. Nevertheless, we concluded that 
the small amount of APOL1 production was likely due to the fact that we inserted an uncharacterized 
segment of the baboon genome into the mouse, and that the important regulatory motifs in the locus were 




Figure 29. Integration of the entire baboon APOL1 locus in mice is not sufficient to protect from T. 
b. brucei. A-B) Schematics of the targeting constructs used to insert the baboon APOL1 loci into the 
mouse genome. The spacing and relative sizes of the exons are drawn approximately to scale; however, 
the homology arms are much larger than illustrated (see materials and methods). C-E) Kaplan-Meier 
curves showing the survival proportions of mice infected with 5000 T. b. brucei (427-SRA) parasites i.p.. 
C) Heterozygous or homozygous mice expressing either P. hamadryas APOL1 from the Myh9 locus or P. 
anubis APOL1 from the ROSA26 locus compared to wild type counterparts. D) P. anubis APOL1 and 
human APOA-I-expressing mice compared to wild type counterparts. E) P. anubis APOL1-expressing 
mice expressing P. hamadryas HPR by HGD compared to APOL1 or HPR alone (P = 0.09; Log-rank 
test).  
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2. Integration of the P. hamadryas cDNA Driven by a Ubiquitin Promoter Protects from T. b. brucei 
 When analyzing the RNA expression levels in the mice expressing the entire baboon APOL1 loci 
(Kovacsics and Raper, unpublished data) (Figure 29), we determined that the ROSA26 locus provided 
higher expression levels than the Myh9 locus. We therefore proceeded to target the ROSA26 locus with a 
more synthetic APOL1 construct. We generated mice that expressed the cDNA of P. hamadryas APOL1 
under the control of a ubiquitin promoter (Figure 30A) to ensure transgene expression in a somewhat 
physiological way since APOL1 expression is not cell type specific (GTEx). These mice expressed serum 
circulating APOL1 protein, albeit less than an average baboon, with the homozygous mice expressing 
approximately twice as much protein as heterozygous mice (Figure 30B). Importantly, the APOL1 
migrates the same distance as the APOL1 from baboon plasma on denaturing polyacrylamide gels, 
suggesting that the mice post-translationally modify the protein in a physiological way (Figure 30B). The 
APOL1 localizes to HDL in the mice, thus forming a TLF (Figure 30C). To test whether these P. 
hamadryas APOL1-containing mouse TLFs were capable of protecting mice from T. b. brucei infection, 
we infected the mice with 5000 T. b. brucei parasites. An inoculum of 5000 parasites is thought to fall into 
the range of parasites transmitted by an individual tsetse bite, although the range is very large and not 
well defined (0-40,000 cells per bite; mean of 3,200) (203). With this inoculum of parasites, the APOL1-
expressing mice were fully protected from infection, revealing that this APOL1 expression system is fully 
functional (Figure 30D). Notably, this protection was achieved in mice expressing murine APOA-I (Figure 






Figure 30. Integration of the P. hamadryas cDNA driven by a ubiquitin promoter protects from T. b. 
brucei. A) Schematic of the targeting construct used to insert the P. hamadryas APOL1 cDNA into the 
ROSA26 locus of the mouse genome. The homology arms are much larger than illustrated (see materials 
and methods). B) Anti-baboon APOL1 western blot of baboon and mouse plasma samples. C) Anti-
baboon APOL1 western blot of purified baboon and mouse HDL samples. D) Kaplan-Meier curve 
showing the survival proportions of P. hamadryas APOL1-expressing heterozygous mice compared to 
























3. P. hamadryas APOL1 Expression Does Not Induce Any Detectable Negative Host Phenotypes 
 Before continuing to characterize the mice in the context of trypanosome immunity, we decided to 
analyze the general phenotype of the transgenic lines. We first used multiple litters of mice to test 
whether the APOL1 expression had an obvious negative impact on early post-birth development. We 
observed that the mice gained weight as fast as wild type counterparts (Figure 31A and B) and never 
observed any general abnormalities that were induced by APOL1. In humans, APOL1 mutations cause 
chronic kidney diseases in adults, the most common manifestation of which is focal segmental glomerular 
sclerosis (FSGS). As FSGS progresses, the glomeruli of the kidney begin to decay over time and this 
progressive glomerular cell death leads to the formation of scar tissue. Histologically, the glomeruli resect 
from the walls of the Bowman’s capsule, losing their approximately spherical shape. We therefore 
prepared kidney tissue sections from adult (greater than 1 year old) transgenic and wild type mice for 
basic histological analyses and observed that the glomeruli in the transgenic mice showed no obvious 
signs of resection and instead resembled wild type glomeruli (Figure 31C). We therefore concluded that 







Figure 31. P. hamadryas APOL1 expression does not induce any detectable negative host 
phenotypes. A-B) Weight gain in heterozygous and homozygous transgenic mice compared to wild type 
counterparts as a function of time post-birth (error bars represent the mean +/- the SD for each group 
each week). C) Hematoxylin and eosin stained kidney tissue slices from adult wild type and APOL1-
expressing mice. Images represent three mice from each group. Images were captured using a light 




4. P. hamadryas APOL1-Expressing Mice are Partially Protected from T. b. gambiense 
 We then wanted to characterize the protective potential of P. hamadryas APOL1 expression in 
the context of a wide variety of trypanosome parasites. We first tested whether the mice were immune to 
T. b. gambiense infection, since the only existing direct evidence showing that baboon APOL1 lyses 
these parasites is based on the non-glycosylated rAPOL1s from E. coli. We first infected the mice with 
5000 T. b. gambiense parasites, the same inoculum used in Figure 30D (with T. b. brucei), revealing that 
homozygous mice were partially protected from infection (Figure 32A). The protection was not augmented 
through coexpression of human APOA-I or P. hamadryas HPR (not shown). Inoculating homozygous 
mice with only 500 parasites extended the survival of the mice significantly, although they still were not 
fully protected (Figure 32B). These in vivo data suggest that T. b. gambiense may be more resistant to 
baboon APOL1 than T. b. brucei. A previously published report using rAPOL1 in vitro suggested that 
baboon APOL1 lyses T. b. gambiense with equal efficiency compared to T. b. brucei (160). We 
investigated this using rAPOL1s in our own laboratory conditions and found that this strain of T. b. 
gambiense was indeed approximately two-fold more resistant to P. hamadryas APOL1 than T. b. brucei 
(Figure 32C). Together, these data revealed that physiologically relevant (post-translationally modified) 
baboon APOL1 proteins provide immunity to T. b. gambiense infection, but are not sufficient to mediate 
complete protection in vivo in animals that express low levels of the protein (Figure 30B, Figure 25E), 
consistent with previously reported in vivo baboon infections. These data, while informative for the 
purpose of exploring the APOL1-T. b. gambiense interaction, must also be interpreted with consideration 
of the broader context of generating trypanosome resistant cattle. Cattle are not thought to be a relevant 
reservoir of T. b. gambiense parasites, as compared to T. b. rhodesiense for example, the major reservoir 
of the east African HAT parasites. We would therefore hypothesize that T. b. gambiense immunity is likely 





Figure 32. P. hamadryas APOL1-expressing mice are partially protected from T. b. gambiense. A) 
Kaplan-Meier curve showing the survival proportions of P. hamadryas APOL1-expressing homozygous 
mice compared to wild type counterparts infected with 5000 T. b. gambiense parasites i.p. (**P < 0.01; 
Log-rank test). B) Kaplan-Meier curve showing the survival proportions of P. hamadryas APOL1-
expressing homozygous mice compared to wild type counterparts infected with 500 T. b. gambiense 
parasites i.p.. Note that survival is extended in the experimental group as well as the wild type group with 
this lower inoculum, relative to A (**P < 0.01; Log-rank test). C) 24-hour trypanolysis assay showing the 
lytic capacity of serially diluted P. hamadryas rAPOL1 against T. b. brucei and T. b. gambiense parasites 
(error bars represent the mean +/- SD of three experimental replicates).  
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5. P. hamadryas APOL1-Expressing Mice are Protected from Infection by Livestock-Infective 
Trypanosomes 
 To model the generation of transgenic cattle in the most physiologically relevant way, we tested 
the protective potential of P. hamadryas APOL1 expression in these mice in the context of various 
livestock-infective trypanosome species. We first investigated whether the mice were immune to infection 
by the livestock-infective and globally-distributed T. evansi. This particular strain of T. evansi causes long-
term infections in mice. Therefore, we used microscopic analyses of blood collected intermittently post-
infection to determine if the wild type or transgenic mice were susceptible to infection, rather than simply 
following the survival of the mice. In doing so, we observed that wild type mice develop a high 
parasitemia shortly after infection that subsequently rises and falls until the mice die after 4-6 weeks 
(Figure 33). In contrast, homozygous APOL1-expressing mice never developed a detectable parasitemia, 






Figure 33. P. hamadryas APOL1-expressing mice are protected from T. evansi infection. 
Parasitemia curve showing the number of parasites in the blood of T. evansi infected mice. Mice were 
infected with an inoculum of 5000 parasites i.p.. The curve shows the parasitemia in each individual 
mouse of each genotype. For example, the black circles that are connected by a line that ends on day 25 
post-infection represent the parasitemia measured on each of the indicated days of one wild type mouse 
that died on day 25. Parasitemia is counted by light microscopy; note that the hypothetical limit of 
detection is approximately 3-5 x 106 parasites per ml.  
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We then investigated whether the mice were protected from infection by T. b. rhodesiense, a 
zoonotic pathogen that readily infects both humans and cattle. We observed that heterozygous mice 
infected with T. b. rhodesiense (KETRI243) were partially protected from infection, with a survival 
extension of approximately 2 to 3 weeks relative to wild type controls (Figure 34A). Breeding these mice 
with transgenic human APOA-I-expressing mice decreased the survival extension (Figure 34A), in strong 
contrast to the previously published results using the transiently transgenic model (157). We hypothesize 
that this could be due to differences in the genetic backgrounds of the mice involved. The human APOA-I-
expressing mouse line was generated in the C57 BL/6J background, while the APOL1-expressing mice 
were generated in the C57 BL/6N background. Crossing these two mouse lines has therefore generated 
a human APOA-I and P. hamadryas APOL1-expressing C57 BL/6N-J hybrid line that may have increased 
sensitivity to trypanosome infection in the context of APOL1-mediated immunity, relative to the APOL1-
expressing 6N parent line.  
 Homozygous APOL1-expressing mice were fully protected from infection by T. b. rhodesiense 
(KETRI243), suggesting that APOL1 levels are an important determining factor that dictates whether an 
animal will be fully resistant to infection (Figure 34B). We were also able to achieve full protection by 
coexpression of HPR in the heterozygous mice, suggesting that TLFs that can both lyse the parasites and 
be endocytosed in a receptor-mediated manner are more effective that TLFs that must be taken up by 
fluid phase endocytosis (Figure 34B).  





Figure 34. P. hamadryas APOL1-expressing mice are protected from T. b. rhodesiense (KETRI243) 
infection. A-B) Kaplan-Meier curves showing the survival proportion of P. hamadryas APOL1-expressing 
mice compared to wild type counterparts with or without coexpression of human APOA-I or P. hamadryas 







We then investigated whether the mice were protected from infection by the livestock infective T. 
congolense (STIB 68-Q). This strain has a variable effect on wild type mice. Wild type mice typically 
survive for approximately 15 days, but occasionally some mice will survive for much longer (Figure 35A). 
Therefore, instead of monitoring survival, we intermittently measured parasitemia in the mice. One 
individual heterozygote APOL1-expressing mouse developed a high parasitemia and subsequently died 
within the first 2 weeks of infection, although this was an isolated result that was never replicated (Figure 
35A). More reproducibly, we observed that approximately 25% of the heterozygous APOL1-expressing 
mice developed a high and sustained parasitemia approximately one month after infection (Figure 35A). 
This was never observed in homozygous or HPR-expressing mice (Figure 35A), consistent with previous 
data using T. b. rhodesiense (Figure 34B). To confirm that homozygous mice were completely protected, 
we followed parasitemia after infecting homozygous mice with a 100-fold higher parasite inoculum and 
never detected any blood borne parasites (Figure 35B).  
Since the heterozygous mice developed a detectable and sustained parasitemia after one month 
of infection, we hypothesized that the parasites had developed an APOL1 resistant phenotype. To 
investigate this possibility, we harvested parasites from a heterozygote mouse that developed a sustained 
detectable level of parasitemia after an initial infection, and re-infected those parasites into naïve APOL1-
expressing mice. We observed that the heterozygous and the majority (80%) of the homozygous APOL1-
expressing mice infected with this derived strain of T. congolense (STIB 68-Q-APOL1r) developed a high 
parasitemia within the first two weeks of infection (Figure 35C). We therefore concluded that the parasites 
had indeed developed an APOL1 resistance phenotype, either through selection of previously existing 
parasites or de novo mutation(s).  
Wild type mice infected with the parent line of T. congolense parasites reproducibly develop a 
high parasitemia 5 days post-infection, while wild type mice infected with the APOL1 resistant line 
develop a high parasitemia 8-12 days post-infection (Figure 35C). We hypothesized that the APOL1 
resistance was therefore associated with some sort of fitness cost. To investigate this, we harvested T. 
congolense STIB 68-Q-APOL1r parasites from wild type mice one month post-infection, hypothetically 
long enough for the resistant population to be out grown by non-resistant clones. These parasites were 
then re-infected into wild type mice and homozygous mice. The homozygous mice were partially resistant 
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to the infection, with an 11 day delay in the onset of detectable parasitemia relative to wild type mice 
(Figure 35D). We have not determined the genetic source of the resistance, although this revertible 
phenotype is reminiscent of the SRA-mediated APOL1 resistance mechanism used by T. b. rhodesiense. 
It would therefore be of interest to determine if the APOL1 resistance in T. congolense restricts them to 






Figure 35. T. congolense parasites develop APOL1 resistance in P. hamadryas APOL1-expressing 
mice. A) Parasitemia curve showing the number of parasites per ml in mice infected with 5000 T. 
congolense (STIB 68-Q) parasites. B) Parasitemia curve showing the number of parasites per ml in mice 
infected with 500,000 T. congolense (STIB 68-Q) parasites. C) Parasitemia curve showing the number of 
parasites per ml in mice infected with 5000 T. congolense (STIB 68-Q-APOL1r) parasites. D) Parasitemia 
curve showing the number of parasites per ml in mice infected with 5000 T. congolense (STIB 68-Q-
APOL1r) parasites after the parasites were passaged through a wild type mouse for approximately one 
month. A-D) The curves show the parasitemia in each individual mouse of each genotype. Parasitemia is 
counted by light microscopy; note that the hypothetical limit of detection is approximately 3-5 x 106 
parasites per ml. 
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We hypothesized that the more endogenously resistant any particular strain of trypanosome is to 
APOL1-mediated lysis, the more likely it would be to develop APOL1 resistance and therefore establish 
an infection in our mice, especially the low expressing heterozygous mice. To investigate this, we infected 
the mice with another strain of T. b. rhodesiense (RUMPHI) which can be cultivated in vitro and can 
therefore be used for both trypanolysis assays and in vivo infections. Again, we observed that 
heterozygous mice were partially protected from infection (Figure 36A). However, we determined that this 
strain was equally sensitive to baboon TLF in vitro as compared to the standard T. b. brucei 427 (Figure 
36B) which cannot establish an infection in our heterozygous mice (Figure 30D). Together, these data 
then suggested that the development of APOL1 resistance in these mice may be a more complex 






Figure 36. P. hamadryas APOL1-expressing mice are partially protected from infection by APOL1 
sensitive T. b. rhodesiense (RUMPHI). A) Kaplan-Meier curve showing the survival proportion of P. 
hamadryas APOL1-expressing heterozygous mice compared to wild type counterparts infected with 5000 
T. b. rhodesiense (RUMPHI) parasites i.p. (**P < 0.01; Log-rank test). B) 24-hour trypanolysis assay 
showing the lytic capacity of serially diluted P. hamadryas serum against T. b. brucei and T. b. 





6. APOL1 Resistance May Develop in Extravascular Tissue Spaces 
HDLs circulate in serum and permeate extravascular tissue spaces. However, it has been 
established that the concentration of HDL in those tissue spaces is approximately 10-fold lower than the 
concentration that circulates in serum (204). Since T. b. brucei invades and functionally adapts to 
extravascular tissue spaces (17), we hypothesized that APOL1 resistant T. congolense clones could 
emerge from tissue resident trypanosomes that were being exposed to this hypothetically sub-lethal level 
of TLF exposure. T. congolense is classically referred to as a primarily blood resident parasite, although 
this dogma is based on insensitive autopsy experiments which determined that in infected cattle, “large 
numbers of trypanosomes were found only in the blood vessels (16).” These data do not discount the 
possibility that T. congolense parasites are capable of invading extravascular tissues, but rather that they 
may not do so preferentially.  
To investigate this hypothesis, we first designed a quantitative PCR-based T. congolense 
detection system (see materials and methods). We initially used this system to investigate the tissue 
distribution of T. congolense in wild type mice after perfusing the animals to remove the blood from the 
tissues. We observed that during the early stage of infection there were a relatively small but detectable 
number of parasites in the tissue spaces, and that the proportion of tissue resident parasites increased as 
the infection progressed (Figure 37A and B). Of the tissues that we analyzed, we observed that the most 
frequently enriched extravascular spaces were the adipose tissue and the lung, suggesting that the 
parasites may have some particular tropism for different tissues. The enrichment in both tissue spaces 
was more evident at the later stage of the infection (Figure 37C).  
We then proceeded to investigate whether there were tissue resident parasites in APOL1-
expressing mice. We infected 12 mice and harvested tissues from them at 30 days post-infection, just 
before the expected parasite emergence into the blood (Figure 35A). We detected parasite DNA in four of 
the mice, with one mouse in particular displaying parasites exclusively in the lung and adipose tissue, 
with no detectable blood resident parasites (Figure 37D and E). Notably, no parasites were ever detected 
in homozygous APOL1-expressing mice. These data together suggest that T. congolense parasites can 
invade tissue spaces, which could then provide a niche with sub-lethal levels of APOL1 that selects for 
the emergence of resistant clones in some mice. However, we stress that these data must be expanded 
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on before drawing definitive conclusions. For example, we must microscopically confirm the presence of 








Figure 37. APOL1 resistance may develop in extravascular tissue spaces. A) The calculated number 
of parasites per milligram of tissue in wild type C57 BL/6N-J mice. B) The graph represents the relative 
concentrations of parasites per milligram in each mouse from A. For example, the concentration of 
parasites per milligram of tissue in WT mouse 1 is significantly higher than the concentration of parasites 
in any other tissue. Note that while WT mouse 4 appears to have a relatively high concentration of 
parasites in the adipose tissue, the total number of detected parasites in this mouse (see A) is very low 
and therefore likely unreliable in the context of relative quantifications. C) The average relative 
concentrations of parasites per milligram of tissue in the adipose, lung, and blood in each of the two wild 
type groups. D) The calculated number of parasites per milligram of tissue in APOL1-expressing 
heterozygous mice. E) The graph represents the relative concentrations of parasites per milligram in each 







7. P. hamadryas APOL1 and HPR are Difficult to Coexpress After Genomic Integration 
 Maintaining disease resistance while preventing APOL1 resistance from emerging is one, if not 
the most important attribute to consider when generating transgenic cattle. Together, our data thus far 
suggest that there are two methods by which APOL1 resistance can be prevented: relatively high levels 
of APOL1 expression (Figures 34B and 35A and B); and coexpression of P. hamadryas HPR (Figures 
34B and 35A). We have attempted to generate lines of mice that conform to these restrictions, starting 
with mice that have both P. hamadryas APOL1 and HPR integrated into the genome at the ROSA26 
locus. Initially, we generated mice that had the same P. hamadryas APOL1 expression system as we 
previously described, in addition to a P. hamadryas HPR expression system that was driven by gene 
trapping, a technique commonly used in murine transgenic systems. Gene traps are designed to integrate 
promoter-less transgenes into genomes with a splice acceptor 5' to the coding sequence. In this case, the 
first exon of the ROSA26 RNA was transcribed and then spliced together with the P. hamadryas HPR 
cDNA (Figure 38A).  
 These HPR and APOL1 double transgenic animals were no more effectively protected from 
infection by T. b. rhodesiense (KETRI243) than the mice that only expressed APOL1 (Figure 38B). We 
hypothesized that this could be due to inefficient HPR production. Indeed, we observed that the double 
transgenic mice produced significantly less serum circulating HPR, or HDL localized HPR than mice 
transiently transfected with our P. hamadryas HPR HGD vector (Figure 38C).  
We then considered that the HGD system drives protein expression primarily from hepatocytes, 
which are also the cells that endogenously produce HPR in humans and primates. We therefore created 
another line of transgenic mice whose HPR expression system was based on an albumin promoter 
(Figure 38D). The albumin promoter is not only relatively strong, but also only active in hepatocytes 
endogenously. Still, the survival of these mice was not significantly extended relative to mice that only 
expressed APOL1 (Figure 38E), despite these double transgenic mice producing much higher HPR levels 
than the preceding line (Figure 38F). HPR levels are, however, only relevant if the HPR protein localizes 
to the same HDL complexes as the APOL1 protein. To investigate whether this was the case, we isolated 
HDLs from the mice and immunoprecipitated the HPR-containing complexes. By this technique, we co-
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purified a small amount of APOA-I protein, but none of the APOL1 protein, suggesting that the mice were 






Figure 38. Co-integration of APOL1 and HPR is not sufficient to mediate full protection against 
trypanosome infection. A) Schematic of the targeting construct used to insert the P. hamadryas APOL1 
and HPR cDNAs into the ROSA26 locus of the mouse genome with HPR under the control of a gene trap. 
The homology arms are much larger than illustrated (see materials and methods). B) Kaplan-Meier curve 
showing the survival proportions of mice infected with 5000 T. b. rhodesiense (KETRI243) parasites i.p. 
(**P < 0.01; Log-rank test). C) Anti-human HP western blot showing the serum and HDL HPR protein 
levels in the mice generated based on the construct in A compared to mice expressing HPR by HGD. D) 
Schematic of the targeting construct used to insert the P. hamadryas APOL1 and HPR cDNAs into the 
ROSA26 locus of the mouse genome with HPR under the control of the mouse albumin promoter. The 
homology arms are much larger than illustrated (see materials and methods). E) Kaplan-Meier curve 
showing the survival proportions of mice infected with 5000 T. b. rhodesiense (KETRI243) parasites i.p. 
(**P < 0.01; Log-rank test). F) Anti-human HP western blot showing the serum HPR protein levels in the 
mice generated based on the construct in D compared to the mice generated based on the construct from 
A. G) Western blots showing the HDL proteins associated with HPR by Co-IP in the mice generated 
based on the construct in D. The small amount of APOA-I pulled down by the anti-HP antibody compared 




8. Human APOL1 with a Papio C-Terminal Domain Protects from Infection by Trypanosomes  
 Since we have been unable to suitably coexpress APOL1 and HPR after genomic integration of 
both genes, we have instead pursued the possibility of increasing the APOL1 expression level. P. 
hamadryas APOL1 protein levels are at the low end of the range that is physiological in baboons in our 
transgenic system (Figure 30B), and P. hamadryas APOL1 does not express in high enough quantities to 
mediate full trypanosome protection by HGD (157). However, human APOL1 when expressed by HGD 
reaches levels that are similar to the average level of APOL1 in human plasma (84). We have therefore 
experimented with the possibility of generating transgenic mice with an APOL1 construct that is a 
synthetic chimeric combination of the human and P. hamadryas APOL1 proteins to achieve both high 
expression levels and mediate protection against all of the livestock parasites, including the zoonotic T. b. 
rhodesiense. Previous reports have shown that the SRA protein of T. b. rhodesiense binds to human 
APOL1 at the C-terminal region of the APOL1 protein, but that SRA cannot bind to the baboon C-terminal 
domain (81). We therefore tested chimeric human APOL1 constructs with the P. hamadryas C-terminal 
domain, previously generated by Dr. Russell Thomson (81), in a transiently transgenic system to 





Figure 39. Human/baboon APOL1 chimeras. Schematic illustrating the four APOL1 constructs of 
interest. The full APOL1 domain map is illustrated at the top. Below are the four constructs, color coded 
for clarity. Note that the black line in the center of the four chimera illustrations marks the end of the fourth 
transmembrane domain. The numbers to the right of the bottom two chimeras indicate the amino acid 
residues at the crossover points. 
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The channels formed by baboon APOL1 are less restricted by pH for both membrane insertion 
(Figure 27B) and channel gating (Figure 26B). The primary channel gating mechanism is controlled by 
amino acids at the C-terminal end of the 4th transmembrane domain (Thomson and Raper, unpublished 
data). Chimera 350 therefore forms channels that are more similar to P. hamadryas APOL1 channels, 
while chimera 360 forms channels analogously to the human protein (Thomson and Raper, unpublished 
data). We used both of these chimeras to determine if evasion of SRA (accomplished by both chimeras 
(81)) was sufficient to mediate full immunity to T. b. rhodesiense, or if baboon-like channel formation was 
also required.  
 One day after HGD, mice expressing both chimeras reached APOL1 levels that were similar to 
the levels of APOL1 in mice expressing human APOL1 (Figure 40A). When infected with T. b. 
rhodesiense, the human APOL1-expressing mice were not protected from infection, while the mice 
expressing chimera 350 were partially protected and the mice expressing chimera 360 were fully 
protected (Figure 40B). These data suggested that the more human-like chimera 360 was more efficient 
at mediating immunity than the baboon-like chimera 350, and therefore that baboon-like channel gating is 
less efficient in vivo than human-like channel gating.  
We hypothesized that the baboon-like chimera 350 might be more toxic to the mice, since the 
channels are less regulated, which could then result in premature death by combining trypanosome 
infection with APOL1-induced host damage. However, the serum activity of the normally hepatocyte 
resident enzyme aspartate amino transferase (AST), which is released upon liver cell death, was not 
elevated in the chimera 350-expressing mice relative to the other APOL1 constructs (Figure 40C). We 
have since been unable to determine why chimera 360 is more efficient in this transiently transgenic 
mouse system. Nevertheless, chimera 360 is now the first and currently only APOL1 construct that has 
ever fully protected mice from this strain of T. b. rhodesiense (KETRI243) by HGD, making it a prime 
candidate for the generation of transgenic animals.  
Notably, neither of the chimeras lyse T. b. gambiense parasites in vitro (Figure 40D), suggesting 
both that baboon-like channel gating is not the determining factor that leads to the lysis of T. b. 
gambiense by Papio APOL1 proteins, and that cattle expressing chimera 360 would not be resistant to T. 
b. gambiense. This may, however, be a blessing in disguise. It would be undesirable to create partially T. 
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b. gambiense resistant cattle (mediated by Papio APOL1, which is not a guarantee of T. b. gambiense 
immunity), as it would likely select for stronger APOL1 resistance mechanisms. The cattle must either be 
fully immune to all parasites, or not immune at all. Hypothetically, chimera 360 would never select for any 






Figure 40. Human/baboon APOL1 chimera 360 mediates full immunity to trypanosome infection. 
A) Anti-human APOL1 western blot of serum taken from mice one day post-HGD with the indicated 
constructs. B) Kaplan-Meier curve showing the survival proportions of mice expressing each APOL1 
construct after infection with 5000 T. b. rhodesiense (KETRI243) parasites i.p. (*P < 0.05; Log-rank test). 
C) Calculated AST activity in the serum of mice collected either one or three days post-HGD (bars 
indicate the mean +/- the SD of the indicated number of biological replicates). Serum AST activity is 
commonly used to measure liver damage. D) 24-hour in vitro trypanolysis assay showing the lytic 





9. Human APOL1 Does Not Protect Mice from T. vivax Infection 
 T. vivax is a livestock pathogen that has not been extensively investigated. This is especially true 
in the context of TLF-based immunity. Multiple review articles have made the extraordinary claim that TLF 
mediates human immunity to this parasite, including one published just this past year (9), despite no 
evidence to support the suggestion. We have addressed this issue using transiently transgenic mice. Due 
to an inability to import this parasite into the USA and difficulties in transporting our transgenic lines to 
Africa, these experiments were performed at the National Livestock Research Institute (ILRI) in Nairobi, 
Kenya. ILRI has a large repository of trypanosome isolates of every relevant species, both characterized 
and uncharacterized. The vast majority of the characterized T. vivax strains cannot be cultivated in mice,  
so we first selected a previously only microscopically characterized T. vivax isolate for our studies. We 
then confirmed that this parasite was a T. vivax isolate by PCR with T. vivax specific primers (Figure 
41A). We also used a panel of broadly specific primers and other trypanosome species-specific primers to 
confirm this result (not shown). Once we were confident that the parasites were T. vivax, we transiently 
transfected mice with human APOL1 and HPR by HGD (Figure 41B) and infected the mice. The TLF-
producing mice were not immune to infection, with 100% of the mice developing a high parasitemia by 6 
days post-infection (Table 5). There was no extension of survival, with the majority of both the TLF-
producing and the wild type mice succumbing to the infection within ten days. Some mice survived for 3 
weeks post-infection, although there were more wild type mice alive at the time than TLF-producing mice 
(Table 5), and all of the mice had a detectable parasitemia on day 21.  
Seeking to confirm this result by another method, we then infected six mice with the same strain 
of T. vivax, and then at the first sign of parasitemia (3 days post-infection) we injected 150 µl of human 
serum, containing human TLF, or saline intravenously. The parasitemia was not suppressed by the 
administration of human serum as compared to saline (Figure 41C), confirming that at least this strain of 
T. vivax is resistant to human TLF. While the vast majority of T. vivax isolates cannot be cultivated in 
mice, while this particular strain grew to a high parasitemia very rapidly. Immediately prior to the death of 
any mouse, the parasitemia was, anecdotally, as high as I have ever seen in any mouse infected with any 
trypanosome. I would therefore caution that performing any murine based T. vivax experiments may be 
physiologically irrelevant. It therefore will be important to conclusively determine whether human APOL1, 
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Papio APOL1s, or chimera 360 are capable of lysing a broad range of T. vivax isolates in the future, 
keeping in mind that these experiments might not be physiologically possible until the transgenic livestock 






Figure 41. Human TLF does not protect mice from T. vivax infection. A) Ethidium bromide stained 
agarose gel showing the appearance of the approximately 210 base pair band produced by the T. vivax 
specific primers used to amplify DNA from a T. vivax infected mouse blood sample. B) Anti-APOL1 
western blot showing the levels of APOL1 protein compared to a sample of human serum in mice 
transfected by HGD.  Mouse number four provides an example of a mouse that was not efficiently 
transfected by HGD due to experimenter error. C) Parasitemia in mice before or 24 hours after 
administration of 150 µl of human serum or saline i.v.. 
 
Table 5. T. vivax mouse challenge data 
Mouse Genotype Mice with Detectable 
Parasitemia on Day 6 
Post-Infection 
Mean Parasitemia on 
Day 6 Post-Infection 
Mice Alive on Day 21 
Post-Infection 
Saline 10/10 2.45 X 107 2/10 
Human APOL1 and 
HPR 
























APOL1 is a general antimicrobial. Its channel-forming properties allow it to lyse both 
trypanosomes and the intracellular kinetoplastid Leishmania parasites. APOL1 expression is upregulated 
by interferon signaling, suggesting that it also plays an antiviral role, and indeed APOL1 overexpression 
was shown to limit HIV replication in vitro (85). Since the APOL1 expression system in our mice is not 
cell-type specific, we feel that our genetically modified mouse model is the best suited system that 
currently exists to analyze any and all APOL1-pathogen interactions in a physiological setting. As one 
example, the mice are indeed resistant to Leishmania major infection (Pant and Raper et al., manuscript 
in preparation). We maintain that the study of primate APOL1 antimicrobial function and cell biology must 
continue to address the problems using physiologically relevant systems, such as those presented here. 
However, we acknowledge that this is not an easy experimental system to develop, as evidenced by the 
five separate attempts at designing a fully trypanosome resistant transgenic mouse that we have 
discussed in this thesis. To date, we have been unable to generate transgenic mice that produce fully 
functional TLFs containing both the APOL1 and HPR proteins. We have, however, created fully functional 
TLFs in mice by HGD (137). Further, transiently expressing HPR by HGD in our transgenic APOL1-
expressing mice (the P. hamadryas APOL1 cDNA only mice) forms fully functional TLFs with both 
proteins on the same HDL complexes (Verdi and Raper, unpublished data). We have yet to characterize 
the mechanistic distinction between the transient and the transgenic HPR expression systems, although 
the most obvious differences between them are twofold. Firstly, HGD stimulates an acute phase 
response, which is an inflammatory signaling cascade that results in the increase or decrease in the 
expression levels of various acute phase proteins. Among these proteins are various HDL proteins, which 
could affect TLF function or synthesis. In general, total HDL levels decrease during the acute phase 
response, while certain HDL proteins such as the pro inflammatory serum amyloid alpha increase (205). 
Therefore, we hypothesize that up or down regulation of some HDL protein or proteins could be important 
for TLF synthesis in mice after HGD. The other most obvious difference between the HGD-based and the 
transgenic-based HPR expression systems is the promoter used to drive transgene expression. We have 
tried a gene trapping system using the ubiquitous ROSA26 promoter and a more conventional system 
using the liver-specific albumin promoter in transgenic systems, both of which have effectively failed in 
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this context, while we use the ubiquitin promoter to express HPR by HGD. We compared the efficacy of 
the ubiquitin promoter to that of the haptoglobin and C-reactive protein promoters (both relatively strong 
liver-specific promoters) by HGD and found that the ubiquitin promoter was undoubtedly the most 
effective at driving HPR expression (Verdi and Raper, unpublished data). While the promoter should 
hypothetically only effect the levels of RNA in the cell, rather than biochemically effecting HDL protein 
loading for example, the ubiquitin promoter is clearly the most efficacious at driving TLF synthesis. We 
have therefore recently started generating double transgenic mice that encode both P. hamadryas 
APOL1 and HPR expression systems driven by separate ubiquitin promoters. 
Generating trypanosome resistant cattle can likely be achieved by either high levels of circulating 
APOL1 or HPR coexpression. Given the apparent difficulty associated with driving HPR and APOL1 onto 
the same HDL complexes in mice, we have also recently started generating transgenic mice that express 
APOL1 chimera 360 because it expresses much more efficiently, at least by HGD, than the P. hamadryas 
protein. Mechanistically, it remains unclear why baboon APOL1 is less efficiently expressed than the 
chimera or the fully human protein. We originally hypothesized that differences at the DNA level were 
relevant because the baboon cDNA is predicated to be heavily methylated, while the human gene is 
methylation free (Verdi and Raper, unpublished data). Removal of CpG methylation sites from vectors to 
be used in HGD has previously been shown to increase both the magnitude and duration of protein 
expression in mice (206). However, we removed all 39 of the CpG methylation sites from the baboon 
ORF (while maintaining the same amino acid sequence) and observed no significant change in the 
plasma levels after HGD (Verdi and Raper, unpublished data). It therefore becomes more likely that 
differences between the proteins themselves are more relevant. We hypothesize that the baboon APOL1 
is degraded by serum proteases more efficiently than human APOL1 after secretion, or that the baboon 
APOL1 protein is not as efficiently secreted and loaded onto HDLs. The latter hypothesis could be 
investigated in the future through the generation of additional chimeric proteins in order to determine 
which regions of human APOL1 enhance secretion relative to baboon APOL1. For example, evidence 
from both prokaryotic and eukaryotic systems suggests that particular signal peptides can be more or less 
efficacious at facilitating protein secretion. The signal peptides of the human and baboon APOL1 could be 
interchanged in order to determine if the sub optimal level of baboon APOL1 secretion is a result of a 
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poorly recognized or poorly functioning signal peptide. The human and baboon signal peptides are 84% 
identical (four differences compared to 22 identities), making for a potentially feasible experiment. These 
and other investigations are being undertaken with the underlying future direction of generating 
transgenic cattle that will be immune to trypanosome infection. Although, we acknowledge that it remains 
to be determined whether the transgenic murine system is even a strong model for transgenic cattle in 
this regard. It’s possible that the baboon APOL1 protein, despite not functioning optimally in mice, will be 
produced and secreted efficiently in bovine hepatocytes. Generating transgenic cattle takes a significant 
amount of time and funding, although there are more cheap and rapid options that could serve as better 
models in the future. For example, we have entertained the possibility of generating transgenic APOL1-
expressing goats in the future as a better model for the ruminant system.  
Recently evolved APOL1 variants in the human population are associated with glomerular 
diseases. We have previously used mice to model the so-called renal-risk variants of APOL1 by 
transiently overexpressing them by HGD. In this system, mice expressing the toxic variants display liver 
pathology, while mice expressing the ancestral human variant did not (81). These data, along with many 
other published observations, suggest that the source of the damage is locally produced APOL1 that 
likely kills the cells that are producing it. The outstanding question is whether or not the baboon APOL1 
protein is toxic to the host cells as well. We also expressed the baboon APOL1 variant in this HGD 
system and observed a phenotype that resembled the ancestral human variant (81). Since our germline 
transgenic mice do not display any obvious negative phenotypes either, we arrive at two possible 
hypotheses. One hypothesis is that the baboon APOL1 variant is not toxic to host cells in vivo. In this 
scenario, some uncharacterized aspect of mammalian cell biology prevents baboon APOL1-mediated 
damage. This is the scenario that is currently used to explain why the ancestral human APOL1 variant is 
seemingly not toxic in vivo either. The alternative hypothesis is that the baboon APOL1 is toxic, but that 
no phenotypes are observable in these systems due to the low expression level of the protein, especially 
in the mice that we present here. The plasma APOL1 levels in these mice are significantly lower than the 
plasma APOL1 levels in humans and on the low end of the range of plasma APOL1 levels in baboons. 
Nevertheless, we confidently state that the expression level of baboon APOL1 that is required to at least 
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mediate resistance to trypanosome infection is not deleterious to the host in any obvious way, which is an 
important factor to consider in the context of generating transgenic cattle.  
 Regarding the generation of transgenic cattle, the threat of selecting for APOL1-resistant 
trypanosome strains is a major concern. In a worst-case-scenario, certain APOL1-sensitive parasites like 
T. congolense could hypothetically become human infective after serial passage through the transgenic 
animals. APOL1 resistance in T. congolense has been observed in field isolates (139) and can be 
selected for by serial passage in the presence of low concentrations of human serum (140). We 
hypothesize that many livestock-infective trypanosomes are capable of developing APOL1 resistance. 
However, it is also clear that these isolates rarely establish human infections with only 19 documented 
cases of ‘atypical’ trypanosomiasis in the past century, only one of which was caused by T. congolense 
(135). We hypothesize that while TLF mediates primate immunity to T. b. brucei and T. evansi infection, 
there are likely more factors involved that are responsible for cooperating with TLF to control T. 
congolense, T. vivax, T. lewisi, T. musculi, and other non-human infective, yet seemingly APOL1-
resistant, parasites. One possible explanation involves the concentration of TLF in blood versus 
peripheral tissues and the fact that T. congolense is classically a primarily blood resident parasite. These 
low-HDL niches may select for the emergence of parasites that display fitness costs relative to their 
parent line as a result of effectively being forced out of the bloodstream for a significant amount of time 
and adapting to a new pathogenesis mechanism that is not relatively favourable. These parasites, while 
TLF resistant, may then be incapable of establishing clinical infections in primate hosts. More generally, it 
is possible that TLF resistance in T. congolense is not sufficient to mediate primate infectivity. These 
hypotheses could be addressed in the future by performing in vivo baboon challenges with TLF-resistant 
strains. Despite that possible scenario, we would also like to address the difficulties associated with 
diagnosing trypanosomiasis and disease surveillance in general. It is equally possible that the number of 
‘atypical’ trypanosome infections is significantly underestimated.  
  For transgenic cattle to be effectively implemented, they do not need to be resistant to T. b. 
gambiense. T. b. gambiense is not considered to be a livestock pathogen, nor are cattle considered to be 
a hypothetical sub clinical reservoir. Further, the difficulties associated with achieving strong and 
functional baboon APOL1 expression make us hesitant to even strive for T. b. gambiense resistance in 
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lieu of selecting for gains of function in T. b. gambiense parasites that increase their APOL1 resistance 
potential. This is important to consider because the human G1 renal risk variant provides some 
uncharacterized protective effect against T. b. gambiense infection (144), an effect that could 
hypothetically be overridden by this equally hypothetical gain of function. Additionally, this hypothetical 
gain of function could also generate T. b. gambiense parasites that have an increased capacity to infect 
OWMs.  
 For transgenic cattle to be effectively implemented, they need to be resistant to T. vivax. T. vivax 
and is a major cattle pathogen that causes severe inflammation-associated anemia in susceptible 
livestock (9). This has been investigated by a few research programs using the C57 BL/6 mouse model 
and various knockout strains. However, the fact remains that virtually all of the in vivo T. vivax analyses 
that have been reported to date use T. vivax strains that are derivatives of the TvY468 clone that was 
originally isolated in Nigeria and was found to readily infect mice, rats, and rabbits (207). For this reason, 
we hesitate to draw firm conclusions with respect to the mechanistic pathogenicity of T. vivax and, more 
importantly, its TLF resistance or susceptibility. Here, we have shown that an uncharacterized strain of 
east African T. vivax that is highly virulent in mice is resistant to at least human TLF in vivo. But again, the 
fact that this strain is so virulent in mice is a major confounding factor to consider with respect to whether 
the biology of this parasite is representative of ecologically and agriculturally relevant T. vivax parasites. 
Given that the anecdotal majority of the T. vivax isolates in the world cannot be cultivated in laboratory 
animals (9), we are hesitant to conclude that T. vivax is uniformly TLF resistant. The generation of TLF-
producing cattle (or any other natural T. vivax host) may be the only way to legitimately derive the 
relevant conclusions.  
 The generation of a genetically engineered organism is not exclusively a scientific challenge. 
There are many additional issues surrounding the debate as to whether or not GMOs provide a net 
benefit to both the immediate and the global communities. As such, many parts of the developed world 
have either banned the cultivation and/or sale of GMOs altogether, or created rigorous regulatory bodies 
that work for years to ensure that any novel GMO is both safe and efficacious before permitting its 
distribution. However, these deliberations are a slow process. As an example, the Food and Drug 
Administration (FDA) recently approved the AquAdvantage salmon in May 2019, the world’s first GMO 
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animal to be commercially raised for human consumption. The approval for the salmon’s cultivation finally 
arrived, 3 decades after its original scientific development in 1989, after the FDA concluded that the fish 
did not produce an excessive amount of allergens, did not incur any significant negative impact on the 
environment, etcetera. However, the predicated safety of the fish does not guarantee that it will fly off the 
shelves at your local supermarket. There are additional consumer behaviors and ethical considerations to 
take heed of before producing a new GMO, just as there are for any new drug or product. We must 
therefore assess whether the Mzima cow is likely to be well received by its target consumers at both the 
community and regulatory levels, and whether it will accomplish its goal of reducing the burden of bovine 
and human trypanosomiasis in sub-Saharan Africa.  
 Generating genetically engineered trypanosome resistant cattle may decrease human 
trypanosomiasis transmission and may economically boost small communities, although the central goal 
of this and many other similar projects is to establish a global community with sustainable agriculture and 
food sources. The populace currently has quite dramatically differing views as to what ‘sustainable 
agriculture’ really means, as well as how to build an integrated system that provides for the entire global 
community (rather than exclusively those who live in areas where more food is wasted than other less 
developed communities can even produce). The sustainability of conventional versus or organic farming 
practices is a commonly debated topic in many parts of the developed world, with the usage of GMOs 
typically being at the center of the discussion. For more information on GMOs, I recommend that any 
readers of this thesis either read Lynas’ Seeds of Science, watch the documentary entitled Food 
Evolution, or visit GMOanswers.com. GMO crops have provided extraordinary benefits to many parts of 
the developed world in recent decades, although there remains an unfortunate lack of GMO usage in the 
developing world (in Africa, only Sudan and South Africa commercially cultivate GM crops). As one 
important example, the usage of GM seed that carries genetic resistance to insect pests can significantly 
increase crop yields and increasing crop yields (as opposed to increased land usage, for example) are 
predicted to be the main driver of crop production growth in the future. Rather than speculate as to which 
models of farming are the most ideal, we can examine trends in various parts of the world and determine 
which sources of food and finances are the most beneficial to at least the communities plagued by 
trypanosomiasis. The FAO has predicted that, in the next few decades, the demand for livestock products 
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like milk and beef will double in sub-Saharan Africa, while it will stagnate in places like Europe, Russia, 
and the Americas (208). This is due to many factors, though the most obvious are the population boom 
that is currently and will continue to occur in Africa as well as the continued urbanization of the continent. 
Urbanization is tightly correlated with an increased demand for livestock products (209). While certain 
groups in the developed world have begun to turn towards plant-based diets, the association between 
livestock and sustainability remains critical for billions of people in the developing countries of the world. 
At this moment, there are no suitable substitutes for livestock cultivation in sub-Saharan Africa, and the 
demand for livestock products will continue to grow.   
 As an important first step towards the generation of genetically modified cattle, our collaborators 
have recently produced the world’s first cloned Boran bull by somatic cell nuclear transfer at ILRI in 
Nairobi, Kenya (165). Kenya is one of the many nations plagued by bovine trypanosomiasis wherein 
government officials are currently seeking an increased level of devotion, on the order of tens of millions 
of US dollars, towards the eradication of trypanosomiasis. This highlights the necessity for a product like 
the Mzima cow, although it also highlights the need for an assurance that the product will be efficacious to 
the point where it makes a significant impact in this eradication effort. This will require extensive 
mathematical model efforts in the future, although we can provide a suggestion of efficacy with the 
currently available resources, such as the transmissibility of trypanosome parasites. The basic 
reproduction number (R0) of a particular infection is the presumed number of individuals that will become 
infected by the pathogen as a result of any individual case. In other words, an R0 of 5 would indicate that 
an infected individual is likely to be the source of 5 additional infections during the infectious period. The 
R0 values for trypanosomiasis are not well understood across the continent, and determining these values 
becomes increasingly difficult when one must consider multiple host species, such as both cattle and 
humans. Despite this, the R0 values of T. brucei, T. congolense, and T. vivax have been modeled in the 
most densely settled areas of the Ugandan T. b. rhodesiense transmission zone (210). Using a model 
that incorporates multiple host species, tsetse fly biting behaviors, and a number of additional 
parameters, the authors found that a combination of insecticide spraying and trypanocide administration 
in cattle would reduce the R0 of T. brucei and T. congolense infection to levels befitting of disease 
eradication (210). In one model, the R0 of T. brucei was reduced to <1 if all cattle were treated with 
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insecticide, while only >65% of cattle were treated with trypanocides (210). The proportions required to 
eliminate T. congolense were slightly higher, while the elimination of T. vivax was least likely. 
Nevertheless, these data suggest that various species of trypanosome can be eliminated from even the 
most dense foci through the combined use of insecticides and drug treatment. We propose that the 
Mzima cattle could take the place of this drug, and that in less dense foci such as those in southern 
Kenya, disease eradication is achievable with potentially only partial distribution of the modified breed in 
concert with insecticide application. 
 Should the Mzima cattle be approved, extensive environmental impact studies must be 
conducted. We must investigate issues of land use, feed consumption, and greenhouse gas emission 
expectations, among others. We also must enquire with local communities as to their personal desires. 
How do they feel about genetic engineering altogether? Are they willing to breed genetically engineered 
animals? Preliminarily, we have made efforts to enquire with the relevant parties in order to determine 
where to begin. We have so far hosted two separate workshops at ILRI, wherein the Mzima idea was 
presented to any potential stakeholders including farmers, veterinarians, and government officials 
including representatives from Kenya, Ghana, Nigeria, Uganda, the United States, Brazil, and Argentina. 
We have also included the Kenyan National Biosafety Authority (NBO) in the proceedings, and they have 
responded by collaborating with our representatives to draft the very first “guidelines for regulation of 
genetically modified animals under containment in Kenya.” The Mzima cattle must be properly regulated 
and must be produced in such a way that does not disrupt the current livestock industry or make any 
significant negative environmental impact. Through collaborative efforts, open minds, commitment, and 




We have generated novel transgenic and transiently transgenic murine models that can be used 
in the future to study human and primate TLFs 1 and 2. In doing so, we have identified the origin and 
likely the role of the germline IgM antibodies that are associated with TLFs. We have also significantly 
expanded the number the of available primate APOL1 gene sequences, allowing us to pinpoint particular 
amino acid residues that regulate the function of the protein. Finally, we have extensively modeled the 
possibility of developing genetically modified trypanosome resistant cattle using transgenic mice, 
revealing that the interactions between primate APOL1 and various trypanosome species are far more 
complex in an in vivo setting than previously appreciated. Nevertheless, we maintain that the generation 
of transgenic cattle remains a feasible endeavor that will simply require a significant amount of calibration 





Appendix Table 1. Sources of baboon DNA analyzed in this study. 




L142 Papio anubis Southwest National Primate Research Center (SNPRC) WBC M 
LIV5 Papio anubis Southwest National Primate Research Center (SNPRC) Liver F 
28697 Papio ursinus Southwest National Primate Research Center (SNPRC) N/A F 
28755 Papio ursinus Southwest National Primate Research Center (SNPRC) N/A F 
28547 Papio papio Southwest National Primate Research Center (SNPRC) N/A N/A 
30388 Papio papio Southwest National Primate Research Center (SNPRC) N/A M 
34474 Papio kindae BCM/Blood collected in the wild - in southwest Zambia Blood F 
34472 Papio kindae BCM/Blood collected in the wild - in southwest Zambia Blood M 
34449 Papio kindae BCM/Blood collected in the wild - in southwest Zambia Blood F 
30877 Papio anubis Yerkes National Primate Research Center (YNPRC) - in 
Aberdare region of Kenya 
WBC  
30977 Papio anubis Yerkes National Primate Research Center (YNPRC) - in 




Baylor College of Medicine - collected in central Tanzania WBC F 
16098 Papio 
cynocephalus 
Baylor College of Medicine - collected in central Tanzania WBC F 
97074 Papio 
hamadryas 











Baylor College of Medicine - central Tanzania Blood M 
15978 Papio 
cynocephalus 
Baylor College of Medicine - central Tanzania Blood M 
15982 Papio 
cynocephalus 
Baylor College of Medicine - central Tanzania Blood M 
15991 Papio 
cynocephalus 
Baylor College of Medicine - central Tanzania Blood F 
15997 Papio 
cynocephalus 
Baylor College of Medicine - central Tanzania Blood F 
16005 Papio 
cynocephalus 
Baylor College of Medicine - central Tanzania Blood M 
16011 Papio 
cynocephalus 
Baylor College of Medicine - central Tanzania Blood F 
16036 Papio 
cynocephalus 
Baylor College of Medicine - central Tanzania Blood F 
16050 Papio 
cynocephalus 
Baylor College of Medicine - central Tanzania Blood F 
16053 Papio 
cynocephalus 
Baylor College of Medicine - central Tanzania Blood M 
16094 Papio 
cynocephalus 
Baylor College of Medicine - central Tanzania Blood M 
16169 Papio 
cynocephalus 
Baylor College of Medicine - central Tanzania Blood M 
37930 Papio kindae Washington University School of Medicine/New York 
University/Baylor College of Medicine - southwest Zambia 
Blood M 
37931 Papio kindae Washington University School of Medicine/New York 
University/Baylor College of Medicine - southwest Zambia 
Blood M 
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37932 Papio kindae Washington University School of Medicine/New York 
University/Baylor College of Medicine - southwest Zambia 
Blood M 
37933 Papio kindae Washington University School of Medicine/New York 
University/Baylor College of Medicine - southwest Zambia 
Blood M 
37934 Papio kindae Washington University School of Medicine/New York 
University/Baylor College of Medicine - southwest Zambia 
Blood M 
37935 Papio kindae Washington University School of Medicine/New York 
University/Baylor College of Medicine - southwest Zambia 
Blood F 
37936 Papio kindae Washington University School of Medicine/New York 
University/Baylor College of Medicine - southwest Zambia 
Blood F 
37937 Papio kindae Washington University School of Medicine/New York 
University/Baylor College of Medicine - southwest Zambia 
Blood F 
37938 Papio kindae Washington University School of Medicine/New York 
University/Baylor College of Medicine - southwest Zambia 
Blood M 
37939 Papio kindae Washington University School of Medicine/New York 
University/Baylor College of Medicine - southwest Zambia 
Blood F 
37940 Papio kindae Washington University School of Medicine/New York 
University/Baylor College of Medicine - southwest Zambia 
Blood M 
37942 Papio kindae Washington University School of Medicine/New York 





Appendix Figure 1. APOL1 variation in baboons. The image shows every exonic SNP detected within 
the APOL1 gene of each baboon chromosome analyzed by the Baboon Genome Consortium after 
haplotype phasing. The left axis of the figure shows the sample IDs of each baboon, with both alleles 
being shown separately (one in black and one in red for each individual). The table is organized by 
species, as also highlighted on the right side of the table. Above the table is a schematic of the APOL1 
locus, which consists of 5 coding exons, showing the position of each variant within the open reading 
frame. The sizes of the introns are not drawn to scale. From the start of the first exon to the end of the 
fifth exon is approximately 10,000 base pairs in length. The haplotype table is colored to indicate whether 
any position either remains identical or different to the reference APOL1 sequence from Panu2.0 (which 
is the top row of the table). Green positions are identical, while red positions are different. The blacked-
out positions indicate that data is missing from those indivuals at those positions due to sequencing 
errors. Polymorphisms that alter sequence of the APOL1 protein are identified above the table by the 
listing of the amino acid change at that position, while silent mutations are not marked. The majority of the 
amino acid changes are simple polymorphisms, however, the H38V polymorphism is encoded by 2 linked 
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